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ABSTRACT OF DISSERTATION

INFLAMMATION AND INSULIN DYSREGULATION IN THE HORSE
Insulin dysregulation (ID) in the horse is receiving increasing attention as a serious
health concern, in particular due to its association with the potentially career or life ending
condition, laminitis. The role of inflammation and the immune system in ID as well as its
associated health concerns has also been raised. However, the involvement of inflammation
in and mechanisms behind ID in the horse remain unclear. Therefore, our overall
hypothesis was that due in part to changes in their gut microbiota and plasma lipidome,
horses with ID have changes in circulating proinflammatory markers, in particular in
response to glycemic challenge, that further drive metabolic dysfunction. This work
focuses on 7 potential associations between ID and inflammation to test this hypothesis;
(H1) horses with ID will have an abnormal inflammatory response to glycemic challenge,
(H2) ID horses will have differences in their gut microbiota compared to metabolically
normal controls, (H3) these horses will likewise have differences in their plasma lipidome,
(H4) response to routine vaccination will be reduced in horses with ID compared to
metabolically normal controls, (H5) circulating endotoxin concentrations will be elevated
in horses with ID, in particular in response to glycemic challenge, and their inflammatory
and metabolic responses will be improved following supplementation with a gut
modulating mannan rich fraction of the yeast cell wall, (H6) whole blood stimulation with
endotoxin will induce TLR4 mediated inflammatory gene expression, and (H7) changing
circulating lipid concentrations will improve both glycemic and inflammatory parameters
in ID horses. Overall this work provides insight into contributing factors to ID in the horse,
in particularly as they relate to inflammation.
KEYWORDS: Insulin dysregulation (ID), inflammation, gut microbiota, plasma
lipidome, immune response to vaccination, and supplementation.
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CHAPTER 1 REVIEW OF THE LITERATURE
1.1. Phenotype
The percentage of adults in the United States considered to be overweight or obese
(as measured by body mass index, or BMI) continues to increase, with some stating that
up to 68.8% of the population falls into one these categories [1, 2]. The percentage of
overweight or obese horses is likewise increasing, with reports ranging from 20.6-51% of
U.S. or abroad populations affected [3-7]. There are many negative health concerns that
have been associated with obesity in various species, including the horse. While it is
unclear if obesity precedes these health concerns or if it is a resulting side effect, it is often
considered a risk factor for many conditions. In particular, it is associated with insulin
dysregulation and other endocrinopathic disorders in the horse [8-11].
The term insulin dysregulation (ID) [12] has recently been used in the literature to
describe most forms of abnormal insulin concentrations or signaling in the horse, whether
that be high resting insulin concentrations (hyperinsulinemia), an abnormal response to
glycemic or insulinemic challenge (such as the oral sugar test, or OST [13]), or tissue
insulin insensitivity (insulin resistance, or IR). Arguably of greatest concern is its
association with the potentially fatal condition, laminitis [14-16]. While the mechanisms
behind laminitis remain unclear, it is ultimately a failure of the hoof lamellar structures that
can lead to rotation or sinking of the distal phalanx [17]. This failure typically involves
inflammation, impedes mechanical function, and is extremely painful for the animal [18].
Further support of the connection between ID and laminitis has been demonstrated as
laminitis can be induced with administration of exogenous insulin [19, 20]. While the
prevalence of endocrine associated laminitis (or endocrinopathic laminitis) is not well
known, incidence of laminitis in the equine population has been reported from as little as
1.5% to as much as 34% [21]. Additionally, one study reported that over a period of 16 mo
in an equine referral hospital, 89% of laminitic cases had underlying endocrinopathies [22].
A history of or predisposition to laminitis, increased general or regional adiposity
(fatty deposits around the neck, tail head, behind the shoulder, or in the mammary gland
region), and the presence of ID are the three main defining characteristics of Equine
Metabolic Syndrome (EMS) [23]. Other proposed characteristics for diagnosis of EMS
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include lipid dysregulation such as hypertriglyceridemia or dyslipidemia, hyperleptinemia,
arterial hypertension, and systemic inflammation [23]. EMS is considered to be similar to
metabolic syndrome (MetS) [24, 25] in humans [26]. An individual will qualify as MetS if
he or she exhibits 3 out of the 5 following risk factors: elevated fasting glucose, elevated
systolic and/or diastolic blood pressure, hypertriglyceridemia, low high-density lipoprotein
cholesterol (HDL) levels, and increased central adiposity [25]. Also, individuals with MetS
often have increases in both circulating and adipose tissue levels of inflammation [27].

1.2. Inflammation
Research regarding EMS has concentrated on a better definition of the phenotype
as well as potential underlying mechanisms [23, 28-31]. However, there have been
conflicting results, particularly regarding inflammation. This may be due to several factors.
Often, studies compare ponies rather than horses, or induce hyperinsulinemia with models
such as dexamethasone administration [32] or diet-induced weight gain [33], rather than
utilizing horses with naturally occurring ID. In many instances horses were not tested for
potentially confounding factors, such as pituitary pars intermedia dysfunction (PPID),
which can influence insulin and glucose dynamics [10, 11]. In addition, data regarding
fasted versus fed states is in some instances not reported, assays used to determine insulin
concentrations vary, and cut-off values used for diagnosis of ID are not established for
these different assays in the horse [34-36].
Data concerning fed versus fasted states becomes important not only concerning
insulin and glucose dynamics [37, 38], but also in regards to other parameters such as
markers of inflammation. When indicated, much of the work in the horse has focused on
fasting circulating or fasting tissue markers of inflammation. These results has been
somewhat contradictory, with some reporting that horses with ID have an increase in
inflammatory markers such as circulating tumor necrosis factor alpha (TNF-α) protein and
TNF-α gene expression in adipose tissue [28, 39], as well as positive correlations between
plasma concentrations of serum amyloid A and insulin [40]. Others have seen differences
in inflammatory cytokine gene expression in nuchal adipose tissue between EMS horses
and controls, with EMS horses having increases in IL-1β and IL-6 [41]. However, others
found no differences or lower IL-1 and IL-6 peripheral blood mononuclear cell (PBMC)
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gene expression and a trend for lower TNF-α plasma concentrations in obese horses, and a
trend for a decrease in EMS horses PBMC TNF-α and IL-1β gene expression compared to
metabolically normal controls [31, 42]. These contradicting results may be partly explained
as humans and mice with or without metabolic dysfunction have been observed to have
postprandial increases in inflammatory markers. TNF-α, IL-6, and IL-1β as well as
increases in systemic soluble adhesion molecules, such as Intercellular Adhesion
Molecule-1 (ICAM-1), have been observed in response to a high fat or combination high
fat, high sugar/starch meal [43-45]. There are indications that this may be true in horses as
well, with postprandial increases seen in IL-1β, TNF-α, IFN-γ, and IL-6 in response to oral
feeding or oral administration of sugar/starch [46, 47].
Horses are as hind-gut fermenters able to utilize sugars and starches as an energy
source [48] and easily break down these structural carbohydrates into digestible volatile
fatty acids. Diets rich in these energy sources, particularly in large quantities, have been
shown to promote insulin insensitivity in the horse [49], further associating the role of the
gut in inflammation and ID. In fact, in equine induction models of laminitis utilizing a
carbohydrate polymer made up of inulin-type fructans (oligo-fructose) given orally [50],
horses had an increase in whole blood cytokine gene expression of IL-1β, IL-8, and IL-10
8 h post laminitis induction [51] as well as increases in lamellar IL-2, IL-6, IL-8, and IFNγ at the onset of laminitis [18].
Postprandial increases in inflammatory markers have several possible explanations.
They may be due in part to proposed differences in oxidative stress in humans, mice, and
horses with metabolic dysfunction [31, 52-55]. Similar to inflammation, it has been
suggested that oxidative stress increases postprandially, in particular in individuals with
hyperglycemia and hypertriglyceridemia [56-58]. Increases in inflammatory markers
following administration of a meal may also be due to increases in bacterial endotoxin
concentrations that have been observed in humans in response to dietary fat [59, 60].
Likewise in high fat fed mice, endotoxemia has been shown to induce inflammation and
insulin resistance [61]. Indeed, postprandial changes in bacterial endotoxin concentrations
are not surprising due to the suspected involvement of the gut and its associated microbiota
in both metabolic and inflammatory mechanisms [62, 63].
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1.3. Microbiota
In horses and humans, the gut microbiota is both highly diverse and variable.
Variation can be affected by, among other factors: genetics, age, diet, and disease states
[64-66]. For example, in the healthy horse, the predominant gut bacterial phyla is
Firmicutes [64, 67] and bacteria from the Clostridiales order, in particular the butyrate
producing bacteria Ruminococcaceae and Lachnospiraceae, are positively correlated with
intestinal health [68, 69]. However, following feeding of a high starch diet, horses have
been shown to have an increase in the abundance of the one of the taxa from the Firmicutes
phyla, Veillonellaceae [70]. Veillonellaceae, a gram-negative propionate/acetate producer,
has been positively correlated with markers of metabolic dysfunction in high fat fed rats
[71]. Horses with a history of laminitis have also been shown to have alterations in their
gut microbiota, with previously laminitic horses having increased abundance of two
unassigned members of the Clostridiales genera as well as differences in community
structure, notably having a lower representation of Firmicutes and greater representation
of Verrucomicrobia compared to controls [72]. Changes in bacterial abundance have
likewise been shown in the horse at the onset of laminitis [73, 74]. In addition, decreases
in Clostridiales have been documented in horses with colitis and in mares prior to the onset
of colic [75, 76]. Metabolic dysfunction and obesity have also been associated with
intestinal microbiota changes [77]. For example, an overabundance of the phyla
Verrucomicrobia was observed in diet-induced obese minipigs [78]. Additionally, obesity
has been linked with an overall decrease in microbial diversity in humans [79] and in dogs
[80]. In horses, a decrease in diversity has been observed following antimicrobial
administration [81] and in response to a change in diet [69], as well as in horses with EMS
compared to metabolically normal controls [82]. These same EMS horses were also found
to have differences in overall community structure, suggesting changes in composition due
to overgrowth or decreased growth of specific community members. Given that in mice
changes in the gut microbiota related to age have increased circulating concentrations of a
component gram-negative bacteria cell wall, lipopolysaccharide (LPS), which
subsequently resulted in an increase of inflammatory markers [83], these and other studies
highlight the potential influence of the gut microbiota on metabolic dysfunction and its role
in the induction of systemic, low grade inflammation.
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In humans, diets or supplements that reduce the population of bacteria that produce
LPS, for example the so called Mediterranean diet [84], supplementation with polyphenols
[85], or probiotics [86], are suggested as possible therapeutic targets for individuals with
metabolic dysfunction. Supplementation with pre or probiotics is thought to be particularly
beneficial as they positively influence intestinal health by improving the balance of the
microbiota population by the addition of live favorable bacteria (typically lactic acid
producers) in the case of probiotics, or by promoting the growth of specific members of
the existing bacterial community in the case of prebiotics [87]. One suggested method to
influence the gut microbiota in the horse has been supplementation with the prebiotic,
fructooligosaccharides [88, 89]. Fructooligosaccharides (FOS) exhibit prebiotic properties
as they promote growth of certain intestinal bacteria. They are converted to short chain
fatty acids following fermentation by the gut microbiota [90] and subsequently serve as a
source of energy for intestinal epithelial cells, have a major role in communication between
the gut microbiota and the host, and are thought to have beneficial effects on host
metabolism and even inflammation [91, 92]. Indeed, supplementation with FOS has been
shown to positively impact metabolic parameters in horses [93] as well as in obese dogs
[94]. In addition, it has been shown that utilizing another dietary prebiotic, in the form of
yeast or yeast cell wall, can likewise effect inflammation in dairy cows [95], poultry [96],
humans [97-99], and horses [100, 101]. Yeast cell wall supplementation has in cattle been
shown to influence glucose and insulin concentrations following supplementation and LPS
challenge [102], and reduced circulating triglyceride and cholesterol levels in poultry post
supplementation [103, 104]. Mannan oligosaccharides, thought to be one of the main
effectors found in the yeast cell wall, reduced circulating LPS concentrations in pigs [105],
primarily mediated by positive changes in the gut microbiota.

1.4. Lipids
Not only have increases in LPS been associated with changes in the gut microbiota,
but they have also been associated with inflammation and alterations in lipid metabolism
[106]. EMS and ID horses have abnormal metabolic function [23, 29, 107] as well as
abnormal circulating lipid concentrations [40, 42, 107]. Lipidomic analysis has allowed for
further exploration of lipids and lipid profiles (or lipidome) as well as their relationship to
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metabolism and inflammatory processes [108]. Lipids, in particular the sphingolipid
sphingomyelin as well as the glycerophospholipids ethanolamine or choline plasmalogens,
have a major role in mammalian cellular membrane health [109]. Therefore, they have a
direct impact on cellular function, including cell signaling [110, 111]. Cell signaling, such
as activation of inflammatory pathways in multiple cell types (in particular macrophages,
adipocytes, and hepatocytes) and gene expression of metabolic and inflammatory proteins
(for example SOCS-3 and MCP-1) can be influenced in many species by changes in
circulating lipid concentrations [112-114]. In particular, changes in ceramide
concentrations [113, 115-117] strongly impact cell signaling and metabolism. Bioactive
lipids, such as ceramide, in addition to their influence on inflammatory and insulin
signaling, are able to act as chemoattractants and second messengers for multiple cell types,
including immune cells [118-120]. Further evidence of the role of the lipidome in
metabolic dysfunction is demonstrated considering that changes in nutrition and nutritional
supplementation are able to effect change in the plasma lipidome, resulting in the decrease
of inflammatory markers and an increase in insulin sensitivity in humans [121, 122]. In
one

study,

phosphatidylcholine

and

sphingomyelin

containing

linoleic

and

docosahexaenoic acid (thought to be anti-inflammatory lipids [123]) were found to be
increased in exercised rats whereas phosphatidylcholines, phosphatidylethanolamine, and
phosphatidylinositol containing arachidonic acid (thought to be a pro-inflammatory lipid
[124]) were increased in rats with metabolic dysfunction following feeding of a high fat
diet [125].
Lipids not only influence cell signaling and impact cellular membrane health and
function, but in humans and in mice there is evidence that they also play a role in the
immune response. For example, the immune system can recognize both foreign lipids (for
example KOD2-lipid A from Escherichia coli) [126], and self-lipids (such as gangliosides
and glycosphingolipids) [127-129] as antigens. Lipids are also, as stated previously, able
to act as lymphocyte chemoattractants [118]. Given associations between obesity, insulin
resistance, systemic inflammation, and the immune response [31, 130, 131], questions have
been raised as to the response to vaccination of those with metabolic dysfunction or obesity.
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1.5. Immune responses
Following vaccination, the immune system initially mounts the rapid non-specific
innate immune response [132]. This innate response involves the release of cytokines and
chemokines which promote the activation of the second arm of the immune response, the
adaptive immune response [133], which provides the host with long lasting specific
protection from disease. There have been indications that in response to influenza
vaccination, diet-induced obese mice have a decrease in both their antibody response and
neutralizing capacity compared to metabolically normal controls [134]. Diet-induced obese
mice have likewise been shown to have a decrease in hepatitis specific antibody and T cell
activation, but an increase in T and B cell proliferation as well as increases in levels of
IFN-γ and TNF-α in response to a hepatitis B vaccine [135]. Humans with type 1 diabetes
are considered to be at risk for non-responsiveness to vaccination [136], and in a group of
245 hospital employees >3 yrs post hepatitis vaccination there was a correlation between
increased adiposity and lower levels of circulating antibody [137]. Further, although body
mass index was positively associated with an initially higher IgG antibody response, 12
months following influenza vaccination individuals with a higher body mass index
exhibited a greater decline in antibody titers [138]. In the same study, obese individuals’
virally challenged PBMCs displayed a lower functional protein expression and decreased
CD8+ T-cell activation ex vivo. There is however, no published work to date on the
response to vaccination in the ID or obese horse.

1.6. Inflammatory mechanisms and signaling
While multiple studies have shown probable links between the immune system,
inflammation, lipids, and metabolic dysfunction [127, 139, 140], the underlying
mechanisms of ID and contributing factors to laminitis in the horse remain unclear.
Genetics appear to influence the prevalence of ID in the horse as certain breeds, such as
ponies and Andalusians, are predisposed to its development [23, 141]. Additionally
environmental factors, including nutrition and exercise, play a role in the development of
metabolic dysfunction [142]. There has also been recent discussion as to the role of
corticosteroids in the pathogenesis or severity of ID and laminitis, although at present
supporting evidence is weak [143, 144]. In obese or insulin resistant humans and mice,
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there has been data showing that adipose tissue macrophages, as opposed to adipose tissue,
are the primary producers of inflammatory cytokines, in particular TNF-α [145, 146]. In
the adipose tissue of individuals with obesity and ID, macrophages accumulate in greater
numbers and size, and favor M1 (thought to be pro-inflammatory) macrophages as opposed
to M2 (thought to be anti-inflammatory) macrophages [131, 147]. Macrophages recognize
pathogens principally through pattern recognition receptors (PRR), in particular toll-like
receptors (TLRs) such as TLR-4. TLR-4 has been implicated in ID and obesity as the
primary receptor for recognition of LPS [148]. LPS stimulated signaling through TLR-4
and its co-receptors, CD14 (cluster of differentiation 14) and MD-2 (Lymphocyte antigen
96), activate signaling cascades which ultimately result in activation of NF-κB (nuclear
factor kappa-light-chain-enhancer of activated B cells), which in turn promotes proinflammatory gene expression [149]. This receptor complex has also been shown to
recognize free fatty acids (FFA) as antigens similarly resulting in the production of
inflammatory cytokines, such as TNF-α and IL-6 [148, 150]. There is cross talk between
the TLR-4 and insulin signaling cascades, and it appears that humans with type 2 diabetes
have additional insulin signaling intermediates within their insulin signaling cascade [151].
However, underlying mechanisms of abnormal inflammatory signaling remain unclear. In
particular, it remains to be seen if changes in inflammatory responses or concentrations,
possibly due to increases in circulating LPS concentrations, initiates abnormal insulin
signaling or if the reverse is true.

1.7. Treatment and therapeutic strategies
Considering the large number of horses affected by obesity or ID, there have been
an increasing number of studies examining potential therapies for metabolic dysfunction
in the horse. Classically, horses with ID are treated with exercise and dietary restriction,
which have been shown to decrease insulin resistance as well as markers of inflammation
[29]. However, these changes often over a period of several months and may not be a viable
treatment option in horses with complicating health concerns, such as chronic laminitis.
There are two off-label pharmaceutical drugs commonly administered to horses with ID.
One of which, (Metformin) works in the liver by suppressing glucose production [152],
and the other (levothyroxine sodium) as a synthetic thyroid hormone (T4) upregulates
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metabolic processes by stimulation of the thyroid [153]. However, as stated prior,
metformin and levothyroxine sodium are used off label in the horse and their mechanism
of action is not well established. In addition, published results in the horse are conflicting
regarding their efficacy and long term safety [9, 154-156].
In humans and in other species, omega-3 fatty acid supplementation has been
proposed as a treatment strategy for individuals with metabolic dysfunction [157]. Much
of the research has focused on supplementation with the long-chain polyunsaturated
omega-3 fatty acids docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA).
Supplementation with these fatty acids appear to be dose responsive, as demonstrated in
people and in horses [158, 159]. These fatty acids are readily incorporated and absorbed as
increased concentrations have not only been observed in circulation following
supplementation but in tissue as well; for example in skeletal muscle in horses [160] and
adipose tissue in humans [161]. Supplementation with omega-3 fatty acids is thought to be
beneficial for several reasons. Insulin sensitivity has been shown to be improved in rats,
pigs, and humans [162-166]. In humans it has also been shown to promote body fat
oxidation and reduce lipogenesis [167, 168] and has a positive effect on the plasma
lipidome [169, 170]. In metabolically normal horses, supplementation with omega-3 fatty
acids has indicated a positive effect on glucose clearance [171], improvement in markers
of insulin sensitivity [172], and following dexamethasone administration has reduced
baseline glucose and insulin concentrations and improved the modified insulin to glucose
ratio [173]. It has also been shown in metabolically normal horses to reduce inflammatory
mediators [174-176] and has an effect on circulating DHA, triglyceride, and phospholipid
concentrations [159, 177, 178]. However, no work to date has been carried out regarding
omega-3 fatty acid supplementation in the ID horse.

1.8. Overall hypothesis and specific aims
Overall, data is still limited regarding the pathophysiology of ID in the equine. It
does appear that many biological processes are influenced in horses affected by ID, in
particular the inflammatory process. However, more work needs to be done regarding the
underlying mechanisms of this common and potentially career or life ending disorder.
Therefore, we proposed with this work to investigate the role of inflammation in the horse
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with ID with the hypothesis that due in part to changes in their gut microbiota and plasma
lipidome, horses with ID have changes in circulating proinflammatory markers, in
particular in response to glycemic challenge, which further drive metabolic dysfunction. In
order to assess this overall hypothesis, 7 specific hypotheses (H) were examined.
(H1) Horses with ID will have an abnormal inflammatory response to glycemic challenge.
This hypothesis was generated to investigate the inflammatory and metabolic
responses of the ID horse to an oral glycemic challenge utilizing a high sugar/starch
challenge as well as a commonly used glycoside.
(H2) ID horses will have differences in their gut microbiota compared to metabolically
normal controls.
Fecal DNA was used to determine differences in the composition of the gut
microbiota in a group of ID horses compared to metabolically normal controls for
this hypothesis.
(H3) These horses will likewise have differences in their plasma lipidome.
Differences in circulating plasma lipid concentration in ID horses for this
hypothesis were determined by lipidomics analysis, as well as an analysis of
baseline inflammatory markers.
(H4) Response to routine vaccination will be reduced in horses with ID compared to
metabolically normal controls.
This hypothesis was tested by administration of routine influenza vaccination in a
group of ID as well as metabolically normal control horses to examine humoral and
cell mediated immune responses to vaccination.
(H5) Circulating endotoxin concentrations will be elevated in horses with ID, in particular
in response to glycemic challenge, and their inflammatory and metabolic responses will be
improved following supplementation with a gut modulating mannan rich fraction of the
yeast cell wall.
Markers of inflammation, circulating endotoxin concentrations, and metabolic
parameters and responses were measured in horses both with and without ID prior
to and following supplementation with a gut modulating yeast cell wall product to
test this hypothesis.
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(H6) Inflammatory gene expression in response to a TLR4 agonist, LPS as well as in
response to an oral sugar test will be different in horses with ID.
Whole blood was stimulated with endotoxin in ID and metabolically normal horses
as baseline and following OST to determine inflammatory responses for this
hypothesis.
(H7) Changing circulating lipid concentrations will improve both glycemic and
inflammatory parameters in ID horses.
To test this hypothesis, ID horses were utilized for inflammatory, metabolic, and
lipid concentrations and responses which were assessed both prior to and following
supplementation with omega 3 fatty acids.

Copyright © Sarah E. Elzinga 2017
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CHAPTER 2 METABOLIC AND INFLAMMATORY RESPONSES TO THE
COMMON SWEETENER STEVIOSIDE AND A GLYCEMIC CHALLENGE IN
HORSES WITH EQUINE METABOLIC SYNDROME
Domestic Animal Endocrinology, 2017: 60, 1-8

Extracts derived from the leaves of the stevia plant (stevioside) are commonly used
as sweeteners for humans and horses. Stevioside appears to be safe for human
consumption, including for individuals with insulin dysregulation. In the horse, the safety
or metabolic effects of stevioside on normal animals or on those with metabolic
dysfunction are unknown. Furthermore, the inﬂammatory response to a glycemic challenge
or to stevioside in horses is not well deﬁned. Therefore, the objective of this study was to
measure the effects of stevioside and a glycemic challenge on insulin, glucose, and
inﬂammatory responses in horses with a common metabolic dysfunction (equine metabolic
syndrome or EMS) compared with non-EMS controls. To accomplish this, 15 horses were
selected; 8 EMS and 7 age-matched controls. An oral sugar test was performed using Karo
corn syrup (karo) or stevioside in a random crossover design. Horses were given 0.15
mL/kg body weight of karo or its equivalent grams of sugar in stevia dissolved in water.
Blood samples were collected by jugular venipuncture before administration of either
stevia or karo and at 60 and 240 min after administration. Serum was used for glucose and
insulin determination and plasma for isolation of peripheral blood mononuclear cells
(PBMCs) for inﬂammatory cytokine analysis via ﬂow cytometry and reverse transcription
PCR (RT-PCR). Stevia appeared to stimulate lower glycemic and insulinemic responses
when compared to karo, in particular in EMS horses. EMS and control horses had inverse
inﬂammatory responses to administration of either stevia or karo with EMS horses having
a proinﬂammatory response (P < 0.05). These data provide evidence as to why horses with
EMS may be predisposed to developing laminitis, potentially as a result of an exaggerated
inﬂammatory response to glycemic and insulinemic responses. Furthermore, the data
provide new avenues for exploring mechanisms behind the syndrome, in particular when
using a glycemic challenge.
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2.1. Introduction
Stevioside, a glycoside derived from the leaves of the stevia plant, has been
increasingly used as a sweetener for both horses and humans [179]. It appears in a range
of equine products, such as veterinary pastes, supplements, and anthelmintics. Stevioside
can even be found in equine products intended for use in the insulin resistant animal.
However, the safety and efﬁcacy of stevioside in the metabolically normal or metabolically
dysfunctional animal is unknown. For humans, stevioside is primarily used as a nonglycemic sugar replacer and is classiﬁed as Generally Recognized as Safe by the United
States food and drug administration (Generally Recognized as Safe). Research indicates
that stevioside is safe for human consumption, including for individuals with hypertension
and metabolic dysfunction [180]. Stevioside may even be metabolically beneﬁcial in
individuals with metabolic disorders as it has been shown to increase insulin sensitivity in
insulin resistant rats [181] and to positively influence glucose and insulin dynamics in
people [182-185]. Humans with metabolic dysfunction typically suffer from
hyperglycemia and hyperinsulinemia. Considering that stevioside stimulates insulin
release from the pancreas [184], it can therefore have a potentially positive effect in humans
by lowering circulating glucose concentrations. However, horses with metabolic
dysfunction, unlike humans with metabolic syndrome, typically have circulating glucose
concentrations within the normal range, but are hyperinsulinemic. Thus, increasing the
amount of circulating insulin in the horse may actually exacerbate existing insulin
dysregulation (ID) [12] in the horse with metabolic syndrome (equine metabolic syndrome,
or EMS). Even with the increasing use of stevia in equine products, the effects of stevioside
on glucose and insulin metabolism in the horse have yet to be determined. The oral sugar
test (OST), a common dynamic test used to determine glycemic and insulinemic responses
to a simulated high carbohydrate meal, is typically carried out using a bolus of Karo corn
syrup (karo) as a sugar source. However, no research has characterized the inﬂammatory
response to a glycemic challenge with either karo or stevia. Considering that increases in
inﬂammatory markers such as tumor necrosis factor (TNF-α), interleukin-6 (IL-6), and
interleukin-1β (IL-1β) have been observed postprandially in people with metabolic
dysfunction [43] and in horses [46], as well as the prevalence of stevioside in the equine
market, it is of importance to understand its metabolic and inﬂammatory effects on normal
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and metabolic syndrome horses. Therefore, the experiment was designed not only to
measure the effects of the OST using both stevioside and karo on insulin and glucose
responses but also inﬂammatory responses in horses with EMS compared with non-EMS
controls.

2.2. Materials and methods
2.2.1. Horse selection and EMS determination
Eight EMS horses and 7 controls were selected from the University of Kentucky,
Department of Veterinary Science herd. EMS was deﬁned by the criteria established in the
2010 American College of Veterinary Internal medicine consensus statement [23]. In brief,
EMS was characterized by ID [12], general or regional adiposity, and a history of or
predisposition to laminitis. All EMS horses were predisposed to laminitis given their
increased adiposity and ID status, with 4 of the 8 selected EMS horses having a documented
history of laminitis. A portable agriculture scale (model 700, Tru Test Inc., Mineral Wells,
TX) was used to establish body weight, which was used to determine the amounts of stevia
and karo to administer to each horse for the OST. Body condition score was determined
and averaged between 3 trained investigators (S. E., M. M., and B. R.) using the 1 to 9
Henneke scoring system [186] with 1 representing an extremely emaciated animal and 9
representing an extremely obese animal. The same 3 trained individuals scored and
averaged neck crests via the 0 to 5 cresty neck score (CNS) system established by Carter
et al [187] with 0 representing no neck crest and 5 representing a crest so large it
permanently droops to one side of the neck. Blood collection for serum and plasma samples
was carried out via jugular venipuncture. To ascertain the presence of ID, the OST was
performed similar to previously described [13]. Brieﬂy, morning serum samples were
collected, and oral sugar was administered in the form of 0.15 mL/kg body weight of karo.
A second serum sample was collected 60 min post karo administration. A fasting insulin
level of > 20 μIU/mL was considered indicative of hyperinsulinemia, and an increased
insulin (> 60μU/mL) 60 min post administration of karo was considered diagnostic of ID
[188]. All OST sampling was performed between 8 AM and 12 AM for all sampling time
points. Horses were not fasted before sampling. Screening results from the OST along with
phenotypic data are presented in Tables 2.1 and 2.2. Of the 8 EMS horses, 3 were of mixed

14

breed, 1 was a Thoroughbred cross, 1 horse was a Paint, 1 a Morgan, 1 a Warmblood, and
1 a Standardbred cross. Of the 7 control horses, 4 were Thoroughbreds, 2 were of mixed
breed, and 1 was a Quarter Horse. Of the 7 control horses, 2 were of mixed breed, 4 were
Thoroughbreds, and 1 was a Quarter Horse.

Table 2.1. Characterization of EMS and non-EMS control horses.
(Insulin; μIU/mL)
60 min post oral
Group
sugar administration BCS
CNS
Wt (Kg)
EMS
75 ± 6
6.8 ± 0.3
3.0 ± 1.1
569 ± 88
Control
31 ± 4
6.4 ± 0.1
1.2 ± 1.0
610 ± 56
P-value
<0.001
0.278
0.009
0.307
Abbreviations: BCS, body condition score; CNS, cresty neck score; EMS, equine metabolic
syndrome; Wt, weight.
Italicized values represent statistical significance in the form of P values.
Table 2.2. Characterization of EMS and non-EMS control horses analysis on ranks.
Group
Baseline Serum (Insulin; μIU/mL)
Age
EMS
44 (95% CI: 26-51)
12 (95% CI: 10-13)
Control
16 (95% CI: 13-18)
14 (95% CI: 12-15)
P-value
<0.001
0.054
Abbreviations: EMS, equine metabolic syndrome.
Italicized values represent statistical significance in the form of P values.
Horses were also screened 1 mo before the start of study via thyrotropin releasing
hormone (TRH) stimulation and low-dose dexamethasone suppression testing [189, 190]
to ensure that none were affected by pituitary pars intermedia dysfunction (PPID). TRH
stimulation testing was carried out as previously described [191, 192] at least 2-wk before
the ﬁrst sampling time point, but no further than 2 mo before sampling. In brief, a baseline
blood sample (0800, EST) was taken via jugular venipuncture into EDTA containing tubes.
Following this, a 1 mL dose of TRH dissolved to 1 mg/mL in 0.9% saline (Sigma-Aldrich,
St. Louis, MO) was administered intravenously (IV). Ten min post TRH injection, a second
blood sample was taken. Tubes were kept on ice for transport to the laboratory and
immediately centrifuged and plasma isolated within 3 h after collection [193]. Samples
were stored at -20o C until shipped on dry ice to Cornell University for analysis of ACTH
concentrations. Low-dose dexamethasone suppression testing was also performed 2 days
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following TRH stimulation testing and was performed as previously described [194] and
within the same time frame relative to the start of the study as TRH stimulation testing. In
brief, a baseline jugular blood sample was taken (3:50 PM–6:00 PM), and an intramuscular
dexamethasone (Henry Schein, Dublin, OH) bolus (0.04 mg/kg BW) was administered
with a second blood sample taken 19 h later. A serum separator tube was used to collect
samples. Tubes were centrifuged, serum was isolated and frozen at -20o C until cortisol
analysis. Concentrations of ACTH 10 min after TRH injection in excess of 100 pg/mL or
concentrations of cortisol exceeding 1.0 µg/dL 19 h after dexamethasone injection were
considered positive for PPID. Any animals meeting these criteria were excluded.
Analysis of ACTH, cortisol, and insulin were performed by Cornell University’s
Animal Health Diagnostic Center Endocrinology Laboratory (Ithaca, NY). Serum insulin
concentrations were measured with a commercially available porcine insulin RIA (EMD
Millipore Corp, Billerica, MA) validated by Cornell University’s Animal Health
Diagnostic Center Endocrinology Laboratory for use on equine serum samples. Serial
dilutions of 3 equine samples with assay buffer were parallel to the standard curve, and
samples that were spiked with 4 different quantities of porcine insulin (Sigma-Aldrich, St.
Louis, MO, USA) had observed concentrations that averaged 91% of expected. The
manufacturer did not report the cross-reactivity of the RIA antibody for equine insulin.
However, the cross-reactivity for bovine insulin was reported as 90%, and the homology
between equine and porcine insulins (98%) is greater than the homology between bovine
and porcine insulins (96%). The sensitivity of the assay, as reported by the manufacturer,
is 1.61 IU/mL. The mean intra-assay and interassay coefﬁcients of variation were 3.9%
and 5.3%, respectively. ACTH concentrations were measured via an automated
chemiluminescent enzyme immunoassay system (Immulite, Erlangen, Germany [195], and
cortisol concentrations were determined using the Siemens Immulite Cortisol kit (Siemens,
Erlangen, Germany) [196].
Glucose analysis was performed by Cornell University’s Animal Health Diagnostic
Center Clinical Pathology Laboratory (Ithaca, NY) using a hexokinase kinetic method with
Roche reagents and the Hitachi P Modular from Roche (Roche Diagnostics, Indianapolis,
IN), with a 2 control intra-assay variation of 0.6% to 0.7% and interassay variation of
2.04% and 2.28%.
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2.2.2. Study design
To determine the effect of stevioside on the equine, 15 mixed breed and mixed sex
animals (8 EMS and 7 age-matched controls, all non-PPID) were selected. Horse
demographics are presented in Tables 2.1 and 2.2. Horses were maintained on an all forage
diet with access to minimal mixed-grass pasture and ad libitum access to mixed-grass hay,
a trace mineralized salt block, and water. They were housed at the University of Kentucky’s
Department of Veterinary Science’s facilities. An OST was performed in July of 2015 on
all horses, as previously described, but with the addition of a third blood sample taken 240
min after oral administration of either Karo corn syrup or stevioside (stevia). Blood
samples for metabolic and inﬂammatory parameters (as described in the following) were
collected concurrently at the 0, 60, and 240 min time points. Horses were provided either
0.15 mL/kg of karo or its stevioside equivalent in g stevia. For example, a 500 kg horse
would be administered 75 mL karo, which contains 25 g sugar. Therefore, a 500 kg horse
would receive 25 g of stevioside. The study was designed as a crossover with a 1-wk
washout period; therefore, each horse received both Karo corn syrup and stevioside. Horses
were randomly assigned to receive either karo or stevioside on week 1 vs week 2.
2.2.3. Peripheral blood processing for inflammatory cytokine production measured by
flow cytometry
Heparinized blood was used to isolate peripheral blood mononuclear cells
(PBMCs) by Ficoll-Paque PlusTM (Amersham Biosciences, Piscataway, NJ) gradient
centrifugation [197]. For in vitro stimulation, 4 x 106 PBMC in 1 mL c-RPMI (RPMI1640; Gibco, Grand Island, NY) supplemented with 2.5% fetal equine serum (FES; SigmaAldrich, St. Louis, MO), 100-U/mL penicillin/streptomycin (Sigma), and 55-mM 2mercaptoethanol (Gibco) media was incubated at 37o C, 5% CO2 with Brefeldin A (10
mg/mL; Sigma) and select wells with the positive control phorbol 12-myristate 13-acetate
(PMA; 25 ng/mL; Sigma) and ionomycin (1 mM; Sigma) for 4 h. Following this,
determination of cytokine gene expression was carried out by separating aliquots of the
cells and placing them into Trizol (Ambion) to isolate RNA (described in the following).
Remaining cells were assayed by ﬂow cytometry for IFN-γ and TNF-α production by the
following: cells were ﬁxed in 2% paraformaldehyde (Sigma) and stored overnight at 4o C.
After overnight storage, IFN-γ and TNF-α intracellular staining were carried out as
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previously described [198]. After the cells were stained, aliquots of cells were resuspended
in FACS ﬂow, and ﬂow cytometric acquisition was performed on a FACSCalibur (Becton
Dickinson, San Jose, CA). Determination of IFN-γ and TNF-α protein production by
lymphocytes was accomplished with the use of CELL QUEST (Becton Dickinson).
2.2.4. Inflammatory cytokine gene expression measured by real time-polymerase chain
reaction (RT-PCR)
A modiﬁed Trizol method was used to extract total RNA. One microgram of RNA
was reverse transcribed into cDNA as previously described [197]. In brief, 0.5 µg of each
RNA sample and a reverse transcription master mix (Promega, Madison, WI) were
incubated for 15 min at 42o C and for 5 min at 95o C. Five microliters of Master Mix
(SensiMix HI-ROX 2x, Bioline) and 4.5 µL of cDNA were combined with 0.5 µL of the
primer-probe of interest (TaqMan, Equine-speciﬁc, intron-spanning primers and probes;
Applied Biosystems). Samples were run using Applied Biosystems Real-Time PCR (ABI
Viia7) against the following genes: Housekeeping gene beta-glucuronidase (β-gus;
Ec0347-0630_m1), interferon gamma (IFN-γ; Ec03468606_m1), IL-6 (Ec03468678_m1),
IL-1β (Ec04260298_s1), TNF-α (Ec03467871_m1), and TLR4 (Ec03468994_m1) [199].
Samples were processed in duplicate and incubated for 95o C for 10 min. They then
underwent 10 cycles at 95o C for 15 s and 60o C for 60 s. Relative changes in gene
expression were determined by the CT method [200] with mean CT for time 0 set as
the calibrator for all samples. Relative quantity (RQ) was calculated as 2-CT and used to
express results.
2.2.5. Data analysis
Study data were analyzed using a 2-period crossover design with repeated measures
ANOVA. Analyses were completed using PROC MIXED, SAS 9.4 (SAS Institute Inc,
Cary, NC, USA). In a typical crossover design, the group is determined by the sequence in
which the treatment is applied. In this study, both EMS and control horses were in both
sequences. To accurately test sequence and EMS vs control, a group variable was created.
There were 4 groups based on period (week = 1 or 2), Stevia vs Karo, and EMS vs control.
The main effects of sequence (if the horse received karo vs stevia week 1) and EMS vs
control, as well as, the interaction of sequence x EMS vs control were tested using the error
term of Horse ID (Group). This model also included the main effects of period, Stevia vs
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Karo, and time (0, 60, and 240 min). The interactions included Stevia vs Karo x EMS vs
Control, time x EMS vs Control, time x Stevia vs Karo, and time x Stevia vs Karo x EMS
vs Control. Horse ID was the subject, and the repeated measure was set as time. Mauchly’s
Sphericity Test was used to test the form of the common covariance matrix. The sphericity
assumption was not violated; therefore, compound symmetry covariance structure was
selected. Pairwise comparisons were made using protected LSD. Only variables that found
signiﬁcant in the ANOVA were selected to apply pairwise comparisons. Screening data
were analyzed with Sigma Plot, version 12 (Systat Software, San Jose, CA) with a 1-way
ANOVA to compare EMS vs controls. For data not normal per Shapiro-Wilk testing, a
Kruskal-Wallis 1-way ANOVA on ranks was performed. Differences were considered
statistically signiﬁcant when P < 0.05.

2.3. Results
2.3.1. Metabolic responses
There was an observed EMS vs Control by time point interaction (P < 0.0001) for
serum glucose (Figure 2.1) with control horses at time point 60 higher compared with
control horses at time points 0 and 240. Control horses at time points 0 and 240 were lower
compared with EMS horses at all 3 time points. Control horses at time point 60 were not
different from EMS horses at time point 60. There was also a stevia vs karo by time point
interaction (P = 0.0001) with horses given karo lower at time points 0 and 240 compared
with time point 60 in horses given karo. Horses given karo were higher at time point 60
compared with all 3 time points in horses given stevia. Horses given stevia were not
different regardless of time point. There were also several overall differences observed.
EMS horses were higher compared with controls (P = 0.0033), horses given karo were
higher compared with those given Stevia (P = 0.0002), horses were higher at the 60 min
time point compared with time points 0 and 240 (P = 0.007), and horses were higher in
serum glucose concentrations during period 2 compared with period 1 (P = 0.0015).
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Glucose
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90
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65
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Control
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55

0

60
Time Point (min)

240

Figure 2.1. Serum glucose concentrations in EMS (n=8) and control (n=7) horses given
Karo corn syrup and stevioside at baseline (0) and after administration (60 and 240 min).
Differences (P < 0.05) within time point between EMS and non-EMS controls are
represented by (*). EMS, equine metabolic syndrome.
There was an observed 3-way EMS vs control by stevia vs karo by time point
interaction (P = 0.0073; Figure 2.2) for serum insulin. At time 0 control, horses given karo
were lower compared with time point 60 for control horses given karo, EMS horses given
karo, EMS horses given stevia, and time point 240 for EMS horses given stevia. At time
point 60, control horses given karo were higher compared with time point 240 for control
horses given karo, control horses given stevia at all time points, and time points 0 and 240
for EMS horses given karo. However, they were lower compared with time point 60 for
EMS horses given karo. At time point 240, control horses given karo were lower compared
with time point 60 for EMS horses given karo, and time points 60 and 240 for EMS horses
given stevia. Control horses given stevia at all time points were lower compared with time
point 60 for EMS horses given karo. At time point 240, control horses given stevia were
also lower compared with time points 60 and 240 for EMS horses given stevia. EMS horses
given karo were lower at time point 0 compared with time point 60 for EMS horses given
karo. At time point 60, EMS horses given karo were higher compared with time point 240
for EMS horses given and EMS horses given stevia for all 3 time points. No time point
differences were observed between control or EMS horses given stevia. Overall, horses
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given karo had higher serum insulin concentrations compared with those given stevia (P <
0.0001), and insulin was higher at the 60 min time point compared with time points 0 and
240 (P < 0.0001).

Insulin

Serum Insulin (µIU/mL)

40

*

EMS Karo

35

30

Control
Karo

25
20

*

*

EMS Stevia

15

10

Control
Stevia

5
0

60
Time Point (min)

240

Figure 2.2 Serum insulin concentrations in EMS (n=8) and control (n=7) horses given
Karo corn syrup and stevioside at baseline (0) and after administration (60 and 240 min).
Differences (P < 0.05) within time point are represented by (*). EMS, equine metabolic
syndrome.

2.3.2. Inflammatory cytokine production measured by flow cytometry
Flow cytometry results are presented in Figure 2.3. PBMCs stained intracellularly
for IFN-γ had several differences in both the percentage of lymphocytes producing IFN-γ
(% gated) and the mean ﬂuorescence produced per lymphocyte (MFI). There was an EMS
vs control by time point interaction (P = 0.0016) for IFN-γ % gated. Regardless of
administration of karo or stevia, control horses had a higher percent gated at time point 0
compared with control horses at time points 60 and 240. Control horses at time point 0
were also higher than EMS horses at time point 240. However, control horses at time points
60 and 240 were lower compared with EMS horses at time point 60 for IFN-γ % gated.
EMS horses at time point 60 were higher compared with EMS horses at time points 0 and
240. There was also an overall effect of period for IFN-γ % gated with horses higher period
1 compared with period 2 (P = 0.0346). IFN-γ MFI exhibited interactions between EMS
vs control by Stevia vs karo (P = 0.0355) and EMS vs control by time point (P = 0.0003).
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Regardless of administration of karo or stevia, control horses had a higher IFN-γ MFI at
time point 0 compared with control horses at all other time points as well as compared with
EMS horses at time points 0 and 240. Control horses at time points 60 and 240, however,
were lower compared with EMS horses at time point 60. EMS horses were higher at time
point 60 compared with EMS horses at time points 0 and 240 for IFN-γ MFI. No
differences were observed between EMS and control horses at time point 240. Overall,
IFN-γ MFI was lower in control horses given karo vs control horses given stevia.
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Figure 2.3. Flow cytometry results for PBMCs stained for IFN-γ and TNF-α in EMS (n=8) and control (n=7) horses given Karo corn
syrup and stevioside at baseline (0) and after administration (60 and 240 min). Differences (P < 0.05) within time point between EMS
and non-EMS controls are represented by (*). EMS, equine metabolic syndrome; PBMCs, peripheral blood mononuclear cells.

Results for TNF-α % gated and MFI were similar to those seen for IFN-γ. There
was an interaction between EMS vs control and time point (P < 0.0001) for TNF-α % gated.
Control horses given either karo or stevia were higher at time point 0 compared with control
horses at time point 60 and EMS horses at time points 0 and 240. Control horses at time
point 240 were also higher than EMS horses at time point 240. However, EMS horses at
time point 60 were higher compared with control horses at time point 60 as well as EMS
horses at time points 0 and 240. TNF-α MFI exhibited an EMS vs control by Stevia vs karo
interaction (P = 0.0402) with control horses given karo lower compared with controls given
stevia. In addition, there was an EMS vs control by time point interaction (P = 0.0001) with
control horses at time points 60 and 240 lower compared with EMS horses at time point
60 and EMS horses at time point 60 higher compared with EMS horses at time points 0
and 240. In addition, there was an overall effect of period, with horses higher in TNF-α %
gated and MFI in period 2 compared with period 1 (P = 0.0496).
2.3.3. Inflammatory cytokine gene expression measured by RT-PCR
PBMC gene expression results expressed as RQs and as measured by RT-PCR are
presented in Figure 2.4. Gene expression results followed a similar pattern as ﬂow
cytometry results. There were several interactions for IFN-γ RQ as well; EMS vs control
by time point (P < 0.0001), and EMS vs control by stevia vs karo (P = 0.0021). Control
horses at time point 0 had a higher IFN-γ RQ compared with control horses at time point
60 and EMS horses at time points 0 and 240 regardless of whether horses were given karo
or stevia. Control horses at time point 240 were higher compared with EMS horses at all
time points. However, control horses at time point 60 were lower compared with control
horses at time point 240 and EMS horses at time point 60. EMS horses at time point 60
were higher for IFN-γ RQ than EMS horses at time points 0 and 240. In addition, there was
an overall difference of IFN-γ RQ for EMS vs control (P = 0.0028) with EMS horses higher
compared with controls, and an overall stevia vs karo (P = 0.017) difference with horses
given stevia higher compared with those given karo.
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Figure 2.4. RT-PCR PBMC gene expression results in EMS (n=8) and control (n=7) horses given Karo corn syrup and stevioside at
baseline (0) and after administration (60 and 240 min). Differences (P < 0.05) within time point between EMS and non-EMS controls
are represented by (*). EMS, equine metabolic syndrome; PBMCs, peripheral blood mononuclear cells; RT-PCR, reverse transcription
PCR.

For IL-6 RQ, there was an interaction between EMS vs control by time point (P <
0.0001). Control horses given either karo or stevia were higher at time point 0 compared
with control horses at time points 60 and 240 and EMS horses at all time points. Control
horses at time point 60 were lower compared with control horses at time point 240. Control
horses at time point 240 were higher compared with EMS horses at time point 0. EMS
horses at time point 60 were higher compared with EMS horses at time points 0 and 240.
Overall, horses during period 1 had a higher IL-6 RQ compared with period 2 (P = 0.0117).
TLR-4 RQ results were similar to those for IL-6 RQ with an interaction between EMS vs
control by time point (P = 0.0282). Regardless of administration of stevia or karo, control
horses at time point 240 were lower compared with EMS horse at time point 0. EMS horses
at time point 0 were higher compared with EMS horses at time point 60. An overall period
effect was also observed for TLR-4 RQ, with horses higher in period with compared with
period 1 (P = 0.0277).
There was an interaction between EMS vs control and time point (P = 0.0231) for
TNF-α RQ. There were no differences in TNF-α RQ between horses given stevia or those
given karo. Control horses at time point 0 were higher compared with control horses at
time point 60 and EMS horses at time points 0 and 240. EMS horses at time point 60 were
higher compared with EMS horses at time point 240.

2.4. Discussion
Horses had expected glycemic and insulinemic responses to karo corn syrup with
an increase in insulin and glucose at time point 60 and with EMS horses having a greater
increase in insulin at time point 60 compared with controls.
Stevia is generally recognized as safe in humans [201] and is thought to decrease
circulating glucose concentrations by stimulating the pancreatic beta cells to release insulin
[184]. In this study, an oral bolus of stevioside produced a lower glycemic response when
compared with karo corn syrup. In horses given stevioside, there was no signiﬁcant
increase in serum glucose at time point 60 compared with time points 0 or 240 in contrast
to the marked rise in serum glucose in horses given karo. Although EMS horses had a
decrease in serum glucose at time point 60 when given stevia compared with an increase
when given karo, there was no signiﬁcant interaction between EMS vs controls and karo
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vs stevia. In addition, at time point 60, EMS horses given karo had higher serum insulin
concentrations compared with EMS horses given stevia at any time point. At time point
60, EMS horses given stevia had similar serum insulin concentrations compared with
control horses given karo, although control horses given karo were higher compared with
control horses given stevia. Glucose and insulin responses in horses to stevia at time 60
indicate that in horses, in particular those with metabolic dysfunction, stevia may provide
a protective effect on postprandial increases in these metabolic parameters. It is unlikely in
horses that stevia stimulates insulin release from the pancreas to the extent that it does in
rats [184], as increases in insulin at time point 60 in horses given stevia were signiﬁcantly
lower than those give karo. It is possible that stevia may induce an increased insulin
receptor sensitivity in horses with EMS; however, more work needs to be done to discover
possible explanations for differences in glucose and insulin responses to a glycemic
challenge with karo or stevia.
There were observed differences for the ﬂow cytometry analysis of IFN-γ and TNFα intracellularly stained PBMCs. Regardless of administration of either karo or stevia, EMS
horses had an increase in markers of inﬂammation at time 60, whereas control horses had
a decrease in these same markers of inﬂammation. Similar results were observed for PBMC
gene expression of inﬂammatory cytokines with EMS and control horses having
contrasting inﬂammatory responses to an OST. These data suggest that EMS horses have
an abnormal proinﬂammatory response to glycemic challenge when given karo or stevia.
Data on postprandial inﬂammation in humans and other species, in particular in those with
metabolic dysfunction are scarce. Most report an increase in systemic soluble adhesion
molecules, such as Intercellular Adhesion Molecule-1 (ICAM-1) in response to either a
high-fat meal or high-fat meal combined with glucose [43, 44]. Soluble adhesion molecules
are involved in the immune and inﬂammatory responses [202] and have been linked to
cardiovascular disease in humans [203, 204]. Some report an increase in adhesion
molecules or proinﬂammatory cytokines in both normal and diabetic subjects in response
to a meal with diabetic subjects having a signiﬁcantly greater increase compared with
normal controls [43, 45]. Others did not see this same increase [205], however, this may
be due to differences in meal type or carbohydrate complexity [206].
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In horses, most of the data regarding inﬂammation and glycemic and insulinemic
responses have been focused on either basal circulating or tissue inﬂammatory markers at
rest. Data have been somewhat conﬂicting with some groups showing increases in
inﬂammatory markers such as TNF-α [28] and serum amyloid A [40] and others showing
no differences between horses with ID and normal controls [31]. There has also been work
in the horse focused on oligofructose-induced laminitis models with whole-blood
inﬂammatory markers IL-1β, IL-8, and IL-10 increasing 8 h post induction of laminitis
[51] in 1 study and increases in IL-2, IL-6, IL-8, and IFN-γ noted at the onset of laminitis
in another study [18]. The available data regarding postprandial inﬂammation in the horse
are scarce but have shown postprandial rises in IL-1β in response to feeding a high sugar
high starch meal [46]. Increases in inflammatory markers following a meal may in part be
due to oxidative stress or, to increases in bacterial endotoxin concentrations. These
increases in inflammation appear to mirror the higher insulinemic responses in EMS horses
and may be a possible mechanism that predisposes these animals to the development of
laminitis. However, this remains to be further characterized.
Given these data, stevia appears to be well tolerated in EMS horses, considering
that stevia did not induce the same metabolic responses as karo corn syrup on challenge.
Thus, stevia may be a possible candidate as a non-glycemic sugar replacer in horses with
ID. Further work is needed to explore inﬂammatory effects of stevia in metabolically
normal animals and possible metabolically beneﬁcial effects in horses with EMS. Also,
these data reveal new questions about the response of EMS horses to an oral sugar
challenge, in particular with regard to postprandial inﬂammation.

Copyright © Sarah E. Elzinga 2017
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CHAPTER 3 COMPARISON OF THE FECAL MICROBIOTA IN HORSES WITH
EQUINE METABOLIC SYNDROME (EMS) AND METABOLICALLY NORMAL
CONTROLS FED A SIMILAR ALL FORAGE DIET
Journal of Equine Veterinary Science, 2016: 44, 9-16

Equine metabolic syndrome (EMS) is an ever-increasing problem in the equine
industry, especially considering that it is a risk factor for the development of laminitis.
Equine metabolic syndrome is similar to metabolic syndrome in humans, which has been
associated with alterations in intestinal microbiota. However, no work to date has been
published to characterize the fecal microbiota in the EMS horse to determine differences,
if any, from the metabolically normal animal. Therefore, our objective was to characterize
the fecal microbiota of horses with EMS compared with non-EMS controls. Ten horses
were classified as having EMS, and 10 non-EMS controls were selected for this work.
Equine metabolic syndrome was determined as: insulin resistance, general or regional
adiposity, and a history of or predisposition to laminitis. Blood collection via jugular
venipuncture was performed, along with an oral sugar challenge. Concurrent with blood
collection, phenotypic measurements and fecal grab samples were taken. Fecal samples
were used to extract DNA for next generation sequence-based analysis of the bacterial
microbiota. Equine metabolic syndrome horses exhibited a decrease in fecal microbial
diversity, and there were differences in overall community structure between EMS horses
and controls. The operational taxonomic unit with the highest linear discriminant analysis
effect size in association with EMS horses was a member of subdivision 5 of
Verrucomicrobia incertae sedis (uncertain classification). Interestingly, the control group
had an overrepresentation of genus Fibrobacter. These data demonstrate that EMS horses
have differences in their fecal microbiota compared with controls.

3.1. Introduction
Horse are hindgut fermenters and as such, their gut microbiota is predominantly
populated by bacteria from the phyla Firmicutes [64, 67]. However, even in healthy horses,
the gut microbiota is naturally highly diverse and highly variable. It is influenced by factors
such as diet, age, and individual variation [64-66]. Disease states in particular can have a
significant impact on the gut bacterial population in the animal. For example, there is

29

evidence that a high-starch diet may increase the abundance of certain taxa from the family
Veillonellaceae [70]. In addition, horses with chronic laminitis have differences in both
microbiota abundance and diversity compared with controls [72], and the microbiota has
significant changes in abundance during the onset of laminitis [73, 74].
Insulin resistance, general or regional adiposity, and a history of or predisposition
to laminitis are the three main characteristics associated with equine metabolic syndrome
(EMS) [23]. Equine metabolic syndrome is considered to be especially concerning to the
equine population considering its connection to laminitis, which can result in inability for
the animal to resume normal work or even euthanasia. Equine metabolic syndrome is
comparable to metabolic syndrome (MetS) in humans, which is associated with similar
factors, such as visceral obesity, glucose intolerance, and dyslipidemia [207-209].
In humans and mice, MetS and obesity have been linked to alterations in the
intestinal microbiota [77]. It has been shown in high fat–fed mice that bacterial
lipopolysaccharide (LPS) endotoxemia can induce inflammation and insulin resistance
[61], both of which are considered to be influential in the pathophysiology of MetS [210].
Furthermore, age-related changes in the gut microbiota of mice have resulted in increased
plasma LPS concentrations and a subsequent increase in markers of inflammation,
indicating that shifts in the microbiota may play a major role in inducing low-grade
systemic inflammation [83]. Studies in humans have shown that dietary changes can have
a positive impact on the gut microbiota by reducing LPS producing bacteria and are
proposed as a possible therapeutic target for individuals with metabolic dysfunction [84,
85]. However, no data to date have been presented exploring possible differences in the
gut microbiota of horses with EMS compared with metabolically normal controls, nor what
impact these differences may have on the pathophysiology of the syndrome.
Investigation into the mechanisms and factors contributing to EMS is becoming
increasingly important considering its negative health consequences in these horses, in
particular, the increased risk of laminitis. Therefore, the objective of this study was to
investigate and characterize the fecal microbiota of horses with naturally occurring EMS
compared with metabolically normal non-EMS controls.
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3.2. Materials and Methods
3.2.1. Horse Selection and Sample Collection:
Twenty horses of mixed gender and breed were selected on the basis of EMS
criteria as defined in the following section from the University of Kentucky’s Department
of Veterinary Science herd in the spring of 2014. Of these horses, 10 were classified as
EMS, and 10 were classified as non-EMS controls. There was no significant difference in
age between EMS and control horses (P = .903). All horses were housed at the University
of Kentucky’s Main Chance or Woodford farm facilities, maintained on a similar all forage
diet of free choice mixed bluegrass, orchard and fescue hay (Table 3.1), and minimal
pasture of a similar mixed grass type, and had access to water and a mineral block ad
libitum. Horses were acclimated to their respective pastures for at least 2 months before
sampling. All materials and methods were approved by the Institutional Care and Usage
Committee of the University of Kentucky.
Table 3.1. Nutrient composition of mixed grass hay.
Component
As fed
Dry Matter
% Moisture
7.8
% Dry Matter
92.2
% Crude Protein
7.6
8.3
% Adjusted Crude Protein
7.6
8.3
% Acid Detergent Fiber
43.0
46.6
% Neutral Detergent Fiber
63.9
69.3
% NFC
15.8
17.1
% TDN
52.0
56.0
NFL, Mcal/Lb
0.41
0.44
NEM, Mcal/Lb
0.45
0.48
NEG, Mcal/Lb
0.21
0.23
Relative Feed Value
71
% Calcium
0.39
0.43
% Phosphorus
0.26
0.28
% Magnesium
0.13
0.14
% Potassium
1.65
1.79
% Sodium
0.0005
0.005
PPM Iron
427
463
PPM Zinc
17
18
PPM Copper
7
7
PPM Manganese
92
100
PPM Molybdenum
0.5
0.6
Horse DE, Mcal/Lb
0.80
0.86
Nutrient composition of mixed grass hay fed to all horses ad libitum. Analysis provided by
Dairy One Forage Testing Laboratories (Ithaca, NY).
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Equine metabolic syndrome was determined by the following criteria from the 2010
ACVIM consensus statement by Frank et al [23]: insulin dysregulation, general or regional
adiposity, and a history of or predisposition to laminitis. To ascertain the presence of
insulin dysregulation, an oral sugar test was performed after overnight fasting as previously
described [13]. A fasting insulin level of >20 μIU/mL was considered indicative of
hyperinsulinemia, and an increased insulin (>60 μIU/mL) 60 minutes after administration
of oral sugar (Karo corn syrup) was defined as insulin resistance [13, 23]. The presence of
either hyperinsulinemia or insulin resistance was considered positive for insulin
dysregulation. Obesity and adiposity were determined by body condition score (BCS) and
cresty neck score (CNS). Body condition score was established using the 1 to 9 Henneke
scoring system [186], and CNS was determined via the 0-5 system established by Carter et
al [187]. For both BCS and CNS, three trained investigators scored the animals, and theses
scores were averaged to determine final BCS and CNS. Individuals scoring were blinded
to which horses were positive for insulin dysregulation. Equine metabolic syndrome was
defined as having increased adiposity with a BCS of 6.5 or above or a CNS greater than
2.5. All EMS horses had a history of or predisposition to laminitis. Insulin, BCS, and CNS
data are presented in Table 3.2.

Table 3.2. Characterization of phenotypic measures in equine metabolic syndrome (EMS)
versus non-EMS control horses.
Basal Insulin
Post oral sugar
Group
BCS
CNS
(µIU/mL)
Insulin (µIU/mL)
EMS
7.13 ± 0.15
3.57 ± 0.27
33.85 ± 2.66
63.26 ± 5.29
Control
5.85 ± 0.23
1.95 ± 0.18
13.03 ± 1.46
26.11 ± 3.77
P value
<.001
<.001
<.001
<.001
Average body condition score (BCS) and cresty neck score (CNS), and basal insulin and
insulin 60 min post oral sugar administration in n = 10 EMS and n = 10 non-EMS control
horses. Results are represented as the mean plus or minus the standard error of the mean.
All animals were also examined to ensure that none were affected by pituitary pars
intermedia dysfunction (PPID) by conducting thyrotropin-releasing hormone (TRH)
stimulation and low-dose dexamethasone suppression testing. Thyrotropin-releasing
hormone stimulation testing was accomplished similar to previously described [191, 192].
In brief, a morning baseline blood sample was taken via jugular venipuncture after which
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1-mL IV dose of TRH dissolved to 1 mg/mL in 0.9% saline (Sigma-Aldrich, St. Louis,
MO) was administered. Ten minutes after TRH injection, a second blood sample was
collected. Blood samples were collected in EDTA-containing tubes, placed on ice, and
transported to the laboratory for immediate centrifugation for plasma isolation [193].
Plasma was stored at -20oC and shipped on dry ice to Cornell University for analysis of
adrenocorticotropic hormone (ACTH) concentrations.

Low-dose dexamethasone

suppression testing was performed as previously described [194] by taking an afternoon
(3:50 PM–6:00 PM) baseline jugular blood sample, administering an intramuscular
dexamethasone bolus (0.04 mg/kg BW), and taking a second blood sample 19 hours later.
Samples were collected in a gel serum separator tube and serum isolated and frozen at 20oC until cortisol analysis. Adrenocorticotropic hormone concentrations 10 minutes after
TRH injection >100 pg/mL or cortisol concentrations in excess of 1.0 μg/dL 19 hours after
dexamethasone injection were considered indicative of PPID and any positive animals
excluded. All blood samples were sent to Cornell University’s Animal Health Diagnostic
Center Endocrinology Laboratory for determination of insulin, ACTH, and cortisol
concentrations. Insulin was measured using the Millipore Porcine Insulin RIA Kit (EMD
Millipore

Corporation,

Darmstadt,

Germany),

ACTH

using

an

automated

chemiluminescent enzyme immunoassay system (Immulite, Erlangen, Germany) [195],
and cortisol using Siemens Immulite Cortisol kit (Siemens, Erlangen, Germany). All blood
samples and phenotypic measures for all horses were collected within a period of 2 weeks
in the spring of 2014.
3.2.2. DNA extraction and 16s rRNA gene PCR
DNA was extracted from fecal samples using a commercial kit (E.Z.N.A. Stool
DNA Kit, Omega Bio-tek Inc, Doraville, GA), according to manufacturer’s instructions.
Quantity and quality of DNA were assessed by spectrophotometry (NanoDrop; Roche,
Mississauga, Canada), the V4 region of the 16S rRNA gene was amplified [211], and
amplicons were sequenced by Illumina MiSeq (San Diego, CA). Sequence files are
available

at

the

University

of

Guelph

Research

http://dx.doi.org/10.5887/ UGRDR/10864/XER6B.
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Data

Repository,

DOI:

3.2.3. Data Analysis
Phenotypic data (insulin, BCS, and so forth) were analyzed by SIGMAPLOT
version 12.3 (Systat Software Inc). A mixed model one-way analysis of variance was used
for each quantitative variable and ordinal data analyzed via the Wilcoxon Mann-Whitney
test. One EMS horse’s CNS was not collected and thus not included in the analysis. Fixed
effects were set as EMS versus control. Data were normally distributed and of equal
variance. Data were considered statistically significant when P < .05.
Microbiota data were analyzed using the open-source platform mothur (v1.35)
[212]. Initial sequence processing involved aligning paired-end reads, with a series of
quality control steps to remove sequences that contained any ambiguous base calls, were
not consistent with the target amplicon size (240 bp), contained holopolymers > 8 bp in
length, or did not align with the correct 16S rRNA gene region. Chimeras were identified
using UCHIME [213] and removed. Taxonomy was assigned using the Ribosomal
Database Project taxonomy database (http://rdp.cme.msu.edu/index.jsp).
Subsampling was performed to normalize sequence numbers by random selection of
number of sequences from each sample that corresponded to the sample with the smallest
number of sequences. Comparison of the relative abundances of taxa between groups was
done by linear modeling using robust (Huber) estimation to down-weight outliers, with P
values that were adjusted for false discovery rate using the Benjamini–Hochberg technique.
Alpha diversity was calculated using Chao1 richness, inverse Simpson’s diversity, and
Shannon’s evenness tests and compared using Wilcoxon test or Steel–Dwass test. A P
value of <.05 was considered significant.
Sequences were binned into phylotypes, and subsampling was performed to
normalize sequence number for subsequent analyses [214]. Dendrograms for community
membership (classical Jaccard index, a measure of shared OTUs) and structure (Yue and
Clayton index of dissimilarity, which considers shared OTUs and their relative
abundances) were created and compared using unifrac and analysis of similarity
(ANOSIM). Community membership and structure were also visualized using principal
coordinate analysis. Linear discriminate analysis effect size (LEfSe) [215] was used to
identify overrepresented OTUs between horses with metabolic disease and controls.
Samples were also evaluated using the Dirichlet multinomial mixtures method for
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probabilistic modeling [216] to determine the number of different metacommunities
(enterotypes) that they could be assigned to, with the K value that derived the minimum
Laplace approximation indicating the number of different metacommunities. The observed
learning technique, random forests [217], was used to determine whether a set of predictive
features could be used to accurately identify samples from EMS versus control groups.
Phylogenetic Investigation of Communities by Reconstruction of Unobserved
States (PICRUSt) [218] was used to predict the relative abundance of predicted Kyoto
Encyclopedia of Genes and Genomes biochemical pathways and ortholog groups, and
those were compared between horses with metabolic disease and controls using LEfSe.

3.3. Results
At the time of sampling, EMS horses were aged 13 ± 5 years (range 8–20 years),
and non-EMS controls were aged 13 ± 3 years (range 10–19 years). Equine metabolic
syndrome horses had greater values for fasting insulin, insulin 60 minutes after oral sugar
administration, BCS, and CNS compared with controls (Table 3.2).
From the fecal samples analyzed for fecal microbiota differences, sequence
processing and filtering yielded a total of 1,446,359 sequences (mean 72,318/sample,
median 73,371.5, standard deviation 30,815.5, and range 11,491- 137,462). Subsampling
of 11,491 sequences per sample was performed to normalize data. There were no
differences in estimated richness (P = 97), observed richness (P = 79), or evenness (P =
12) between groups; however, diversity was lower in EMS horses (median 6.3 vs. 7.1, P =
026, Figure 3.1).
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Figure 3.1. Intestinal microbiota diversity in equine metabolic syndrome (EMS) versus
non-EMS control horses. Intestinal microbiota diversity as represented by an inverse
Simpson’s index in n = 10 EMS and n = 10 non-EMS control horses.

Based on unifrac analysis, there was a significant difference in community structure
between groups (P = 011, Figure 3.2), with no difference in membership (P = 33, Figure
3.3). A significant difference in community structure was also identified with ANOSIM (P
= 012), whereas the difference in membership approached significance (P = 056).
However, the differences that were present were not to the degree that samples would be
assigned to two different metacommunities. Similarly, random forest modeling was poorly
predictive of group membership, with an error rate of 55%.
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Figure 3.2. Bacterial population structure in equine metabolic syndrome (EMS) versus non-EMS control horses. Representation of
bacterial population structure as measured by Yue & Clayton similarity coefficient in n = 10 EMS and n = 10 non-EMS control horses.
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Figure 3.3. Bacterial membership for equine metabolic syndrome (EMS) versus non-EMS
control horses. Intestinal microbiota membership as measured by a Jaccard index in n = 10
EMS and n = 10 non-EMS control horses.

No significant differences in relative abundances of different phyla were identified
after correction of P values for false discovery rate. Similarly, no significant differences
remained in lower taxonomic orders after correction of P values. Predominant genera are
displayed in Figure 3.4. However, 12 OTUs were significantly different based on LEfSe
(Figure 3.5). No significant differences in predicted functional capacity of the microbiota
were identified by LEfSe analysis of PICRUSt data.
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Figure 3.4. Microbiota genera in equine metabolic syndrome (EMS) versus non-EMS
control horses. Comparison of the most common genera in the fecal microbiota and their
relative abundance in n = 10 EMS and n = 10 non-EMS control horses.
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Figure 3.5. Linear discriminate analysis effect size (LEfSe) analysis in EMS versus nonEMS control horses. Over-represented OTU’s as identified by LEfSe in n = 10 EMS and n
= 10 non-EMS control horses.

3.4. Discussion
As expected, horses with a naturally occurring form of EMS had significantly
greater measures of insulin resistance and obesity compared to a matched population of
controls, considering these were the criteria used to establish the presence of EMS versus
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control. The fecal microbiota of horses with EMS also differed from those of the controls.
Although differences in individual taxa were limited, there were changes in community
structure, an overall measure of the components of the microbiota, and their relative
abundances. There was not a corresponding difference in community membership,
although some results did approach significance. A difference in community structure but
not membership implies alterations in relative abundances of a relatively conserved
microbiota composition, such as might be present when some members are overgrown or
depleted in the community but are still present. This suggests that EMS does not result in
significant differences in bacteria colonization in the intestinal tract but can have an impact
on their relative abundances, resulting in overgrowth or decreased growth of different
members.
Despite the differences in community structure, direct comparison of relative
abundances did not identify specific taxa that were differentially abundant. Yet numerous
differences were identified by LEfSe. Closer evaluation of these groups raises some new
questions and hypothesis. The OTU with the highest LDA score in association with EMS
horses was an incertae sedis (uncertain classification) member of subdivision 5 of
Verrucomicrobia. Verrucomicrobia is an interesting phylum that is getting increasing
attention in obesity and metabolic disease. Akkermansia is a genus of mucin-degrading
bacteria belonging to this phylum that helps maintain the integrity of the mucin layer and
decrease inflammation [219]. Increases in this genus have been shown to improve glucose
homeostasis in obese mice [220]. Similarly, normalization of Akkermansia in obese mice
improved metabolic profiles, potentially through crosstalk between microbiota and host
[219]. In minipigs with diet-induced obesity, Verrucomicrobia was increased compared
with lean counterparts [78], and in humans, Akkermansia muciniphila abundance has been
inversely associated with fasting glucose, waist-to-hip ratio, and subcutaneous adipose
measures [221]. Verrucomicrobia abundance has been suggested as a microbial biomarker
for the progression of glucose intolerance based on higher levels in newly diagnosed
individuals, versus those with normal glucose control or prediabetes [222]. Therefore, it is
possible that the increase in Verrucomicrobia noted here could be an adapted, protective
effect of the microbiota in response to MetS- or EMS-associated obesity.
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Fibrobacter was overrepresented in the control group. This genus of cellulolytic
bacteria is most commonly identified in ruminants and hindgut fermenters, and it
presumably plays an important role in digestion in horses. This genus has been identified
as a component of the core microbiota in horses [223], with numbers increasing as foals
age [224]. Decreased representation of this genus in horses with EMS that were on the
same hay-based diet as control horses was interesting. Fibrobacter is a relatively acidintolerant genus that has been reported (along with Ruminococcaceae, which were also
associated with controls) to decrease concurrent with increases in lactic acid bacteria after
dietary change and intestinal disease [225]. Thus, the association of Lactobacillus with
EMS horses could be a possible explanation for the underrepresentation of Fibrobacter in
that group. Although the individual roles of this, and other, members of the microbiota are
difficult to assess given the relatively limited research, certain groups tend to be recurrently
associated with “gut health.” Particular attention is now being paid to Ruminococcaceae
and Lachnospiraceae, members of the Clostridiales order [68, 69]. These butyrateproducing bacteria are often associated with intestinal health, with decreases associated
with various disease states. For example, recent studies in horses have identified decreases
in Clostridiales in horses with colitis [75], and in mares shortly before the onset of colic
[76]. In the present study, two Ruminococcaceae (Ruminococcus, Saccharofermentans)
and one Lachnospiraceae were associated with the control group, whereas only one
(Cellulosilyticum) was associated with EMS horses. These results may provide potential
links between alterations in gut microbiota, inflammation, and metabolic dysfunction.
However, further work is warranted to explore these connections and to establish if changes
in the gut microbiota in EMS horses contribute to inflammation, which in turn leads to
insulin and glucose dysregulation or if the reverse is more likely.
A decrease in microbial diversity was also identified in EMS horses. Optimal values
for diversity are poorly understood. Increasing diversity probably provides some benefits
because the community may have a broader functional potential and greater ability to
respond to alterations. However, ultimate diversity (all members of the community are
different) is not desirable, and some members of the community should be present in higher
levels because they perform important functions (e.g., cellulolytic bacteria). Lower
diversity in EMS horses identified here could be of concern as decreased diversity has been
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reported in association with obesity in humans [79], dogs [80], and in horses in response
to antimicrobial administration [81] and diet change [69].
No differences in predicted functional capacity of the microbiota were identified
by PICRUSt. This is perhaps not surprising given the relatively limited taxonomic
differences that were noted (as PICRUSt is a predictive model based on taxa) and the small
sample size. Further study of microbiota function through larger studies, either through
inferred function or more specific identification of functional capacity through shotgun
sequencing approaches is needed.
Small sample size is one limitation of this study, and the presence of identifiable
differences indicates that broader studies should be undertaken. This study (similar to most
microbiota studies) involved feces, not contents from different intestinal locations. Feces
have been shown to be a good proxy for colon and to a lesser degree cecum [68], but these
data may not accurately reflect the composition of more proximal regions. There are also
potential impacts of various factors such as geography, management, diet, age, and a range
of other exogenous influences. Although the use of farm-matched controls limits the impact
of these on the analysis, it must be remembered that these data might only reflect horses
under similar management.

3.5. Conclusion
This preliminary study identified differences in the microbiota of horses with EMS
compared with non-EMS control horses. Although the differences were limited, changes
that were present could influence health and be associated with some of the clinical
characteristics of EMS. Understanding the impact of microbiota alterations and factors that
influence these changes may be important for optimizing management of this common
syndrome in horses.

Copyright © Sarah E. Elzinga 2017
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CHAPTER 4 PLASMA LIPIDOMIC AND INFLAMMATORY CYTOKINE
PROFILES OF HORSES F HORSES WITH EQUINE METABOLIC SYNDROME
Journal of Equine Veterinary Science, 2016: 40, 49-55

Equine metabolic syndrome (EMS) is a growing problem in the equine industry,
particularly considering it is a risk factor for the development of laminitis. Equine
metabolic syndrome is similar to metabolic syndrome in humans, which is associated with
abnormal circulating plasma lipid concentrations. Thus, our objectives were to characterize
the plasma lipid profiles, or lipidome, of horses with EMS compared to non-EMS controls
and to further characterize the inflammatory state of these horses. Twenty-three horses of
mixed breed and sex were selected. Of these, 14 were classified as EMS and 9 as non-EMS
controls. Equine metabolic syndrome was determined by insulin resistance, general or
regional adiposity, and a history of or predisposition to laminitis. Fasting serum and plasma
samples were collected via jugular venipuncture. Serum samples were used to determine
insulin, leptin, triglyceride, cholesterol, and nonesterified fatty acid concentrations.
Heparinized plasma samples were used to isolate peripheral blood mononuclear cells for
inflammatory cytokine determination and ethylenediaminetetraacetic acid plasma to
analyze lipidomes. Equine metabolic syndrome horses had increased serum leptin and
triglycerides. Plasma lipidomic analysis indicated that EMS horses had elevated
triacylglycerides, diacylglycerides, monoacylglycerides, and ceramide compared to control
horses. They had lower plasma sphingomyelins, suflatide, and choline plasmalogens.
Peripheral blood mononuclear cell analysis for cytokine protein concentration via flow
cytometry and gene transcription via real-time polymerase chain reaction showed no
differences between the two groups; however, high variability may have influenced results.
These data demonstrate that EMS horses have differences in their plasma lipidome
compared to controls, similar to what has been observed in humans with metabolic
syndrome.

4.1. Introduction
Obesity rates are rising not only in the human population, but in equids as well [2,
3, 7, 49]. Increased adiposity is one of the defining characteristics of equine metabolic
syndrome (EMS). Equine metabolic syndrome was classified in 2010 in an ACVIM
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consensus statement as insulin resistance, general, or regional adiposity and a history of or
predisposition to laminitis [13, 23]. Equine metabolic syndrome is similar to metabolic
syndrome (MetS) in humans, which is categorized by three or more of the following:
visceral obesity, hypertriglyceridemia, glucose intolerance, low high-density lipoprotein
cholesterol, or hypertension [207, 208].
Increased inflammation as well as altered lipid profiles have been associated with
obesity in humans and mice [139, 226, 227]. Considering that abnormal lipid profiles may
be a contributing factor to altered cell signaling or increased inflammation [139], as well
as the influence of certain lipids on insulin resistance [140, 228], it is becoming
increasingly important to examine possible connections between plasma lipid profiles, or
lipidomes, and metabolic dysfunction. Lipidomic analysis is a relatively new field, but is
providing promising new avenues for exploring questions related to metabolic dysfunction
[108].
In humans, over 600 diverse molecular species make up the plasma lipidome [229].
It can be categorized into six primary mammalian lipid categories: fatty acyls, prenols,
sterols, sphingolipids, glycerophospholipids, and glycerolipids. Changes in lipidome
composition may affect human health [229, 230]. Differences in plasma lipidomes have
been observed in humans and mice that experience obesity or hypertension. For example,
changes in ether lipid or plasmalogen concentrations have been shown to be associated
with atherogenic status and hypertension [231-233]. In particular, decreases in plasma ether
phosphatidylethanolamines and phosphatidylcholines are indicative of hypertension in
middle aged men [230] and patients with coronary artery disease with significant stenosis
had a decrease in serum choline plasmalogens compared to patients without significant
stenosis [232]. Additionally, differences in lipid composition between individuals who
exercise regularly and those who consume a high fat diet have been demonstrated [125].
Research is also indicating a role of the immune response in lipid metabolism. The
immune system has been shown to have the ability to recognize lipids as antigens [127].
One notable instance of this is the stimulation of T lymphocytes by CD1 antigen-presenting
cells. CD1 cells recognize both foreign and self-lipids, such as phosphoglycerolipids and
glycosphingolipids as stimulatory antigens [127-129]. Likewise, elevated levels of certain
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lipids have been shown to impact cell signaling, including activation of NF-κB and
programmed cell death [234-236].
Work in humans and mice has allowed for analysis of the lipidome in obese,
hypertensive, or normal individuals, as well as those with metabolic dysfunction [112,
115]. However, no published work has been done to classify the lipidome of horses with
EMS. Existing data in the horse have allowed for characterization of EMS and explored
connections to laminitis, but have yielded conflicting results, particularly in regards to
inflammation [31]. Some studies have shown differences in inflammatory cytokines such
as gene expression of interleukin 1β (IL-1β) and IL-6 in equine nuchal adipose tissue in
EMS horses versus controls [41], and an increase in circulating plasma and serum
concentrations of tumor necrosis factor alpha (TNF-α) in horses with EMS [28] as well as
in ponies with a history of pasture associated laminitis [237]. However, others have shown
a trend for circulating plasma TNF-α concentrations to be lower in obese horses compared
to controls as well as a decrease in gene expression of IL-1β and IL-6 in the peripheral
blood mononuclear cells (PBMCs) of obese horses [31]. Conflicting results may in part
stem from the fact that many studies were carried out on ponies or on horses with an
induced form of hyperinsulinemia [28, 237]. Not only that, but it is unclear if many were
tested for confounding factors, such as pituitary pars intermedia dysfunction (PPID), which
can influence insulin/glucose dynamics.
Considering the negative effects of obesity and insulin dysregulation, in particular
the increased risk of laminitis in horses, it is important to examine contributing mechanisms
to the disorder. Thus, the objective of this study was to investigate and characterize the
plasma lipidome as well as the inflammatory status of horses with naturally occurring EMS
compared to non-EMS controls.

4.2. Materials and Methods
4.2.1 Horse Selection and Sample Collection
Twenty-three horses of mixed sex and breed were selected from the University of
Kentucky’s Department of Veterinary Science herd. Of these horses, n = 14 were classified
as EMS (mean 13 ± 4 years) and n = 9 were non- EMS controls (mean 13 ± 3 years). There
was no significant difference in age between EMS and control horses. Of the horses
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classified as EMS, three were Standardbred or Standardbred crosses, three of mixed breed,
and three were paints. In addition, one EMS horse was a Morgan, one a draft, one a
warmblood cross, one a Walking horse, and one a Thoroughbred. Of the control horses,
two were Quarter horses, three were Thoroughbreds, and four were of mixed breed. Ten of
the 14 EMS horses were mares and four geldings. Seven of the controls were mares, and
the remaining two were geldings. All horses were housed at the University of Kentucky’s
Main Chance or Woodford farm facilities, maintained on a similar all forage diet of free
choice mixed grass hay and minimal pasture, and had access to water and a mineral block
ad libitum. Horses were acclimated to their respective pastures for at least 2 months before
sampling. All materials and methods were approved by the Institutional Care and Usage
Committee of the University of Kentucky.
Equine metabolic syndrome was determined by the following criteria from the 2010
ACVIM consensus statement, insulin dysregulation, general or regional adiposity, and a
history of or predisposition to laminitis. To ascertain the presence of insulin dysregulation,
an oral sugar test was performed following overnight fasting. In brief, fasting serum sample
collection was followed by PO administration of 0.15 mL/kg of Light Corn syrup (Karo;
ACH Food Companies, Cordova, TN) and a second serum sample collected 1 hour later
[13, 23]. All blood collection was carried out via jugular venipuncture. After
centrifugation, aliquots of serum samples were kept at -20oC until analysis. A fasting
insulin level of >20 µIU/mL was considered indicative of hyperinsulinemia, and an
increased insulin (>60µU/mL) 60 minutes post administration of oral sugar was defined as
insulin resistance [13, 23]. The presence of either hyperinsulinemia or insulin resistance
was considered positive for insulin dysregulation. Obesity and adiposity were determined
by body condition score (BCS) and cresty neck score (CNS). Body condition score was
established and averaged between three trained investigators using the 1 to 9 Henneke
scoring system [186] with a 1 representing an extremely emaciated animal and a 9
representing an extremely obese animal. Investigators were blinded to which horses were
positive for insulin dysregulation. The same trained individual’s scores were averaged for
CNS via the 0 to 5 system established by Carter et al [187], with a 0 representing no neck
crest and a 5 representing a crest so large it permanently droops to one side of the neck.
Equine metabolic syndrome was defined as having increased adiposity with a BCS of 6.5
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or above or a CNS greater than 2.5. Equine metabolic syndrome horses also had a known
history of or predisposition to laminitis. Body condition score and CNS scores, as well as
insulin values from the oral sugar challenge are presented in Table 4.1.

Table 4.1. BCS, CNS, basal insulin, and insulin post glycemic challenge in horses with
EMS and controls.
Phenotypic measure
Control
EMS
P value
BCS
5.9 + 0.3
6.9 + 0.2
.025
CNS
2.0 + 0.3
3.2 + 0.3
.015
Basal Insulin (uIU/mL)
13.9 + 2.5
35.5 + 1.9
<.001
Post Sugar Insulin (uIU/mL)
24.3 + 6.1
72.2 + 4.6
<.001
Abbreviation: EMS, equine metabolic syndrome.
Data are presented as least square means, mean + standard error of the mean. n=9 controls
and n=14 EMS. BCS (body condition score) and CNS (cresty neck score) are presented as
an average condition score between 3 trained individuals.
All animals were also examined to ensure that none were effected by PPID by
conducting

thyrotropin-releasing

hormone

(TRH)

stimulation

and

low-dose

dexamethasone suppression testing. TRH stimulation testing was accomplished similar to
previously described [191, 192] by taking an aseptic baseline blood sample, administering
a 1 mg IV dose of TRH dissolved to 1 mg/mL in 0.9% saline (Sigma-Aldrich, St. Louis,
MO) and taking a second sample 10 minutes following TRH injection. Samples were
collected in ethylenediaminetetraacetic acid tubes, stored immediately on ice for transport,
and centrifugation [193]. Plasma aliquots were removed and then stored at _20o C until
shipped on dry ice to Cornell University Animal Health Diagnostic Center’s Endocrinology
Laboratory. Low-dose dexamethasone suppression testing was performed similar to
previously described [194] by taking an afternoon (15:50–18:00 hours) baseline sample,
administering 0.04 mg/kg BW dexamethasone bolus IM and taking a second sample 19
hours later. Samples were collected in a gel serum separator tube and frozen at_2o C until
cortisol analysis. ACTH concentrations 10 minutes post-TRH injection >100 pg/mL and
cortisol concentrations in excess of 1.0 µg/dL 19 hours following dexamethasone injection
were considered indicative of PPID and any positive animals excluded. Samples were sent
to Cornell University’s endocrinology laboratory for determination of insulin, ACTH, and
cortisol concentrations. Insulin was measured using the Millipore porcine insulin RIA kit
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(EMD Millipore Corporation, Darmstadt, Germany), ACTH using an automated
chemiluminescent enzyme immunoassay system (Immulite, Diagnostic Products
Corporation, Los Angeles, CA) [195], and cortisol using Siemens Immulite Cortisol kit
(Siemens, Washington, D.C.). All samples and phenotypic measures were collected within
a period of 2 weeks in the spring of 2014.
4.2.2. Lipid and plasma lipidome analysis
Determination of fasting serum triglyceride, leptin, cholesterol, and nonesterified
fatty acid (NEFA) concentrations were accomplished by Cornell University’s
endocrinology laboratory. Leptin analysis was carried out using the Millipore Multispecies
Leptin RIA (EMD Millipore Corporation) and triglycerides, cholesterol, and NEFA
determined using colorimetric assays with a Roche ModP chemical analyzer (Roche
Diagnostics, Indianapolis, IN). Plasma samples were sent to Dr. Paul Wood at Lincoln
Memorial University’s metabolomics laboratory for lipidomics analysis by direct infusion
electrospray ionization with high resolution (140,000; 0.3–3 ppm mass error) mass
spectrometry of a large array of targeted lipid metabolites, followed by tandem mass
spectrometry for further validation [238].
4.2.3. Inflammatory Cytokine analysis by Flow Cytometry
Heparinized blood was used to isolate PBMCs by Ficoll–Paque PlusTM
(Amersham Biosciences, Piscataway, NJ) gradient centrifugation [197]. For in vitro
stimulation, 107 PBMC in 1 mL c-RPMI (RPMI-1640; Gibco, Grand Island, NY), with
2.5% fetal equine serum (Sigma–Aldrich), 100 U/ml penicillin/streptomycin (Sigma), and
55 mM 2- mercaptoethanol (Gibco) media was incubated at 37oC, 5% CO2 with Brefeldin
A (10 mg/mL; Sigma) and select wells with the positive control C-RPMI media with
phorbol 12- myristate 13-acetate (PMA; 25 ng/mL; Sigma) and ionomycin (1 mM; Sigma)
for 4 hours. Following this, determination of cytokine gene expression was carried out by
separating aliquots of the cells and placing them in Trizol (Ambion, Austin, TX) to isolate
RNA (see below). Remaining cells were isolated for flow cytometry assay for interferon
gamma (IFN-γ) and TNF-α production. Cells were fixed in 2% paraformaldehyde (Sigma)
and stored overnight at 4oC. After overnight storage, IFN-γ and TNF-α intracellular
staining was carried out as previously described [198, 239]. After the cells were stained,
aliquots of cells were resuspended in fluorescence-activated cell sorting flow and flow
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cytometric acquisition was performed on a FACSCALIBUR (Becton Dickinson, San Jose,
CA). Determination of the percent of IFN-γ and TNF-α lymphocytes was accomplished
with the use of CELL QUEST (Becton Dickinson).
4.2.4. Inflammatory Cytokine analysis by Real Time-PCR
A modified Trizol method was used to extract total RNA. RNA purity was assessed
with a NanoDrop Spectrophotometer using 260/280 and 260/230 ratios of ~2.0 and
between 2.0 and 2.2, respectively. One microgram of RNA was reverse transcribed into
cDNA, as previously described [198]. In brief, 0.5 µg of each RNA sample and a reverse
transcription master mix (Promega, Madison, WI) was incubated for 15 minutes at 42oC
and for 5 minutes at 95oC. Reactions included 4.5 µl cDNA and 5 µl of SensiMix (BioLine, Taunton, MA). Equine-specific, inventoried intron-spanning primers and probes
(Life Technologies, Carlsbad, CA) were used with Applied Biosystems (Foster City, CA)
real-time polymerase chain reaction (RT-PCR) (ABI 7900HT) against the following genes:
housekeeping gene beta-glucuronidase [198, 239] and the following genes: IFN-γ (catalog
number 4331182), IL-6 (catalog number 4351372), IL-10 (catalogue number 4331182),
TNF-α (catalog number 4331182), and transferrin (catalog number 4351372). Samples
were processed in duplicate and incubated for 95oC for 10 minutes. They then underwent
10 cycles at 95oC for 15seconds and 60oC for 60 seconds. Relative changes in gene
expression were determined by the CT method [200], with mean CT of nonpositive
controls set as the calibrator for all samples. Relative quantity, or RQ, was calculated as 2CT

and used to express results.

4.2.5. Data Analysis
Data were analyzed by SIGMAPLOT version 12.3 (Systat Software Inc., San Jose,
CA). A mixed model two-way ANOVA was used for each quantitative variable (insulin,
triglyceride concentrations, and so forth). Fixed effects were set as EMS versus control and
age. Data that were not normally distributed as determined by a Shapiro–Wilk test were
log-transformed and resulted in normality. Data were considered statistically significant
when P < .05. Any outliers identified by a modified Thompson tau technique was removed
before statistical analysis.
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4.3. Results
4.3.1. Lipid and lipidomics analysis
Triglyceride and leptin concentrations were significantly higher in EMS horses
compared to controls (Table 4.2). Although there were differences between the two groups
in triglycerides, only two of the horses (both EMS) fell outside the 0.16 to 0.87 mmol/L
normal reference range. Cholesterol and NEFA concentrations did not differ between the
two groups (Table 4.2).

Table 4.2. Serum triglycerides, leptin, cholesterol, and NEFA in horses with EMS and
controls.
Biomarker
Control
EMS
P value
Triglycerides (mmol/L)
0.32 + 0.06
0.62 + 0.04
.002
Leptin (ng/mL)
3.4 + 1.1
7.5 + 0.8
.012
Cholesterol (mg/dL)
91.5 + 3.8
91.6 + 2.9
.975
NEFA (mEq/L)
0.15 + 0.02
0.15 + 0.01
.891
Abbreviation: EMS, equine metabolic syndrome; NEFA, nonesterified fatty acid.
Data are presented as least square means, mean + standard error of the mean, n=9 controls
and n=14 EMS.
Lipidomics analysis revealed that EMS horses had significantly increased plasma
triacylglycerides, diacylglycerides, monoacylglycerides, and ceramide compared to
controls. They also had significantly lower plasma sphingomyelins, suflatide, and choline
ether lipids/plasmalogens (Figure 4.1 and Figure 4.2). No differences were seen between
the two groups for ethanolamine plasmalogens (data not shown).
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Figure 4.1. Plasma triacylglyceride (TAG), diacylglyceride (DAG), and monoacylglyceride (MAG) levels. Values are presented as the
lipid ratio to an internal standard  SEM * indicates significant (p<0.05) differences between EMS and controls. EMS, equine metabolic
syndrome; SEM, standard error of the mean.
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Figure 4.2. Plasma sphingomyelin (SM), sulfatide, ceramide, and choline plasmalogen (PlsCh) levels. Values are presented as the lipid
ratio to an internal standard  SEM * indicates significant (p<0.05) differences between EMS and controls. EMS, equine metabolic
syndrome; SEM, standard error of the mean.

4.3.2. Inflammatory Cytokine analysis
No differences were observed for any of the PBMC values, either for intracellular
protein production analyzed via flow cytometry or for gene expression analyzed via
RTPCR (Table 4.3). However, high variability and low power may have influenced results.
In addition, there was an observed trend for IL-6 and TNF-α RQs, with the EMS horses
lower compared to controls.

Table 4.3. Flow cytometry and RT-PCR data in horses with EMS and controls.
Inflammatory marker
EMS
Control
P value
IFN % gated
8.7 + 2.3
12.8 + 1.8
.208
IFN geo mean
23.2 + 4.0
24.0 + 5.3
.911
TNF % gated
20.7 + 4.2
20.9 + 4.9
.978
TNF geo mean
19.1 + 2.2
17.3 + 3.0
.657
IFN RQ a
2.8 + 0.1
3.1 + 0.2
.251
IL10 RQ
10.7 + 4.1
16.2 + 5.2
.441
IL6 RQ
7.0 + 0.9
9.8 + 1.1
.076
TNF RQ
19.1 + 3.8
31.0 + 5.1
.098
Transferrin RQ
2.2 + 0.8
4.6 + 1.0
.101
Abbreviations: EMS, equine metabolic syndrome; IFN, interferon; IL, interleukin; RTPCR, real-time polymerase chain reaction; RQ, relative quantity; TNF, tumor necrosis
factor.
Data are presented as least square means, mean + standard error of the mean, n=9 controls
and n=14 EMS.
a
Indicates log transformed data.
4.4. Discussion
This study used a group of horses with a naturally occurring form of
hyperinsulinemia. As expected and similar to humans with MetS, EMS horses had an
increase in serum triglycerides and leptin, as well as differences in lipid profiles compared
to controls. These differences, in the plasma lipidome in particular, may have implications
on cell signaling, membrane fluidity, and inflammation.
Cell signaling, including activation of inflammatory pathways in multiple cell types (such
as macrophages, adipocytes, and hepatocytes), and gene expression of proteins involved in
metabolism and inflammation (such as SOCS-3 and MCP-1) have been shown in humans
and mice to be influenced by many different factors, including changes in circulating lipids
[112-114]. Increases in these lipids appear to affect not only inflammation, but insulin
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resistance as well [114, 228, 240]. In addition to influencing inflammation and insulin
signaling, bioactive lipids such as ceramide and other sphingolipids can act as intracellular
messengers and chemoattractants [118, 119], which may contribute to or exacerbate
alterations in insulin dysregulation or inflammation. Further evidence of the role of the
lipidome in metabolic dysfunction is demonstrated considering that nutritional
modification can cause changes in the plasma lipidome, which can result in a decrease in
markers of inflammation and increase in insulin sensitivity [121, 122].
Research has also compared circulating plasma lipidomes with tissue lipid profiles,
finding that serum lipids correlate best with those lipids in the liver [208]. This same study
also observed an increase in ceramide in subcutaneous adipose tissue of humans with fatty
liver disease as well as in skeletal muscle of obese insulin insensitive individuals. Indeed,
changes in ceramide concentrations in particular seem to play a major role in cell signaling
and metabolism [113, 115, 116]. Therefore, increased levels of triacylglycerides,
diacylglycerides, monoacylglycerides, and ceramide in EMS horses point to possible
alterations in normal cell signaling and contribute to a viscous cycle of insulin resistance
and lipid dysregulation in these animals. However, further research is warranted to
understand the relationship between the lipidome and cell signaling in the horse.
Lipids play a vital role in almost all cell types’ membrane health and function [109],
particularly sphingomyelin and plasmalogens. Cell membrane health and function has
direct implications on cell signaling, including influencing voltage-gated ion channels
[110, 111]. Equine metabolic syndrome horses had decreased levels of these critical
membrane lipids, which may point to changes in membrane fluidity and possibly impact
membrane permeability [109-111]. However, results from this work are limited to
circulating plasma, and more work is needed to understand the potential sources and
influences of and on these lipids.
Not only do lipids impact cell signaling and cellular membrane health and function,
there is considerable data linking lipids to immune function in humans and mice. For
example, both foreign lipids such as KOD2-lipid A from Escherichia coli [126], and selflipids such as gangliosides and glycosphingolipids [127-129] can be recognized as
antigens. Not only that, but lipids can act a chemoattractants for lymphocytes [118]
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Although there were differences in plasma lipidomes between EMS and control
horses, there were no significant differences in markers of inflammation measured in
PBMCs. However, high levels of variability, in particular with regard to flow cytometry
data, may have masked differences. It is possible that a larger sample size is required to
detect these differences. It is also important to note that these results are based on PBMCs
stimulated with the mitogen PMA, and a different mitogen may yield different results.
Regardless, EMS animals had numerically lower values for all RT-PCR results and a trend
for lower IL-6 and TNF-α RQs which could point to changes in cell-mediated immunity.
These trends may suggest that EMS horses have reduced systemic inflammation compared
to controls. However, obese humans and mice have been shown to have decreased cellmediated immunity compared to lean individuals [134-137], and some studies in obese
insulin resistant horses have shown increases in inflammatory cytokines compared to
controls [28, 41]. Considering this, as well as the fact that inflammatory data are from
stimulated PBMC cultures which are typically more representative of cellular versus
systemic responses, it is more likely that the trend for reduction in IL-6 and TNF-α RQs is
due to reduced cell-mediated immunity as opposed to a reduction in systemic
inflammation.
It is important to note that work in categorizing the inflammatory state of the obese
insulin resistant horse has been mixed. Some report an increase in gene expression of IL1β and IL-6 in equine nuchal adipose tissue in EMS horses versus controls [41] and others
an increase in circulating plasma or serum concentrations of TNF-α in hoses with EMS
[28] as well as in ponies with a history of pasture-associated laminitis [237]. Correlations
in the horse have likewise been made between insulin sensitivity, obesity, and
inflammatory cytokines where insulin sensitivity decreases with increasing obesity [8].
Also associated with increasing obesity and decreased insulin sensitivity has been elevated
gene expression of TNF-α, IL- 1, and TNF-p, but no change in or decreasing IL-6 [8, 28].
However, these changes in inflammation, such as increasing TNF-α and decreasing IL-6,
were in some instances age dependent [8]. Changes in inflammation have been more
frequently observed in adipose tissue compared to circulation and often are only observed
at the gene expression level [8, 39, 41]. Equine metabolic syndrome horses have also been
observed to have an increase in macrophage and lymphocyte infiltration in adipocytes, as
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well as increased adipocyte diameter [28]. In whole blood when increases in inflammation
were observed in response to endotoxin administration, EMS and control horses both had
an equivalent increase in gene expression of certain cytokines, however, the elevated
expression of some, namely IL-6, IL-8, IL-10, and TNF-α persisted for a longer period of
time in the EMS horses compared to controls [30].
Still, more research is needed in this area to determine true differences in
inflammation in horses with naturally occurring EMS. Future work is also warranted to
examine different cell types and tissues to further determine the presence inflammation as
well as the presence of and effect from changes in lipid profiles. In particular, serological
markers of inflammation should be examined to detect possible levels of low-grade
systemic inflammation, similar to what is observed in humans with MetS.

4.5. Conclusion
These data indicate that horses with EMS have abnormal lipidomes compared to
non-EMS control horses. This may have implications on cell membrane fluidity and cell
signaling. Data support the idea that horses with metabolic dysfunction and obesity have
altered lipidomes, similar to humans with MetS. These results allow for a more targeted
exploration of mechanisms behind EMS, including changes in lipidomes as contributing
factors to the disorder.

Copyright © Sarah E. Elzinga 2017
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CHAPTER 5 DO HORSES WITH EQUINE METABOLIC SYNDROME (EMS)
HAVE REDUCED IMMUNE RESPONSES TO VACCINATION?
Obesity is an increasing problem in the equine population with recent reports
indicating that the percentage of overweight horses may range anywhere from 20.6-51%.
Obesity in horses has been connected to more serious health concerns such as equine
metabolic syndrome (EMS). The potentially devastating condition laminitis, insulin
dysregulation (ID), and obesity are the three main characteristics of EMS, making this
syndrome a serious problem in the equine industry. Ongoing and past research has been
focused on better characterizing and understanding mechanisms responsible for EMS.
However, little research has been conducted to determine the effects of EMS on routine
healthcare of these horses, in particular how they respond to vaccination. It has been shown
that obese humans and mice have decreased immune responses to vaccination. EMS may
have similar effects on vaccine responses in horses. If this is the case, these animals may
be more susceptible to disease, acting as unknown disease reservoirs. Therefore, we
investigated the effects of EMS on immune responses to routine influenza vaccination.
Twenty-five adult horses of mixed-sex and mixed-breed (8-21 years old) horses; 13 EMS
and 12 non-EMS were selected. Within each group, 4 horses served as non-vaccinate saline
controls and the remaining horses were vaccinated with a commercially available equine
influenza vaccine. Vaccination (influenza or saline) was administered on weeks 0 and 3,
and peripheral blood samples taken on week 0 prior to vaccination and on weeks 1, 2, 3, 4,
and 5 post vaccination. Blood samples were used to measure hemagglutination inhibition
(HI) titers and equine influenza specific IgGa, IgGb, and IgGT levels. Blood samples were
also used to isolate peripheral blood mononuclear cells (PBMCs) for analysis of cell
mediated immune (CMI) responses via real-time polymerase chain reaction (RT-PCR). All
horses receiving influenza vaccination responded with significant increases (P < 0.05) in
HI titers, and IgGa and IgGb EIV specific antibodies following vaccination compared to
saline controls. EMS did not significantly affect (P > 0.05) humoral immune responses as
measured by HI titers or IgG antibody isotypes to influenza vaccination. There was an
effect of metabolic status on CMI responses, with influenza vaccinated EMS horses having
lower gene expression of IFN-γ (P = 0.02) and IL-2 (P = 0.01) compared to vaccinated
non-EMS control horses. Given these results, it appears that while metabolic status does
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not influence humoral responses to an inactivated influenza vaccine in horses, horses with
EMS appear to have a reduced CMI response to vaccination compared to metabolically
normal, non-EMS control horses.

5.1. Introduction
An obesity epidemic is emerging in the horse population, with reports of 45% of
319 randomly selected horses classified as “fat” or “very fat” [7]. Still others have reported
that of 300 horses, 54% were overweight or obese [3, 49]. Of these overweight or obese
horses, 18% were hyperinsulinemic compared to only 1.4% of lean horses. While there is
information regarding the number of horses affected by obesity, the prevalence of
metabolic dysfunction in the horse is unknown. Both obesity and metabolic dysfunction
are considered risk factors for the development of laminitis in the horse [14, 15]. All three
of which (obesity, metabolic dysfunction, and laminitis) are components of equine
metabolic syndrome (EMS).
EMS is closely related to MetS (metabolic syndrome) in humans. Associated
characteristics of MetS include: adipose tissue dysfunction, insulin resistance,
inflammation, and hypertension [207, 208]. Equine metabolic syndrome was defined in a
2010 ACVIM consensus statement [23]. The statement ascribes three major characteristics
to horses with EMS; general or regional (fatty deposits around the neck, tail head, behind
the shoulder, or in the mammary gland region) adiposity, an abnormal glycemic or
insulinemic response upon challenge, and a history of or predisposition to laminitis.
Hypertriglyceridemia, dyslipidemia, hyperleptinemia, arterial hypertension, abnormal
reproductive cycling in mares, and an increase in systemic makers of inflammation
associated with obesity are also considered possible hallmarks of EMS [23].
Considering

correlations

between

obesity,

insulin

resistance,

systemic

inflammation, and the immune response [31, 130, 131], it begs the question; is there an
effect of obesity and metabolic dysfunction on the immune response to vaccination in
horses? Work in naïve mice has indicated that obesity significantly reduces antibody
responses and antibody neutralizing capability to influenza vaccination [134]. In response
to a hepatitis B vaccine, diet-induced obese mice exhibited an increased proliferation of T
and B cells, increased levels of IFN-γ and TNF-α, but decreased levels of hepatitis specific

59

antibody and hepatitis specific T cell activation [135]. Type 1 diabetes in adult humans has
also been associated with a risk for non-responsiveness to vaccination [136], and obesity
is considered a risk factor for low levels of circulating antibody >3ys post hepatitis
vaccination [137]. A human influenza vaccination study [138] positively correlated body
mass index with higher initial IgG antibody responses, however 12 months following
vaccination a greater body mass index was correlated with a greater decline in influenza
antibody titers. In vivo, investigators also found that obese individuals had lower
expression of functional proteins and decreased activation of their CD8+ T-cells.
Additionally, both adult and elderly obese individuals had impaired B cell function in
response to influenza vaccination [241] and obese adult human PBMCs upon viral
challenge with influenza, had a lower production of IFN-γ by their γδ T cells compared to
lean controls [242]. In spite the evidence in humans and mice linking increased adiposity
to an impaired immune response to vaccination, there has been no work to date regarding
response to vaccination in the EMS horse.
Therefore, this study was designed to compare humoral and cell-mediated immune
(CMI) responses to influenza vaccination of EMS and non-EMS horses, with the
hypothesis that EMS horses would have a decreased immune response to vaccination
compared to metabolically normal controls.

5.2. Materials and Methods
Horses of mixed-breed and mixed-sex (ranging in age from 8-21 years old) were
utilized from the University of Kentucky’s existing Department of Veterinary Science
Main Chance herd. Criteria to determine EMS was as previously described; insulin
resistance, regional or general adiposity, and a predisposition to or history of laminitis [13,
23]. Two weeks prior to the start of the study, EMS and non-EMS horses were screened
for insulin resistance, existing HI influenza antibody titers, and to insure that they did not
have Pituitary Pars Intermedia Dysfunction (PPID). PPID determination was established
using both dexamethasone suppression and Thyroid Releasing Hormone (TRH) testing as
previously described [191-194]. This was deemed especially important by investigators, as
horses with PPID may have similar metabolic dysfunction as those with EMS [11]. Horses
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were housed in a dry lot with ad libitum access to water, trace mineralized salt blocks, and
a mixed-grass hay.
5.2.1. Phenotype determination
A portable agriculture scale (model 700, Tru Test Inc., Mineral Wells, TX) was
used to determine body weight. General adiposity was measured by body condition scoring
(BCS). BCS was established by three trained investigators using the 1Henneke scoring
system [186]. The same trained individuals also performed cresty neck scoring (CNS) on
horses with the 0-5 scale system established by Carter et al. [187] to measure regional
adiposity. To ascertain the presence of insulin resistance, an oral sugar test was performed;
following overnight fasting and 0800-1100 EST serum sample collection, 0.15 ml/kg of
Karo Light Corn syrup was administered orally, and a second serum sample collected 60
min later [13, 23]. Serum samples were kept at -20º C until sent on dry ice to Cornell
University’s endocrinology lab for insulin determination. A fasting insulin level of >20
μIU/mL was considered indicative of hyperinsulinemia, and an increased insulin
(>60μU/mL) 60 minutes post administration of oral sugar classified as insulin resistance
[13, 23]. Horses were pre-screened and tested via HI as described below to establish IgG
antibody levels specific to influenza. All animal methods were approved by the University
of Kentucky’s IACUC (institutional animal care and use committee).
5.2.2. Vaccination and Sample Collection
Thirteen EMS and 12 non-EMS horses were used in this study. Within each
category (EMS vs non-EMS controls) horses were blocked by pre-existing antibody titers
(HI titers) and systematically allocated to one of the following treatment groups: 1)
vaccinate (Fluvac InnovatorTM, Zoetis, vaccine containing KY/97) (n=8 non-EMS control
horses or n=9 EMS horses) or 2) saline controls (n=8, 4 horses within each metabolic
group). There was no significant difference in median age between vaccine group vs saline
(P = 0.55, vaccine group median age 11 years; IQR 9.5 – 16 years, and saline median 13
years; IQR 11.3 – 16.3 years), Nor was there a significant difference in median age between
EMS group vs non-EMS control horses (P = 0.4, EMS group median age 13 years; IQR 10
– 18 years vs non-EMS control group median 12.5 years; IQR 9.3 – 14.8 years).
Blood collection was carried out via jugular venipuncture for all time points. For
baseline and phenotypic determination, serum and plasma sample collection was
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performed following fasting on day -14. As some horses had an unknown vaccine history
as well as to determine if a second vaccination would result in additional effect on immune
responses measured, horses received an inactivated influenza vaccination or saline at both
weeks 0 and 3. Peripheral serum and heparinized blood samples were taken on week 0 prior
to vaccination and on weeks 1, 2, 3, 4, and 5 post vaccination. Throughout the study horses
were monitored for vaccine site reactions.
5.2.3. Equine Influenza Virus (EIV)-Specific Antibody Assays
5.2.3.1. HI assay
Humoral immune total IgG responses were determined using serum samples from
all sampling time points by HI (hemagglutination inhibition) assay with ether treated
KY/97 equine influenza virus, as previously described [243].
5.2.3.2. ELISA assay
Serum samples were also used as previously described [197] in a modified ELISA
procedure to determine influenza specific antibody isotype responses to vaccination. The
assay was carried out as follows: purified influenza virus (Eq/KY/97; 10 HA units per well)
was used to coat a 96-well polystyrene plate (IMMULON®, Dynatech Laboratories Inc.,
Chantilly, VA) and incubated at 4°C overnight. The next morning, plates were washed
(PBS/0.05% TWEEN®-20 (PBS-T; Sigma, St. Louis, MO)) and blocked (2% non-fat dried
milk powder in PBS-T (Sigma)) at 37°C for 1 hr. Serum samples from an influenza virus
hyperimmune horse were serial diluted and used to create a standard curve. Experimental
serum samples were diluted in a volume of PBS-T to ensure that OD values were within
the standard curve and plates were incubated at 37°C for 90 min. Plated were washed and
incubated at 37°C for 1 hr with IgGa (CVS 40), IgGb (CVS 39), and IgG(T) (CVS 48)
specific monoclonal antibodies. After being washed again, an incubation at 37°C for 1 hr
took place with horseradish peroxidase-conjugated goat-anti-mouse IgG antibody (Jackson
Laboratories Inc., West Grove, PA). Following the incubation, plates were washed and a
substrate (KPL, Gaithersburg, MD) used for development. Development was stopped by
the addition of a stop solution (KPL). A 450 nm optical density was determined with the
use of an ELISA reader (BioRAD, Hercules, CA). Serum antibody concentrations relative
to the standard curve were calculated and are represented as ELISA units.
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5.2.4. EIV-specific CMI Assays
5.2.4.1. Peripheral blood processing
Heparinized blood was used to isolate peripheral mononuclear cells (PBMCs) by
Ficoll-Paque PlusTM (Amersham Biosciences, Piscataway, NJ) gradient centrifugation
[197]. For EIV in vitro stimulation, aliquots of 107 PBMC were plated in 1 ml c-RPMI
[RPMI-1640 (Gibco, Grand Island, NY); supplemented with 2.5% fetal equine serum
(FES; Sigma–Aldrich, St. Louis, MO), 100 U/ml penicillin/streptomycin (Sigma), and 55
mM 2-mercaptoethanol (Gibco) media. Select aliquots were incubated at 37 °C, 5% CO2
for 45 min with influenza virus homologous strain used in the vaccine (KY/Eq/97). After
incubation all flu simulated cells were pelleted by centrifugation at 500 × g for 5 min to
remove the virus inoculum. All virus-stimulated and unstimulated PBMC were
resuspended with c-RPMI. Brefeldin A (10 mg/ml; Sigma) was added to all wells. For all
time points and horses an addition well was (non-flu stimulated) was stimulated with
phorbol 12-myristate 13-acetate (PMA; 25 ng/ml; Sigma) and ionomycin (1 mM; Sigma)
to serve as a positive control. Cells were incubated for an additional 4 hrs. Following this,
determination of cytokine gene expression was carried out by separating an aliquot of the
cells and placing them into Trizol (Ambion) to isolate RNA (see below).
5.2.4.2. Real Time-PCR
A modified Trizol method was used to extract total RNA. One µg of RNA was
reverse transcribed into cDNA, as previously described [197]. In brief; 1 µg of each RNA
sample and a reverse transcription master mix (Promega, Madison, WI) was incubated for
15 min at 42oC and for 5 min at 95oC. Reactions included 5µl cDNA and 20µl of master
mix. Master mix included; 6.25µl nuclease-free water (Qiagen), 1.25µl primer/probe 20X
assay mix (Applied Biosystems, Foster City, CA), and 12.5µl TaqManTM (Applied
Biosystems). Equine-specific, intron-spanning primers and probes were used with Applied
Biosystems Real-Time PCR (ABI 7900HT) against the following genes: Housekeeping
gene beta-glucuronidase (β-gus) and CMI induced cytokine genes; interferon gamma (IFNγ), GrzB, and Perforin [244]. Samples were processed in duplicate and incubated for 95oC
for 10 min. They then underwent 10 cycles of 95oC for 15s and 60oC for 60s. Relative
changes in gene expression were determined by the CT method [200], with mean CT
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for week 0 from all horses set as the calibrator for all samples. Relative quantity, or RQ,
was calculated as 2-CT and was used to express results.
5.2.5. Statistical analysis
Data were analyzed utilizing SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA).
Data were analyzed with proc mixed with the repeated measure set at time and subject as
horse ID. Horse ID, metabolic status, vaccination vs saline, and time point (week) were set
as fixed effects and all possible interactions analyzed. A first-order autoregressive
variance/covariance structure was used the statistical model. Results are expressed as least
square means ± standard error of the mean (SEM). Normality was assessed using
studentized residuals with a visual analysis as well as skew (>2) and kurtosis (>7). Nonnormal data were natural log transformed and resulted in normality.

5.3. Results
Phenotypic data, including OST results used for EMS determination are presented
in Table 5.1. As expected, EMS horses had a greater CNS (P = 0.002), and insulin (both
pre (P = 0.003) and post (P < 0.001) oral sugar administration) compared to non-EMS
control horses. However, EMS and non-EMS control horses did not different in BCS (P =
0.227) or weight (P = 0.514).
Table 5.1. Phenotypic and endocrine data for EMS and non-EMS horses.
Phenotypic measure
EMS horses
Non-EMS horses
Basal Insulin (µIU/ml)
37.4 ± 4.7 b
13.3 ± 5.4 a
Insulin 60 min post oral sugar
81.6 ± 5.8 b
23.8 ± 6.5 a
administration (µIU/ml)
BCS
6.9 ± 0.3
6.6 ± 0.2
CNS
3.0 ± 0.3 b
1.6 ± 0.2 a
Weight (kg)
588.1 ± 22.1
604.4 ± 18.6
Phenotypic measures and endocrine data in EMS (n=13) versus non-EMS (n=12) horses.
Results are presented as least square means (± SEM). Within a row, differences (P < 0.05)
are represented by differing superscripts.
5.3.1. Antibody responses
All horses that received influenza vaccination had a significant antibody response
to vaccination as compared to those given saline (P < 0.05) measured by HI titers against
KY/97 (Figure 5.1). Horses given saline had lower HI titers compared to vaccinated horses
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for all weeks post vaccination. Vaccinated horses at week 0 had lower HI titers compare to
vaccinated horses at all other time points, whereas saline horses did not differ over time.
Vaccinated horses at week 4 had higher HI titers compared weeks 2, 3, and 5. There was
not effect of metabolic status on HI titers in response to vaccination.

KY/97 HI titers log 2-2.3

Hemagglutination Inhibition Titers
5
4.5
4
3.5
3
2.5
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1.5
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0
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b, c *

b*

b*
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a

Control
Saline
Control
Vaccinate
EMS
Saline
EMS
Vaccinate

Week 0 Week 1 Week 2 Week 3 Week 4 Week 5
Time Point (week)
Figure 5.1. HI titers over time in vaccinated EMS horses (n = 9), vaccinated control horses
(n = 8), EMS horses given saline (n = 4), and control horses given saline (n = 4). Results
are presented as least square means (± SEM). Differences (P < 0.05) within time point
between all vaccinated horses and all given saline are represented by *. Within all
vaccinated horses differences between time points are represented by differing alphabetic
superscripts. There were no significant differences over time point within all horses given
saline. Arrows represent time points of vaccination or saline administration.

IgGa isotype flu specific antibody responses are represented in Figure 5.2. All
vaccinated horses responded to vaccination, with higher levels of IgGa compared to horses
given saline at all weeks post vaccination (Figure 5.2). Vaccinated horses were lower at
week 0 compared to all other weeks. In addition, vaccinated horses were lower at week 3
compared to weeks 1, 2, 4, and 5. Again, there was no effect of metabolic status on flu
specific IgGa isotype antibody responses.
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Figure 5.2. IgGa isotype flu specific antibody responses over time in vaccinated EMS
horses (n = 9), vaccinated control horses (n = 8), EMS horses given saline (n = 4), and
control horses given saline (n = 4). Results are presented as least square means (± SEM).
Differences (P < 0.05) within time point between all vaccinated horses and all given saline
are represented by *. Within all vaccinated horses differences between time points are
represented by differing alphabetic superscripts. There were no significant differences over
time point within all horses given saline. Arrows represent time points of vaccination or
saline administration.

Similar to HI and IgGa antibody results and regardless of metabolic status, all
vaccinated horses responded to vaccination in respect to their flu specific IgGb isotype
antibody responses as compared to horses given saline (Figure 5.3). Horses given saline
were lower in IgGb antibody compared to vaccinated horses for all weeks following
vaccination, with the exception of week 1. Vaccinated horses were lower at week 0
compared to all other weeks.
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Figure 5.3. IgGb isotype flu specific antibody responses over time in vaccinated EMS
horses (n = 9), vaccinated control horses (n = 8), EMS horses given saline (n = 4), and
control horses given saline (n = 4). Results are presented as least square means (± SEM).
Differences (P < 0.05) between all vaccinated horses and all given saline are represented
by *. Within all vaccinated horses differences between time points are represented by
differing alphabetic superscripts. There were no significant differences over time point
within all horses given saline. Arrows represent time points of vaccination or saline
administration.

There were no significant differences for time point, vaccine versus saline, or
metabolic status, nor were there any significant interactions for IgGT isotype flu specific
antibodies (data not shown). For all measures of humoral responses to vaccination, with
the exception of IgGT isotype responses, vaccinated horses responded to vaccination
compared to saline controls. There was, however, no effect of metabolic status on antibody
responses to vaccination.
5.3.2. Flu specific cell mediated (CMI) responses
For granzyme B flu stimulated gene expression (Figure 5.4), there was a significant
overall effect of vaccination (P = 0.023), with horses given saline lower in granzyme B
compared to vaccinated horses. There was also an overall effect of time (P = 0.018); with
horses having higher gene expression at weeks 2 and 3 compared to week 0. In addition,
horses were higher at weeks 2, 3, and 5 compared to week 4. There were no differences or
interactions for any variable for PMA stimulated granzyme B gene expression, data not
shown.
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Figure 5.4. Relative quantity (RQ) of granzyme b gene expression for flu stimulated
PBMCs (A) in vaccinated horses (n=17) and in horses given saline (n=8) and (B) over time
for all horses (n = 25). Results are presented as least square means (± SEM). Differences
(P < 0.05) between vaccinated horses and those given saline are represented by * and
differences between time points are represented by differing alphabetic superscripts.
Arrows represent time points of vaccination or saline administration.
Flu stimulated IFN-γ gene expression (Figure 5.5) was different between
vaccinated horses and horses given saline, with horses given saline having lower
expression compared to vaccinated horses (P = 0.032). In addition, there was an overall
time point difference (P = 0.002). Horses were higher in flu stimulated IFN-γ gene
expression at weeks 1, 2, and 3 compared to weeks 0 and 4. For PMA stimulated IFN-γ
gene expression there were observed interactions (Figure 5.6). There was a metabolic status
by vaccine vs saline (P = 0.019) interaction. Non-EMS control horses administered saline
were lower in IFN-γ gene expression compared to non-EMS control horses administered
vaccine. Non-EMS control vaccinated horses were higher compared to EMS horses
regardless of vaccination status. In addition, there was a significant metabolic status by
time point (P = 0.015) interaction, with non-EMS control horses lower in gene expression
at weeks 0, 1, 2, and 3 compared to weeks 4 and 5. Non-EMS control horses at weeks 1
and 3 were higher compared EMS horses at those time points in IFN-γ gene expression.
EMS horses were higher in gene expression at week 0 compared to weeks 1, 3, 4, and 5,

68

and higher at week 2 compared to weeks 1 and 5. Additionally, EMS horses at week 4 were
higher compared to week 5.
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Figure 5.5. Relative quantity (RQ) of IFN-γ gene expression for flu stimulated PBMCs
(A) in vaccinated horses (n = 17) and in horses given saline (n = 8) and (B) over time for
all horses (n = 25). Results are presented as least square means (± SEM). Differences (P <
0.05) between vaccinated horses and those given saline are represented by * and
differences between time points are represented by differing alphabetic superscripts.
Arrows represent time points of vaccination or saline administration.
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Figure 5.6. Relative quantity (RQ) of IFN-γ gene expression for PMA stimulated PBMCs (A) in vaccinated horses (EMS n = 9; nonEMS control n = 8) and in horses given saline (EMS n = 4; non-EMS control n = 4) and (B) over time in EMS (n = 13) vs non-EMS
control horses (n = 12). Results are presented as least square means (± SEM). Differences (P < 0.05) between EMS vs non-EMS control
horses within time point are represented by * and differences between time points within non-EMS control horses and for (A) are
represented by differing alphabetic superscripts. Differences between time points within EMS horses are represented by differing
numeric superscripts. Arrows represent time points of vaccination or saline administration.

Vaccinated horses were not significantly different from horses given saline for flu
stimulated IL-2 gene expression (P = 0.461; data not shown). However, there was an
overall effect of metabolic status, with non-EMS control horses higher compared to EMS
horses (non-EMS control horses ln RQ = 1.28 ± 0.13, EMS horses ln RQ = 0.83 ± 0.11; P
= 0.016). There was also an effect of time, with horses at week 0 lower in IL-2 gene
expression compared to horses at week 3. Horses at week 1 were also lower compared to
weeks 2 and 3, and horses at week 3 were higher compared to weeks 4 and 5. Similar to
PMA stimulated IFN-γ gene expression, there were significant interactions for PMA
stimulated IL-2 gene expression (Figure 5.7). There were significant interactions for
metabolic status by vaccine vs saline (P = 0.013) and metabolic status by time point (P =
0.029). The only significant pairwise comparison for the metabolic status by vaccination
status interaction involved vaccinated horses, where non-EMS controls were higher in
PMA stimulated IL-2 gene expression than EMS horses. Metabolic status by time point
differences showed non-EMS control horses to be higher at week 0 compared weeks 1, 4,
and 5. Non-EMS control horses at week 1 were also higher compared to weeks 4 and 5.
Additionally, at week 1 non-EMS control horses were higher in IL-2 gene expression
compared to EMS horses. EMS horses were lower in gene expression at week 0 compared
to all other time points, and EMS horses at week 5 were lower than week 2.
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Figure 5.7. Relative quantity (RQ) of IL-2 gene expression for PMA stimulated PBMCs (A) in vaccinated horses (EMS n = 9; nonEMS control n = 8) and in horses given saline (EMS n = 4; non-EMS control n = 4) and (B) over time in EMS (n = 13) vs non-EMS
control horses (n = 12). Results are presented as least square means (± SEM). Differences (P < 0.05) between EMS vs non-EMS control
horses within time point are represented by * and differences between time points within non-EMS control horses and for (A) are
represented by differing alphabetic superscripts. Differences between time points within EMS horses are represented by differing
numeric superscripts. Arrows represent time points of vaccination or saline administration.

Perforin gene expression (data not shown) for flu stimulated lymphocytes had a
significant vaccine vs saline by time point interaction (P = 0.026). Horses given saline had
a lower gene expression at week 5 compared to all other weeks. Vaccinated horses were
highest in perforin gene expression at weeks 1 and 4 compared to week 2. For gene
expression of perforin in PMA stimulated lymphocytes, there was a significant metabolic
status by time point interaction (P = 0.007; data not shown). Non-EMS control horses at
weeks 0, 1, and 3 were higher compared to week 2, and higher at week 3 compared to week
5. EMS horses at weeks 0, 1, and 4 were higher in perforin gene expression compared to
week 5. Within time point there were no differences between EMS and non-EMS control
horses.
There was an observed metabolic status by time point interaction for flu stimulated
lymphocyte TNF-α gene expression (P = 0.009; data not shown). Non-EMS control horses
were lower at week 0 compared to weeks 1, 3, 4, and 5. Non-EMS control horses at weeks
1 and 3 were higher compared to week 2. Similar to perforin gene expression, within time
point there were no differences between EMS and non-EMS control horses. There was
likewise a metabolic status by time point interaction for PMA stimulated lymphocyte TNFα gene expression (P = 0.032; Figure 5.8). Non-EMS control horses were highest at week
0 compared to weeks 2, 4, and 5, and at week 1 were higher compared to weeks 2 and 5.
Non-EMS control horses were higher at week 3 compared to weeks 2, 4, and 5. Non-EMS
control horses at week 4 were also higher compared week 5. At week 3, non-EMS control
horses were higher compared to EMS horses at that same time point. EMS horses were
highest in TNF-α gene expression at week 0 compared to weeks 2 and 5. EMS horses were
also higher weeks 1 and 4 compared to week 5.
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Figure 5.8. Relative quantity (RQ) of TNF-α gene expression for PMA stimulated PBMCs
over time in EMS (n = 13) vs non-EMS control horses (n = 12). Results are presented as
least square means (± SEM). Differences (P < 0.05) between EMS vs non-EMS control
horses within time point are represented by * and differences between time points within
non-EMS control horses are represented by differing alphabetic superscripts whereas
differences between time points within EMS horses are represented by differing numeric
superscripts. Arrows represent time points of vaccination or saline administration.

Overall and time point dependent effects of vaccination were seen for lymphocyte
gene expression of flu stimulated granzyme B, flu and PMA stimulated IFN-γ, PMA
stimulated IL-2, and flu stimulated perforin with vaccinated horses higher than controls.
There were also both overall and time point dependent effects of metabolic status for
lymphocyte gene expression of PMA stimulated IFN-γ, flu and PMA stimulated IL-2,
PMA stimulated perforin, and flu and PMA stimulated TNF-α with EMS horses lower
compared to non-EMS control horses.

5.4. Discussion
All horses responded to vaccination regardless of metabolic status as determined
by influenza specific antibody responses. Vaccinated horses had an increase in HI titers,
and IgGa and IgGb antibody isotypes following both the initial (week 0) and the second
administration (week 3) of Fluvac InnovatorTM, whereas horses given saline did not change
over time. There was, however, no effect of metabolic status on humoral immune measures.
It is possible that obesity plays a larger role in the immune process as compared to
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metabolic status. EMS horses all met the three criteria necessary for classification as EMS.
However, some had increased regional but little to moderate general obesity. Indeed,
although EMS horses had a significantly higher CNS (a measure of regional adiposity)
compared to non-EMS control horses, they did not differ in BCS (a measure of general
adiposity). In naïve, diet induced obese mice, differences in primary humoral immune
responses to influenza vaccination [134, 135] have been observed. This has similarly been
observed in humans where type 1 diabetes was associated with a risk for nonresponsiveness to influenza vaccination [136], however investigators found no differences
in humoral immune responses due to metabolic status. Obesity in humans was a risk factor
>3ys post hepatitis vaccination for lower circulating levels of antibody [137] and body
mass index, but not diabetes status, was positively correlated with a greater decline in
influenza antibody titers 12 months following influenza vaccination [138]. A greater body
mass index in a group of non-diabetic women given a HIV vaccine was associated with
decreased HIV specific IgG titers and obese women had a greater likelihood to be nonresponders [245]. Further, independent from age and in response to influenza vaccination
obese humans had lower HI titers, decreased percentage of memory B cells, increased B
cell production of the pro-inflammatory IL-6, and decreased B cell production of the antiinflammatory IL-10 [241]. Also, the number of human γδ T cells is negatively correlated
with obesity and obese individuals γδ T cells produce less IFN-γ upon in vitro influenza
challenge compared to lean controls [242]. It is important to note that for human studies
with influenza vaccine, similar to this work, participants presumably have been previously
exposed to influenza and responses to vaccination are primarily recall responses.
Inactivated or killed vaccines, similar to the inactivated vaccine used in this study,
tend to produce a robust humoral immune response, but a weaker CMI response [246].
This may have contributed to the results seen here considering that differences between
EMS and non-EMS controls were observed not for humoral but for CMI responses. For
this study, results for CMI responses when comparing vaccinated horses to those given
saline were few. An overall effect of vaccination was seen for flu stimulated PBMC
granzyme B and IFN-γ gene expression, and a vaccine vs saline by time point interaction
for perforin. Vaccinated horses were higher overall for granzyme B and IFN-γ compared
to horses given saline. Within time point, there were no differences between vaccinated
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horses and those given saline for flu stimulated perforin gene expression, however
vaccinated horses did have increases in gene expression at weeks 1 and 4 (the weeks
following vaccine administration).
There was an overall effect of metabolic status for flu stimulated PBMC IL-2 gene
expression with EMS horses lower compared to non-EMS controls. There was also an
interaction between metabolic status and time point for flu stimulated PBMC TNF-α gene
expression. Although within time point there were no differences due to metabolic status,
the non-EMS control horses had significant changes over time in TNF-α whereas the EMS
horses did not. There were several interactions between metabolic status and vaccination
status and/or time point for PMA stimulated PBMC gene expression of IFN-γ, IL-2,
perforin, and TNF-α. EMS horses were lower in gene expression of IFN-γ at weeks 1 and
3 compared to non-EMS controls. Also, EMS horses were lower in IL-2 gene expression
at week 1 compared to non-EMS controls. Vaccinated EMS horses were overall lower in
IFN-γ and IL-2 compared to vaccinated non-EMS control horses.
Lower gene expression of IL-2 in flu and PMA stimulated PBMCs indicate that
EMS horses may have a decrease in lymphocyte proliferation [247] compared to
metabolically normal controls. Pro-inflammatory cytokines TNF-α and IFN-γ play an
important role in antigen-specific CMI responses [248, 249]. A lack of change in TNF-α
gene expression in flu stimulated PBMCs and over time in EMS horses and lower gene
expression of IFN-γ in PMA stimulated PBMCs at weeks 1 and 3 compared to non-EMS
control horses, further points to a reduced CMI response to vaccination in these animals.
Further supporting a reduced CMI in EMS horses were the differences in PMA stimulated
PMBCs between vaccinated EMS and vaccinated non-EMS control horses for IFN-γ and
IL-2, with vaccinated non-EMS controls significantly higher compared to vaccinated EMS
horses.
These data indicate that the EMS horse is able to produce a robust humoral immune
response to vaccination. However, their ability to mount a CMI response may be reduced
in comparison to horses without metabolic dysfunction, and requires further study. In
particular, the impact of obesity as opposed to metabolic status, as well as a better
characterization of CMI responses to vaccination in horses with metabolic dysfunction
utilizing an attenuated live or other vaccine able to induce stronger CMI responses should

76

be investigated. Furthermore, given data in other species and indications here of potential
differences in CMI responses, vaccine efficacy and duration of immunity in the obese or
EMS horse should be evaluated to further understand the effects of theses parameters on
immune responses.

Copyright © Sarah E. Elzinga 2017
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CHAPTER 6 EFFECTS OF SUPPLEMENTATION WITH YEAST CELL WALL ON
METABOLIC AND INFLAMMATORY MEASURES IN INSULIN
DYSREGULATED HORSES
Insulin dysregulation (ID) is a common problem associated with serious health
concerns in the equine, however its pathogenesis and underlying mechanisms are not well
understood. There has been increasing attention on the role of the gut in metabolic
dysfunction, including the influence of an oral glycemic or meal challenge on both
metabolic and inflammatory processes. Therefore, the objective of this study was to
determine the effects of supplementation with a mannan-rich fraction of the yeast cell wall
(ActigenTM) on metabolic and inflammatory measures in ID horses compared to non-ID
controls. To accomplish this, we supplemented 24 ID and non-ID control horses (13 ID
and 11 non-ID, 4 non-supplemented horses within each metabolic group) with
supplemented horses receiving 6 g/horse/day of ActigenTM for 45 days, with blood samples
collected via jugular venipuncture both pre and post oral glycemic challenge (time point)
as well as pre and post the 45-day supplementation period (period). Samples were analyzed
for serum glucose and insulin concentrations, circulating and peripheral blood
mononuclear cells (PBMCs) inflammatory markers at both the protein and gene expression
levels, and circulating plasma endotoxin concentrations were established. Metabolic results
indicated that serum glucose and insulin increased following the supplementation period
and in response to oral glycemic challenge, with the ID horses having a greater increase
compared to non-ID controls (P < 0.04). There was no effect of treatment on either serum
glucose or insulin concentrations. Few effects of metabolic status or treatment on
inflammatory markers were observed, however non-supplemented horses or non-ID
controls often had a decrease in markers of inflammation at both the protein and gene
expression levels in response to the oral sugar challenge, as opposed to ID horses. There
were, however, multiple inflammatory parameters affected by period, including LPS
stimulated lymphocyte or whole blood gene expression and lymphocyte inflammatory
protein as well as circulating LPS plasma concentrations. Overall these results indicate that
supplementation had minimal effects on metabolic and inflammatory responses, however
these variables were affected by both oral sugar challenge and period. In addition, it appears
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that metabolic and inflammatory responses of horses with ID may be especially sensitive
to changes in either metabolic stimuli or season, however further investigation regarding
the influence of these factors is needed.

6.1. Introduction
Insulin dysregulation (ID) is a major problem in the equine industry, particularly as
it predisposes the horse to the development of laminitis, which can be a career or even life
ending condition [12, 14, 15]. However, underlying mechanisms of ID remain unclear.
Some have proposed a role of inflammation in ID, but results concerning this have been
mixed with reports of both increases in circulating or tissue markers of inflammation [28,
40, 41] as well as no differences or a trend for lower circulating markers of inflammation
[31, 42]. This may in part be explained as in some cases ponies were utilized instead of
horses, or ID was induced rather that naturally occurring. In addition, many studies were
carried out in a fasted state. Establishing fed versus fasted state becomes important
considering the role of the gut in metabolic regulation and hormonal control [250, 251].
Further, it has been demonstrated in humans and mice that inflammatory markers increase
postprandially following a meal high in fat or high in both fat and sugar/starch [43-45].
This has similarly been observed in the horse in response sugar/starch given either as a
meal or orally administered [46, 47].
Yeast cell wall supplementation has been shown to reduce inflammation in dairy
cows [95], poultry [96], humans [97-99], and horses [100, 101]. Supplementation with
yeast cell wall has also influenced metabolic parameters in cattle [102], and reduced
circulating triglyceride and cholesterol levels in poultry [103, 104]. The mannan
oligosaccharides (MOS) found in the yeast cell wall modulate the immune response by
binding to mannose-specific lectin on gram negative bacteria, thus preventing it from
binding to intestinal epithelial cells [252, 253]. Concentrations of lipopolysaccharide
(LPS), a component of the outer membranes of gram negative bacteria, have been shown
to be reduced following MOS supplementation in pigs [105], and modulated the
inflammatory response to LPS challenge in chickens [254]. Given the fact that there have
been multiple studies showing probable links between inflammation and metabolic
dysfunction [127, 139, 140], there is ample evidence to further investigate not only these
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relationships in the horse with ID, but also possible ways to improve these parameters.
Therefore, the aim of this study was to further establish the role of inflammation in the ID
horse in response to an oral sugar challenge as well as the ability of the gut modulating
product ActigenTM to modify circulating LPS concentrations, and improve metabolic and
inflammatory parameters in these animals.

6.2. Materials and methods
6.2.1. Horse selection and study design
Twenty-four horses of mixed-breed and mixed-sex, both ID (n=13) and non-ID
controls (n=11) [12], were selected from the University’s Department of Veterinary
Science Woodford County herd for use in this study. ID was established three months prior
to the start of the study with an oral sugar test (OST) as previously reported [13, 47], with
hyperinsulinemia diagnosed as a fasting insulin level of > 20 μIU/mL and a concentration
of insulin > 60μU/mL 60 minutes post OST considered further indicative of ID. General
and regional adiposity were assessed for all horses by body condition scoring (BCS; based
on the 1-9 Henneke scoring system [186]) and cresty neck scoring (CNS; based on the 0-5
Carter et. al. scoring system [187], respectively. Screening results presented in Table 6.1.
Of the 13 ID horses (7 geldings and 6 mares), 4 were of mixed breed, 2 were Warmbloods,
2 were Standardbred or Standardbred cross, 2 were walking horses, 1 was a Thoroughbred
cross, 1 a Morgan, and 1 a Quarter Horse. Of the 11 non-ID control horses (6 geldings and
5 mares), 5 were of mixed breed, 4 were Thoroughbreds or Thoroughbred cross, 1 was a
Quarter Horse, and 1 a walking horse cross.

Table 6.1. Endocrine and measures of adiposity in ID and control horses.
Insulin 60 min
Baseline
post oral sugar
Insulin
administration
BCS
CNS
ID
36.8 ± 6.3
76.5 ± 12.1
7.0 ± 0.2
2.7 ± 0.3
Non-ID control
12.9 ± 0.9
24.2 ± 3.7
6.1 ± 0.1
1.4 ± 0.2
p value
0.0026
0.00095
0.0019
0.00131
Data are presented as least square means ± standard error of the mean for n = 13 ID and n
= 11 controls. Body condition score (BCS) and cresty neck score (CNS) are presented as
an average score between 3 trained individuals.
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To ensure that none of the horses were affected with PPID (Pituitary Pars
Intermedia Dysfunction), all horses were screened at least 3 mo prior to the start of the
study via thyrotropin releasing hormone (TRH) stimulation testing as previously described
[47, 191, 192]. Briefly, a.m. (between 0800 and 1000, EST) blood samples from jugular
venipuncture were collected and a subsequent 1 mg/mL of TRH (Sigma-Aldrich, St. Louis,
MO) given intravenously (IV). Ten min following TRH administration, a second blood
sample was collected. All samples were collected in ethylenediaminetetraacetic acid
(EDTA) containing tubes which were kept on ice for transport to the lab and immediate
centrifugation and isolation of plasma [193]. ETDA plasma was stored -20 º C until sent
on dry ice for ACTH analysis by Cornell University’s Animal Health Diagnostic Center
Endocrinology Laboratory (Ithaca, NY) by chemiluminescence (Immulite, Erlangen,
Germany) as previously described [195]. A 10 min post TRH administration ACTH
concentration of > 110 pg/mL was considered positive for PPID and any horse exceeding
this concentration excluded.
To determine the response of metabolic and inflammatory parameters following
supplementation with a mannan-rich fraction of the yeast cell wall (YCW) (ActigenTM;
Alltech Inc., Nicholasville, KY) in the equine, 24 non-PPID mixed-breed and mixed-sex
animals (13 ID and 11 non-ID controls; 4 non-supplemented horses in each metabolic
group) were selected as described above. Horses were blocked by insulin responses to the
OST as well as age and randomly assigned to either the YCW supplemented or nonsupplemented groups. All horses were acclimated to their respective paddocks at the
University of Kentucky’s Department of Veterinary Science Woodford County facility for
> 9 months with ad libitum access to mixed-grass hay, a trace mineralized salt block, and
water. None of the horses received any form of concentrate prior to the study. Two weeks
prior to the start of supplementation, all horses were acclimated to study feeding protocols,
with a 0800-0900 EST individual pen feeding with 0.45 kg balancer pellet (M30; Mc
Cauley Bros Inc., Versailles, KY) which was used for the duration of the study. The OST
was performed as described above prior to supplementation (July of 2016) as well as
following 45 days of supplementation (September of 2016) with 6 g/horse/day of
ActigenTM top-dressed on balancer pellet or balancer pellet only for the non-supplemented
horses. For both the OST 0 and 60 min time points, blood samples were collected for
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determination of metabolic (serum glucose and insulin), inflammatory (cytokine or TLR
protein and gene expression in lymphocytes as well as circulating), and plasma LPS
concentrations.
6.2.2. Metabolic parameters
All serum samples for insulin determination from the OST were sent to Cornell
University’s Animal Health Diagnostic Centers Endocrinology Laboratory using a
commercially available radioimmunoassay for human insulin (RIA) (EMD Millipore Corp,
Billerica, MA). This RIA assay was validated for use on equine serum samples as follows;
serial dilutions of 4 equine samples with assay buffer were parallel to the standard curve,
and samples that were spiked with four different quantities of porcine insulin (SigmaAldrich, St. Louis, MO) had observed concentrations that averaged 96% of expected. The
manufacturer did not report the cross-reactivity of the RIA antibody for equine insulin.
However, the cross-reactivity for porcine insulin was reported as 100%, and the homology
between equine and porcine insulin is 98%. The sensitivity of the assay, as reported by the
manufacturer, is 2.72 IU/mL. The mean intra- and inter-assay coefficients of variation
were 7.4 and 6.3%, respectively. In addition to serum insulin analysis, serum was analyzed
for glucose concentrations. Glucose analysis was performed by Cornell University’s
Animal Health Diagnostic Center Clinical Pathology Laboratory (Ithaca, NY) with a
hexokinase kinetic method as previously described [47].
6.2.3. Inflammatory parameters
6.2.3.1. Lymphocyte inflammatory cytokine production as measured by flow
cytometry
Heparinized blood samples were taken both pre and post OST as well as pre and
post supplementation. Peripheral blood mononuclear cells (PBMCs) were isolated from
heparinized blood by Ficoll-Paque PlusTM (Amersham Biosciences, Piscataway, NJ)
gradient centrifugation [197]. PBMCs at a concentration of 2 X 108 were frozen suspended
in media (10% dimethyl sulfoxide (DMSO; Sigma-Aldrich, St. Louis, MO), 40% fetal
bovine serum (FBS; Sigma), and 50% RPMI-1640 (Gibco, Grand Island, NY)) in liquid
nitrogen until the end of the study, at which point they were thawed by horse for stimulation
and analysis. For in vitro stimulation, cells were thawed in c-RPMI media [RPMI-1640
supplemented with 2.5% fetal equine serum (FES; Sigma–Aldrich, St. Louis, MO), 100
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U/mL penicillin/streptomycin (Sigma), and were plated and incubated for 4H at 37 ° C,
5% CO2. Select wells were incubated with 10 mg/mL Brefeldin A (Sigma) and select wells
additionally incubated with 25 ng/mL phorbol 12-myristate 13-acetate (PMA; Sigma) and
ionomycin (1 mM; Sigma) as a positive control. Separate select wells were also incubated
with 10 ng LPS (catalogue #L5293; Sigma) for 2 H. Following incubation, aliquots of the
cells were isolated for determination of gene expression by a Trizol (Ambion) method to
isolate RNA (see below). Remaining cells incubated with BFA alone, or the combination
of BFA and PMA, were used to determine IFN-γ and TNF-α protein production by flow
cytometry. In brief, using 2% paraformaldehyde (Sigma), cells were fixed and allowed to
incubate at 4º C overnight. Following this, intracellular staining was performed as
previously described [198]. Stained cells were re-suspended in FACS flow (Becton
Dickinson (BD), San Jose, CA) and a BD AccuriTM (BD) used for flow cytometric
acquisition and determination of IFN-γ and TNF-α protein production.
6.2.3.2. Lymphocyte gene expression measured by real-time polymerase chain
reaction (RT-PCR)
RNA was extracted using a modified Trizol method. cDNA was generated by
reverse transcription using 1 µg of RNA as previously described [197]. Briefly, RNA
sample and a master mix (Promega, Madison, WI) were combined and incubated at 42º C
for 15 min and at 95º C for 5 min. cDNA (4.5 µL) was then combined with a Master Mix
(5 µL; SensiMix, HI-ROX 2x, Bioline) and the equine-specific, intron-spanning, primerprobe of interest (0.5 µL; TaqManTM, Applied Biosystems). An Applied Biosystems RTPCR ABI 7900HT was used to run samples for the following genes of interest: betaglucuronidase (house-keeping gene; β-gus; Ec03470630_m1), interferon gamma (IFN-γ;
Ec03468606_m1),

IL-6

(Ec03468678_m1),

IL-1β

(Ec04260298_s1),

TNF-α

(Ec03467871_m1), and TLR4 (Ec03468994_m1) [199]. All samples were run in duplicate.
Following a 10 min incubation at 95o C, they underwent 40 cycles of 15 sec at 95o C and
60 sec at 60o C. The CT method [200] was used to determine relative changes in gene
expression, with the average pre supplementation time 0 samples mean CT for all horses
set at the calibrator for all samples. Results are expressed as relative quantities (RQ),
calculated as 2-CT.
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6.2.3.3. Whole blood gene expression measured by real-time polymerase chain
reaction (RT-PCR)
Samples (3 ml whole blood) were collected pre and 60 minutes post oral sugar test
as well as pre and post supplementation into Tempus™ Blood RNA Tubes (Life
Technologies, Grand Island, NY). Tubes were shaken vigorously following blood
collection and incubated at room temperature for 24 hrs. Following incubation, they were
stored at -20 ºC for later analysis. Prior to analysis, tubes were thawed and total RNA
extracted using iPrep RNA isolation kit (Thermo Fisher Scientific, Waltham, MA)
following the manufacturer's instructions. Following this, reverse transcription reactions
and RT-PCR took place as described above.
6.2.3.4. Serum inflammatory parameters as measured by enzyme-linked
immunosorbent assay (ELISA) and Luminex bead-based multiplex assay
The commercially available equine TNF-α ELISA (R&D Systems, Inc.,
Minneapolis, MN) was used for determination of serum concentrations of TNF-alpha
protein both pre and post OST as well as pre and post supplementation. Assay was carried
out per the manufacturer’s instructions, with the exception the following: dilutions were
performed with buffer (2.5 mmol NaH2PO4, 7.5 mmol Na2HPO4, 145 mmol NaCl, 0.1%
(v/v) Tween 20, pH 7.2) and samples plated in duplicate in a 96-well plate. The sensitivity
of the ELISA was 15.6 pg/ml with a mean intra- and inter-assay coefficients of variation
of 2.0% and 5.4%, respectively.
Serum C-reactive Protein (CRP) concentrations were also measured pre and post
OST as well as pre and post supplementation. CRP concentrations were determined by the
equine specific commercially available kit (Kamiya Biomedical Company, Tukwila, WA)
and was used according to the manufacturer’s instructions.
Pre and post OST as well as pre and post supplementation, a multiplex assay using
a Luminex x200 (Luminex Corporation, Austin, TX) was used to further measure serum
markers of inflammation. The equine specific assay (EMD Millipore Corporation Billerica,
MA; EQCYTMAG-93K) contained antibodies against IL-6, IFN-γ, and MCP-1 (Monocyte
chemotactic protein-1). The protocol was performed per manufacturer’s instructions.
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6.2.4. LPS as measured by LAL chromogenic endotoxin assay
Heparinized plasma collected from all time points and immediately isolated using
sterile techniques following collection upon arrival to the lab. Plasma was transferred to
LPS free glass 15 ml tubes and frozen at -20 º C until further analysis. Samples were
analyzed using a Pierce™ LAL Chromogenic Endotoxin Quantitation Kit (Thermo Fisher
Scientific, Waltham, MA) per the manufactures’ instructions, with the following
exceptions; plasma samples were diluted 1:3 in endotoxin free water and reactions were
mixed by gently swirling plates.
6.2.5. Data analysis
Prior to analysis, data points within variables determined to be outliers were
removed from the analysis. Outliers were established as being 1.5 times the interquartile
range below or above the 1st or 3rd quartiles, respectively. Analysis of data were completed
with a repeated measures ANOVA using PROC MIXED, SAS 9.4 (SAS Institute Inc.,
Cary, NC, USA). Horse ID, metabolic group (ID vs non-ID controls), period (pre vs post
supplementation), time (0 vs 60 min OST time points), and treatment (supplemented vs
non-supplemented horses) were set at fixed effects and all potential interactions between
these effects analyzed. Horse ID was set as a random effect and time and period with the
subject horse set as the repeated measures. Pairwise comparisons were made using
protected LSD. Significance was set at P < 0.05 and trends considered at P < 0.10. Pairwise
comparisons were examined for both trends and significant differences as determined by
ANOVA. Normality was determined by analysis of residuals. Data with residuals not
visually normal or with a skew of < 2 and/or kurtosis of < 7 were natural log transformed
and resulted in normality.

6.3. Results
6.3.1. Metabolic parameters
Metabolic results are presented in Figures 6.1 and 6.2. There was no effect of
treatment on serum insulin concentrations (Figure 6.1). All horses responded to OST (P =
0.0005) with an increase in insulin concentrations from time point 0 to time point 60.
Overall (P = 0.0003), ID horses had higher insulin responses compared to non-ID controls
and there was a significant metabolic group (ID vs non-ID controls) by period (pre vs post
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supplementation) interaction (P = 0.0067). Prior to supplementation, non-ID control horses
were lower compared to ID horses (P = 0.0111) in serum insulin. This did not change
following supplementation, with non-ID control horses still lower in serum insulin
compared to ID horses (P < 0.0001) however, ID horses had a significant increase in insulin
following the supplementation period (P = 0.0023) whereas non-ID control horses did not
(P = 0.4116).
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Figure 6.1. Mean (± SEM) natural log of serum insulin concentrations (µIU/mL) in supplemented non-ID control horses (n = 7), nonsupplemented non-ID control horses (n = 4), supplemented ID horses (n = 9) and non-supplemented ID horses (n = 4) at two different
time points (baseline prior to oral sugar administration (time point 0; represented in black) and 60 min following (time point 60;
represented in gray) as well as at the pre (represented by solid bars) and post (represented by corregated bars) supplementation periods.
Significant (P < 0.05) group by period interaction with non-ID control horses having lower insulin than ID horses regardless of period,
and ID horses higher at the post supplementation period compared to pre. Significant overall effect of time with time point 0 lower
compared to time point 60. Significant overall effect of group with ID horses higher compared to non-ID controls horses.

Serum glucose concentrations (Figure 6.2) were likewise not affected by YCW
supplementation. However, there was a trend for a metabolic group by treatment by period
interaction (P = 0.0737) where YCW supplemented ID horses increased in serum glucose
from pre to post supplementation (P = 0.0084) and were higher post supplementation
compared to supplemented non-ID control horses (P = 0.0295). There was an effect of OST
on serum glucose, with a significant time (time point 0 vs time point 60) by period (pre vs
post supplementation) interaction (P = 0.0137) where time point 0 was consistently lower
compared to time point 60, regardless of period (P < 0.0001), and glucose concentrations
increased pre vs post supplementation within time point 0 (P = 0.002). Further, there was
also a significant metabolic group by time interaction (P < 0.0001) for serum glucose, with
ID and non-ID control horses both having a significant increase in glucose in response to
the OST (P < 0.0001). ID horses had no differences in glucose compared to non-ID controls
at time point 0 (P = 0.4415), but were higher at time point 60 (P = 0.0233). In addition,
there was an overall effect of period (P = 0.0401), with horses higher in serum glucose
following the supplementation period.
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Figure 6.2. Mean (± SEM) serum glucose concentrations (mg/dL) in supplemented non-ID control horses (n = 7), non-supplemented
non-ID control horses (n = 4), supplemented ID horses (n = 9) and non-supplemented ID horses (n = 4) at two different time points
(baseline prior to oral sugar administration (time point 0; represented in black) and 60 min following (time point 60; represented in gray)
as well as at the pre (represented by solid bars) and post (represented by corregated bars) supplementation periods. Significant (P < 0.05)
time by period interaction with horses lower in glucose at time point 0 compared to time point 60 regardless of period, and horses within
time point 0 at the pre supplementation period lower compared to post. Significant group by time interaction with both groups increasing
in glucose from time point 0 to time point 60 and ID horses higher compared to non-ID control horses at time point 60. Significant
overall effects of time and period with horses higher at time point 60 compared to time point 0 and higher at the post supplementation
period compared to pre, respectively.

While there was no effect of treatment, horses responded as expected to the OST
for both serum insulin and glucose, and had an increase in both of these metabolic
parameters from the pre to post supplementation period.
6.3.2. Inflammatory parameters
6.3.2.1. Lymphocyte inflammatory cytokine production
Lymphocytes stimulated with PMA and intracellularly stained with TNF-α for flow
cytometric cytokine protein analysis (Figure 6.3) were not significantly affected by YCW
supplementation. However, there was a trend for a four-way metabolic group by treatment
by time by period interaction (P = 0.0828). When examining pairwise comparisons, for
most horses there was a decline in TNF-α % gated (percentage of the lymphocyte
population stained positive for TNF-α %) in response to OST and from pre to post
supplementation. Prior to supplementation, non-supplemented non-ID control horses at
time point 0 had the highest TNF-α % gated, and were higher compared to all other periods
and time points (P < 0.0233). They were also higher compared to supplemented non-ID
control horses for all time points and periods (P < 0.0247), with the exception time point
60 prior to supplementation. Supplemented non-ID control horses did not change in TNFα % gated in response to OST ether pre (P = 0.247) or post supplementation (P = 0.383).
Prior to supplementation, supplemented non-ID control horses at time point 0 were lower
compared to supplemented ID horses (P = 0.0355). This was similarly true for the post
supplementation period (P = 0.0434). Supplemented non-ID control horses decreased
significantly from pre supplementation at time point 60 compared to that same time point
post supplementation (P = 0.0024). They were also lower compared to ID horses,
regardless of treatment, for all periods and time points (P < 0.0302), with the exception of
non-supplemented ID horses post supplementation at time point 60 (P = 0.9203). Finally,
supplemented ID horses at time point 0 decreased from pre to post supplementation in
TNF-α % gated (P = 0.022). There was an overall trend (P = 0.0773) for an effect of time,
with horses decreasing in TNF-α in response to OST. There was a significant overall effect
of period (P < 0.0001) for TNF-α % gated where, regardless of metabolic status or
supplementation, horses were overall lower following the supplementation period.
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Figure 6.3. Mean (± SEM) percentage of PMA stimulated lymphocytes intracellularly stained positive for TNF-α in supplemented nonID control horses (n = 7), non-supplemented non-ID control horses (n = 4), supplemented ID horses (n = 9) and non-supplemented ID
horses (n = 4) at two different time points (baseline prior to oral sugar administration (time point 0; represented in black) and 60 min
following (time point 60; represented in gray) as well as at the pre (represented by solid bars) and post (represented by corregated bars)
supplementation periods. Significant (P < 0.05) overall effect of period, with horses higher pre vs post supplementation.

There was no effect of treatment on PMA stimulated lymphocytes intracellularly
stained with IFN-γ (data not shown). While there was a trend for a metabolic group by
treatment interaction (P = 0.0544), there were no significant pairwise comparisons. There
was also a treatment by period interaction (P = 0.0628) with non-supplemented horses
lower in IFN-γ post supplementation compared to pre (P = 0.0029). There was no effect of
OST on IFN-γ in PMA stimulated lymphocytes. However, there was a significant overall
effect of period (P = 0.0021) with horses lower post supplementation compared to pre
supplementation, and a metabolic group by period interaction (P = 0.0822) with non-ID
control horses lower post supplementation compared to pre supplementation (P = 0.0015).
6.3.2.2. Lymphocyte gene expression
For lymphocytes stimulated with PMA (data not shown) cytokine and TLR gene
expression did not differ significantly for any of the variables measured, with the exception
of IFN-γ. There was a significant effect of time (P = 0.0319) on IFN-γ PMA stimulated
gene expression with all horses decreasing in response to OST. There were a number of
trends observed. There was a trend (P = 0.0883) for a metabolic group by time by period
interaction for TNF-α gene expression where post supplementation, non-ID control horses
were lower compared to ID horses at time point 60 (P = 0.012). TLR-4 gene expression
had trends for overall difference of time (P = 0.0554; horses increasing in response to OST)
and period (P = 0.066; horses increasing from pre to post supplementation). There was also
a trend for metabolic group by time interaction (P = 0.0886) for IL-6 gene expression,
however none of the pairwise comparisons were significant.
There were differences or trends for cytokine and TLR gene expression of
lymphocytes stimulated with LPS (Figures 6.4 - 6.7). There was no effect of treatment on
LPS stimulated TNF-α gene expression, however there was a trend for a metabolic group
by treatment by period interaction (P = 0.0676). Non-supplemented ID horses prior to
supplementation were higher compared to supplemented ID horses both pre (P = 0.0411).
There was also a trend for an overall effect of treatment (P = 0.0966), with nonsupplemented horses having a trend to be higher compared to supplemented horses. The
only significant effect on LPS stimulated TNF-α gene expression (P = 0.0379) was an
effect of time, with all horses increasing in response to the OST (Figure 6.4).
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Figure 6.4. Mean (± SEM) relative quantity (RQ) of LPS stimulated PBMC TNF-α gene
expression in supplemented non-ID control horses (n = 7), non-supplemented non-ID
control horses (n = 4), supplemented ID horses (n = 9) and non-supplemented ID horses (n
= 4) at two different time points (baseline prior to oral sugar administration (time point 0;
represented in black) and 60 min following (time point 60; represented in gray)) as well as
at the pre (represented by solid bars) and post (represented by corregated bars)
supplementation periods. Significant (P < 0.05) overall effect of time point with horses
lower at time point 0 compared to time point 60.

There was no significant effect of treatment on TLR-4 LPS stimulated gene
expression (Figure 6.5), however there was a trend for a metabolic group by treatment by
period interaction (P = 0.0934), with non-supplemented ID horses post supplementation
lower in TLR-4 gene expression compared to pre supplementation (P = 0.0395). There
were significant effects of OST on TLR-4, with an overall increase in response to OST for
all horses (P = 0.007). Further, there was a significant metabolic group by time by period
interaction (P = 0.0334) where ID horses had a decrease in TLR-4 gene expression from
the pre to post supplementation periods within time point 60 (P = 0.0042). Prior to
supplementation, ID horses also had a significant increase in gene expression in response
to OST (P = 0.0005). In addition, there was a significant metabolic group by period
interaction (P = 0.039) for TLR-4 LPS stimulated gene expression, but no pairwise
comparisons were significant.
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Figure 6.5. Mean (± SEM) relative quantity (RQ) of LPS stimulated PBMC TLR-4 gene
expression in supplemented non-ID control horses (n = 7), non-supplemented non-ID
control horses (n = 4), supplemented ID horses (n = 9) and non-supplemented ID horses (n
= 4) at two different time points (baseline prior to oral sugar administration (time point 0;
represented in black) and 60 min following (time point 60; represented in gray) as well as
at the pre (represented by solid bars) and post (represented by corregated bars)
supplementation periods. Significant (P < 0.05) group by time by period interaction with
ID horses increasing in TLR-4 between time points where they were higher at time point
60 compared to non-ID controls at the pre supplementation period. Significant group by
period interaction with no significant pairwise comparisons and an overall significant effect
of time point with horses lower at time point 0 compared to time point 60.

LPS stimulated IL-6 lymphocyte gene expression (data not shown) had no
significant differences for any of the variables measured. There was however a trend for a
metabolic group by treatment by time interaction (P = 0.0585), with non-supplemented
non-ID control horses increasing in IL-6 gene expression in response to OST (P = 0.0479).
Non-supplemented non-ID control horses at time point 60 were also higher compared to
supplemented non-ID control horses at that same time point (P = 0.0275).
There was an overall effect of treatment (P = 0.0041) for IL-10 (Figure 6.6), with
treated horses lower compared to non-supplemented horses. There were no effects or trends
of metabolic status, time, or period on IL-10 LPS stimulated gene expression. For IFN-γ
(Figure 6.7), there was a significant metabolic group by treatment by time by period
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interaction (P = 0.036). Post supplementation, non-supplemented horses had a significant
increase in IFN-γ in response to OST (P = 0.042). Time points 0 and 60 pre
supplementation were lower compared to time point 0 post supplementation for nonsupplemented horses (P < 0.0265). Supplemented horses at the post supplementation
period had a significant increase in IFN-γ LPS stimulated gene expression (P = 0.0183).
Supplemented horses post supplementation at time point 60 were also higher than
compared to pre supplementation at that same time point (P = 0.0182). Further, there was
a treatment by time interaction (P = 0.0259), with supplemented horses increasing in IFNγ in response to OST (P = 0.0328). Similarly, there was a significant metabolic group by
time interaction (P = 0.0239) for IFN-γ LPS stimulated gene expression, with a trend for
ID horses to have an increase in gene expression in response to OST (P = 0.0631). Finally,
there was a significant effect of period (P = 0.0107) with horses increasing from the pre to
the post supplementation period.
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Figure 6.6. Mean (± SEM) relative quantity (RQ) of LPS stimulated PBMC IL-10 gene
expression in supplemented non-ID control horses (n = 7), non-supplemented non-ID
control horses (n = 4), supplemented ID horses (n = 9) and non-supplemented ID horses (n
= 4) at two different time points (baseline prior to oral sugar administration (time point 0;
represented in black) and 60 min following (time point 60; represented in gray) as well as
at the pre (represented by solid bars) and post (represented by corregated bars)
supplementation periods. Significant (P < 0.05) overall effect of treatment with nonsupplemented horses lower compared to supplemented horses.
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Figure 6.7. Mean (± SEM) relative quantity (RQ) of LPS stimulated PBMC IFN-γ gene
expression in supplemented non-ID control horses (n = 7), non-supplemented non-ID
control horses (n = 4), supplemented ID horses (n = 9) and non-supplemented ID horses (n
= 4) at two different time points (baseline prior to oral sugar administration (time point 0;
represented in black) and 60 min following (time point 60; represented in gray) as well as
at the pre (represented by solid bars) and post (represented by corregated bars)
supplementation periods. Significant (P < 0.05) treatment by time by period interaction
with non-supplemented horses higher in IFN-γ at the post supplementation period for time
point 0 compared to time point 60 as well as pre supplementation for time point 0, and
supplemented horses were higher in IFN-γ at the post supplementation period for time point
60 compared to time point 0 as well as pre supplementation for time point 60. Significant
treatment by time interaction with supplemented horses lower in IFN-γ at time point 0
compared to time point 60. Significant group by time interaction, no significant pairwise
comparisons. Significant overall effect of period with horses higher at the post
supplementation period compared to pre.

6.3.2.3. Whole blood inflammatory gene expression
There were no differences in whole blood gene expression of TLR-4 (data not
shown), regardless of time point, metabolic group, period, or treatment. There was an effect
of period on IL-6 (P = 0.0009) and IL-10 (P = 0.0009) gene expression (data not shown).
Horses had higher IL-6 but lower IL-10 at the pre supplementation period compared to
post. There were no other effects on IL-6 or IL-10 whole blood gene expression. There
were no significant effects for any variable measured on TNF-α, but there was a trend for
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an effect of period (P = 0.0539) (Figure 6.8), where horses increased in TNF-α from the
pre supplementation to post supplementation period. Additionally, there was a trend for a
metabolic group by period interaction (P = 0.0766), however while results reflected an
increase in gene expression of TNF-α in non-ID control horses from the pre to post
supplementation period, pairwise comparisons were only trending.
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Figure 6.8. Mean (± SEM) relative quantity (RQ) of whole blood IFN-γ gene expression
in supplemented non-ID control horses (n = 7), non-supplemented non-ID control horses
(n = 4), supplemented ID horses (n = 9) and non-supplemented ID horses (n = 4) at two
different time points (baseline prior to oral sugar administration (time point 0; represented
in black) and 60 min following (time point 60; represented in gray) as well as at the pre
(represented by solid bars) and post (represented by corregated bars) supplementation
periods.

6.3.3. Serum inflammatory protein markers
There were no differences or trends for serum inflammatory markers as measured
by CPR ELISA, or Luminex multiplex assay for IL-6, MCP-1, or IFN-γ concentrations for
any variable measured (data not shown). There was an effect of time on TNF-α serum
protein concentrations (P = 0.0302) (Figure 6.9) as measured by ELISA, with horses
decreasing in TNF-α in response to OST.
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Figure 6.9. Mean (± SEM) natural log of serum TNF-α concentrations (ELISA) in
supplemented non-ID control horses (n = 7), non-supplemented non-ID control horses (n
= 4), supplemented ID horses (n = 9) and non-supplemented ID horses (n = 4) at two
different time points (baseline prior to oral sugar administration (time point 0; represented
in black) and 60 min following (time point 60; represented in gray) as well as at the pre
(represented by solid bars) and post (represented by corregated bars) supplementation
periods. Significant (P < 0.05) overall effect of time point with horses higher at time point
0 compared to time point 60.

6.3.4. Plasma LPS concentrations
LAL assay was able to detect differences in LPS plasma concentrations (Figure
6.10). There was a metabolic group by treatment by period interaction (P = 0.0261). Nonsupplemented non-ID control horses at prior to supplementation were higher compared to
post (P = 0.009), as well as compared to supplemented ID horses post supplementation (P
= 0.042). They also had trends to be higher compared to non-supplemented ID horses at
either periods (P = 0.0761 pre, P = 0.0562 post). Additionally, there was a treatment by
period interaction (P = 0.0338) with non-supplemented horses decreasing in LPS
concentrations from the pre to post supplementation period (P = 0.0159), and an overall
effect of period (P = 0.0338) with horses having lower LPS concentrations following the
supplementation period.
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Figure 6.10. Mean (± SEM) natural log of plasma LPS concentrations in supplemented
non-ID control horses (n = 7), non-supplemented non-ID control horses (n = 4),
supplemented ID horses (n = 9) and non-supplemented ID horses (n = 4) at two different
time points (baseline prior to oral sugar administration (time point 0; represented in black)
and 60 min following (time point 60; represented in gray) as well as at the pre (represented
by solid bars) and post (represented by corregated bars) supplementation periods.
Significant group by treatment by date interaction, with non-supplemented non-ID controls
higher in LPS pre supplementation period compared to post. Significant (P < 0.05)
treatment by period interaction, with non-supplemented horses higher pre supplementation
period in LPS compared to post, and an overall effect of date with horses higher pre
compared to post supplementation period.

6.4. Discussion
There was no effect of supplementation with a manna-rich fraction of the YCW on
either serum insulin or glucose concentrations in either ID or non-ID control horses.
However, there was a trend for a metabolic group by treatment by period interaction for
serum glucose. This trend indicated that supplemented ID horses increased in serum
glucose from pre to post supplementation, and at the post supplementation period were
higher compared to supplemented non-ID controls. In a bovine study, the opposite effect
was seen in metabolically normal heifers supplemented for 52 days with Saccharomyces
cerevisiae yeast cell wall [102], where heifers had a decrease in serum glucose and an
increase in insulin. However, while the increase in insulin was seen following
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supplementation, the decrease in glucose was observed following supplementation but only
in response to an endotoxin challenge in supplemented heifers. In addition, pigs fed a high
chromium yeast supplement had an increased glucose tolerance and clearance following
23-30 days of supplementation [255]. The differences in these results may indicate that
yeast cell wall supplementation contributes to an increase in serum glucose concentrations
in horses with ID. Conversely, this increase in glucose may be due to an increased
susceptibility to dietary changes in ID horses, be it caloric or other nutrient intake, or
treatment period or dosing may have been inadequate to positively impact the metabolic
parameters measured. Metabolically, horses responded as expected to glycemic challenge
in the form of an OST, increasing in glucose and insulin concentrations between the 0 and
60 time points, with ID horse having greater serum concentrations compared to non-ID
control horses. There was an effect of period on concentrations of both glucose and insulin,
with horses increasing from the pre supplementation (July) to post supplementation
(September) period. This may indicate an effect of season on metabolic parameters, which
have been proposed to be higher in the fall months in horses with PPID [256] and higher
in February compared to August and November and June compared to November in
healthy horses [257]. However, others have not observed the same in a group of healthy or
ID horses [258]. Regardless, these data support an effect of season on serum concentrations
of both glucose and insulin, in particular in horses with ID.
Effects of YCW supplementation on inflammatory markers were minimal. Nonsupplemented horses had a decrease in LPS concentrations following the 45 day
supplementation period whereas supplemented horses did not. Further, when examining
pairwise comparisons for the metabolic group by treatment by period interaction, it was
the non-ID control horses who were non-supplemented that had this decrease in LPS
concentrations between periods. For LPS stimulated lymphocyte IFN-γ gene expression,
there was a significant treatment by time by period interaction, indicating that both
supplemented and non-supplemented horses had an increase following the 45 day
supplementation period (within time point 60 for supplemented horses and within time
point 0 for non-supplemented horses). Interesting, post supplementation, supplemented and
non-supplemented horses had opposing responses to the OST with supplemented horses
increasing from time point 0 to time point 60 in LPS stimulated lymphocyte IFN-γ gene
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expression whereas non-supplemented horses decreased. There was also a significant
overall effect of treatment on LPS stimulated lymphocyte IL-10 gene expression, with nonsupplemented horses having higher gene expression compared to those who received
YWC. There were no other significant effects of treatment, although several trends were
observed. Of interest was the trend for the 4 way interaction between metabolic group,
treatment, time, and period for the percentage of lymphocytes stained positive for TNF-α.
Within time point 0, ID supplemented horses had a decrease in TNF-α following
supplementation. Non-ID control horses, regardless of supplementation status, had a
similar decrease between periods. However, non-supplemented ID horses had no
difference in their percentage of lymphocytes stained positive for TNF-α between the pre
and post supplementation period. These data suggest that supplementation with yeast cell
wall in horses may have some impact on lymphocyte mediated inflammation.
Differences due to metabolic status, in particular in response to the OST, in respect
to inflammatory parameters were varied. We and others have previously shown that in
response to a meal or an oral sugar challenge, ID and non-ID control horses have an
inflammatory response [46, 47], and that this response can differ between the two
metabolic groups [47]. There was a significant metabolic group by time by period
interaction for LPS stimulated lymphocyte TLR-4 gene expression. ID horses had a large
increase in TLR-4 gene expression in response to oral sugar prior to supplementation that
was not seen post supplementation or in the non-ID control horses. There was also a
significant metabolic group by time interaction for LPS stimulated lymphocyte IFN-γ gene
expression with ID horses having a trend to increase in IFN –γ in response oral sugar
administration whereas non-ID horses had a (non-significant) decrease. For TNF-α gene
expression in PMA stimulated lymphocytes, post supplementation ID horses were higher
in TNF-α gene expression compared to non-ID control horses at time point 60. In addition,
there was a trend for a metabolic group by treatment by time interaction for LPS stimulated
lymphocyte IL-6 gene expression. This trend was due to the higher IL-6 gene expression
in non-supplemented non-ID control horses at time point 60. There were also trends for an
effect of metabolic group on the percentage of lymphocytes stained positive for both TNFα and IFN-γ. ID and non-ID control horses supplemented with yeast cell wall decreased in
TNF-α following supplementation, as discussed above, whereas non-supplemented ID
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horses did not. For IFN-γ, non-ID control horses decreased in IFN-γ between the two
periods, whereas the ID horses did not change. Finally there was a trend for a metabolic
group by period interaction for whole blood IFN-γ gene expression, and while pairwise
comparisons were only trends, they indicated that post supplementation non-ID controls
had a tendency to be lower compared to ID horses regardless of period. These data may
further point to an increased sensitivity to changes in season in horses with ID.
In respect to overall differences between the 0 and 60 time points, PMA stimulated
lymphocyte IFN –γ gene expression and TNF-α serum protein concentrations (ELISA) in
horses were overall higher at time point 0 vs time point 60. However, for LPS stimulated
lymphocyte TNF-α and TLR-4 horses were higher at time point 60 compared to time point
0. Further indications of an effect of time were observed in significant interactions for LPS
stimulated lymphocyte TLR-4 gene expression (discussed above) and LPS stimulated
lymphocyte IFN –γ gene expression. Interactions involving time point seen with IFN –γ
show that following the supplementation period, supplemented horses had an increase in
gene expression in response to the OST whereas non-supplemented horses had a decrease.
Further, regardless of period and treatment, this pattern was observed in respect to
metabolic status (discussed above). Trends were observed for an overall effect of time as
well. They indicated that gene expression of TLR-4 in PMA stimulated lymphocytes was
increased in response to OST, likely due to a large increase prior to supplementation in the
ID horses. Gene expression of IL-6 in PMA and LPS stimulated lymphocytes was also
increased in response to OST, but this increase was seen in non-ID controls or nonsupplemented non-ID controls, not in ID horses or horses receiving YCW supplementation.
Additionally, the percentage of lymphocytes producing TNF-α (% gated) had a trend to
decrease from the 0 to 60 time points and a trend for a 4 way interaction indicating that
non-supplemented non-ID control horses pre supplementation were primarily responsible
for this decrease in TNF-α % gated in response to the OST.
Similar to metabolic parameters, there was an apparent effect of period on
inflammatory markers. There was an overall increase following the 45 day
supplementation period in IFN-γ gene expression of LPS simulated lymphocytes, and
horses had trends to be higher in TLR-4 gene expression of PMA simulated lymphocytes
and TNF-α gene expression in whole blood. On the other hand, they had a decrease
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following the supplementation period in plasma LPS concentrations, the percentage of
lymphocytes stained positive for both TNF-α and IFN-γ, whole blood gene expression of
IL-10, and whole blood gene expression of IL-6. There have been indications in other
species, such as baboons, fish, and rodents that season is able to impact the immune
response [259-261]. Specifically, serum concentrations of CRP were greater in June
compared to December, and a seasonal influence was also seen for serum IL-6 levels in
baboons [259]. In fact, a decrease in IL-6 and IL-1β in Siberian hamsters in response to
LPS and shorter day lengths indicate a that the immune response may be reduced in the
winter months [260]. There has been some work related to the immune response and season
in the horse [262-264]. Seasonal allergy responses in PBMCs in particular have been
utilized [265, 266] and show increased PBMC production of IFN-γ and a decreased
production of IL-4 in the winter compared to summer months [265]. However, another
study in horses with summer pasture-associated obstructive pulmonary disease (SPAOPD)
as well as controls, showed increases in PBMC IFN-γ gene expression in the summer as
compared to the winter [266]. For this study horses had an increase from July to September
in pro-inflammatory cytokine or TLR gene expression of IFN-γ, TNF-α, and TLR-4.
However, horses had a decrease in gene expression of the anti-inflammatory IL-10 as well
as IL-6, lymphocyte protein concentrations of IFN-γ and TNF-α, and plasma LPS
concentrations. This may point to seasonal variations in post transcriptional factors, but
more research is needed to better understand possible seasonal influences on inflammatory
responses in both the ID and metabolically normal horse.
Metabolic parameters were increased from pre to post supplementation and in
response to oral sugar administration, in particular in ID horses. However there was not a
significant effect of YCW supplementation on either basal or OST responses of serum
insulin or glucose. There were limited effects of treatment and metabolic status on
inflammatory markers, however non-supplemented horses or non-ID controls frequently
had a decrease in pro-inflammatory markers of inflammation at both the protein and gene
expression levels in response to OST whereas ID horses increased. Overall, these data show
a strong effect of period and OST on the variables measured and suggest that ID horses
may be particularly sensitive to changes in metabolic stimuli or season.
Copyright © Sarah E. Elzinga 2017
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CHAPTER 7 EQUINE WHOLE BLOOD INFLAMMATORY GENE EXPRESSION
IN INSULIN DYSREGULATED (ID) AND CONTROL HORSES IN RESPONSE TO
A TLR-4 AGONIST, LPS
Insulin dysregulation (ID) in the horse is considered to be an increasing problem,
due in large part to its association with the often career or life ending condition, laminitis.
However, underlying mechanisms of ID and the development of laminitis, in particular as
they relate to inflammation, remain unclear. There have been reports that horses with ID
have increased levels of inflammatory cytokines, especially in response to oral glycemic
challenge. It has also been shown that both levels of inflammation as well as bacterial
endotoxin, or lipopolysaccharide (LPS), are increased in humans in response to a meal.
The primary pattern recognition LPS receptor in humans and horses is a member of the toll
like receptor family, TLR-4 (toll like receptor 4). It can function in response to LPS through
the MyD88 (Myeloid differentiation primary response gene 88) dependent or independent
pathways. However, it remains to be seen if differences in postprandial inflammatory
responses in ID horses are driven in part by differential regulation of LPS TLR-4
inflammatory signaling. We therefore hypothesized that horses with ID would have
differences in their TLR4 mediated inflammatory response to an oral glycemic challenge
in response to LPS stimulation. To accomplish this, a total of 14 adult, non-PPID, mixedbreed and mixed-sex horses (7 ID and 7 non-ID controls, not different in age) were used in
this study. Horses were administered an oral sugar test (OST), and blood collected via
jugular venipuncture prior to (time point 0) and 60 min post oral sugar administration (time
point 60). Blood was analyzed at both time points for serum insulin concentrations as well
as whole blood inflammatory markers in both LPS stimulated and unstimulated samples.
As expected, ID horses had significantly greater serum insulin at time point 60 in
comparison to controls (P < 0.0001). LPS was able to induce gene expression in relation
to unstimulated samples in all horses for all inflammatory markers, with the exception of
the chemokine CCL2 (chemokine (C-C motif) ligand 2; P < 0.005). Inflammatory markers
associated with the MyD88 independent pathway were however only minimally increased
or did not change in response to LPS stimulation. There was an effect of oral sugar
administration, with decreases in CCL2 and TLR-4 in LPS stimulated samples. Further,
whole blood gene expression of the chemokines IL-8 (interleukin 8) and CCL2 were lower
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in ID compared to control horses. This indicates that in whole blood, LPS stimulates
inflammatory responses primarily of MyD88 dependent associated genes, regardless of
metabolic status, and that horses with ID may have an impaired innate immune response.
However, more work is needed to understand possible differences in immune responses of
ID compared to metabolically normal horses.

7.1. Introduction
Metabolic dysfunction, in particular insulin dysregulation, is considered to be of
concern in the equine due to its association with numerous health concerns including the
potentially fatal condition, laminitis [12, 15]. In humans, low grade systemic inflammation
is often observed in individuals with metabolic dysfunction [267], but although this is
suggested to be the case in the horse as well [127, 139, 140], the link between inflammation
and ID, as well as underlying mechanisms of ID and relationship to laminitis in the horse
remains unclear. Environmental factors, in particular over-nutrition and a lack of exercise
leading to an increased fat mass are thought to be influential in the development of
metabolic dysfunction in the horse [142]. Adipose tissue is itself categorized as an
endocrine organ, and as such is capable of producing inflammatory cytokines [268]. There
has been evidence in obese or insulin resistant humans and mice however, that adipose
tissue macrophages, not adipose tissue, have a greater role in the production of
inflammatory cytokines, such as tumor necrosis factor alpha (TNF-α) [145, 146]. Adipose
tissue dysfunction is often a prominent aspect of obesity and ID. This dysfunction involves
macrophage accumulation, wherein these cells accumulate in greater numbers and size in
the tissue, and favor M1 (largely proinflammatory) over M2 (largely anti-inflammatory)
macrophages [131, 147].
Recognition of pathogens by macrophages principally occurs via pattern
recognition receptors (PRR). In particular, the PRR toll-like receptor 4 (TLR4), is primarily
responsible for recognition of bacterial lipopolysaccharide (LPS) [148]. Once triggered by
LPS, TLR4 (along with its co-receptors cluster of differentiation 14 (CD14) and
lymphocyte antigen 96 (MD-2)) activate a signaling cascade which ultimately allows the
release of NF- κB (nuclear factor kappa-light-chain-enhancer of activated B cells) and its
translocation into the cell’s nucleus for induction of proinflammatory gene expression
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[149]. TLR-4 predominantly functions in response to LPS through one of two pathways;
MyD88 (Myeloid differentiation primary response gene 88) dependent TIRAP (TIR
Domain Containing Adaptor Protein) pathway, resulting in proinflammatory cytokine
production (such as TNF-α and IL-6 (interleukin 6)), or the MyD88 independent TRIF
(TIR-domain-containing adapter-inducing interferon-β) pathway, resulting in the
production of type I interferons (such as interferon beta, or IFN-β), and chemokines such
as CCL5 (Chemokine (C-C motif) ligand 5, or RANTES) and CCL2 (Chemokine (C-C
motif) ligand 2, or MCP-1) [269, 270]. Not only is this receptor complex able to recognize
LPS, but it is also able to recognize free fatty acids (FFA), resulting in a similar activation
of NF- κB and subsequent production of proinflammatory cytokines, including TNF-α
[148, 150, 270].
There have been reports that TLR4 concentrations and gene expression are elevated
in both animals and humans with metabolic dysfunction [271, 272]. Indeed, high fat fed
mice have been used to show that endotoxemia can induce both inflammation and insulin
resistance [61]. Further, increases in inflammatory markers and endotoxin concentrations
[43, 46, 47, 59, 60, 273] have been observed in multiple species, including the horse,
following a meal. Considering the proposed involvement of the gut both in metabolism and
the inflammatory process, these postprandial increases in concentrations of bacterial
endotoxin are not surprising [62, 63]. Therefore, the goal of this work was to examine
mechanisms relating to differences in inflammatory responses in ID horses, possibly due
to alterations in TLR-4 inflammatory signaling in response to glycemic challenge as well
as endotoxin stimulation.

7.2. Materials and methods
7.2.1. Horse selection and study design
A total of 14 mixed-breed and mixed-sex horses were selected from the
University’s Department of Veterinary Science Woodford County herd; 7 ID and 7 nonID controls. ID was established using an oral sugar test (OST) [13, 47], with
hyperinsulinemia diagnosed as a fasting serum insulin level of > 20 μIU/mL and a
concentration of insulin > 60μU/mL 60 minutes post OST was considered further
indicative of ID. Horses were also scored for body condition (BCS) based on the 1-9
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Henneke scoring system [186] and cresty neck score (CNS) based on the 0-5 Carter et. al.
scoring system [187] to determine overall and regional adiposity, respectively. Phenotypic
data is presented in Table 7.1. Breed distribution of the ID horses (3 geldings and 4 mares;
average age 13.6 yrs) was as follows; 1 was of mixed breed, 2 were Warmbloods, 2 were
Standardbred or Standardbred cross, 1 a Morgan, and 1 a Quarter Horse. Breed distribution
of the 7 non-ID controls horses (3 geldings and 4 mares; average age 13.1 yrs) was as
follows; 3 were of mixed breed, 3 were Thoroughbreds, and 1 was a Quarter Horse. Horses
were housed at the University of Kentucky’s Department of Veterinary Sciences Woodford
County facility and allowed to acclimate for > 9 mo to their respective pastures prior to the
start of the study. They were provided ad libitum access water and a trace mineralized salt
block. While none of the horses were fed any form of concentrate and pasture was minimal
and composed of mixed-grass, they were given unrestricted access to a mixed-grass hay.

Table 7.1. Phenotypic measures of ID and control horses.
Insulin 60 min
Baseline
post oral sugar
Group
Insulin
administration
BCS
CNS
Control
13.9 ± 11.4
21.8 ± 11.4
6 ± 0.3
1.8 ± 0.3
ID
40.7 ± 11.4
113.8 ± 11.4
7 ± 0.4
2.8 ± 0.4
p value
0.1108
< 0.0001
0.1061
0.0798
Data are presented as least square means ± standard error of the mean for insulin, body
condition score (BCS), and cresty neck score (CNS). n = 7 ID and n = 7 controls. BCS and
CNS are presented as an average score between 4 trained individuals.
This was an observational study with all horses sampled during the winter season
of 2017. Fourteen non-PPID (see below) mixed-breed and mixed-sex animals (7 ID and 7
non-ID controls) were selected. An OST (described above) was administered, and blood
samples from time points 0 and 60 were collected for determination of serum insulin
levels as well as whole blood gene expression of markers of inflammation.
Thyrotropin resealing hormone (TRH) stimulation was used to rule out any horses
affected by Pituitary Pars Intermedia Dysfunction (PPID). TRH stimulation testing was
performed as previously described [47, 191, 192], with a blood sample collected via jugular
venipuncture in the a.m. (between 0800 and 1000, EST). Following this, TRH (1 mg/mL;
Sigma-Aldrich, St. Louis, MO) was administered intravenously and 10 min later a second
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blood sample collected. Blood tubes (containing ethylenediaminetetraacetic acid, or
EDTA) were placed on ice, transported to the lab, and upon arrival were centrifuged to
isolate plasma [193] which was stored at -20 º C. Samples were sent on dry ice to Cornell
University’s Animal Health Diagnostic Center Endocrinology Laboratory (Ithaca, NY) for
ACTH analysis. Analysis of ACTH was accomplished with a chemiluminescent assay
(Immulite, Elangen, Germany) as previously described [195]. ACTH concentrations
exceeding either > 35 pg/mL for the baseline sample or > 180 pg/mL for the 10 min sample
were considered positive for PPID and were the basis for exclusion from the study.
7.2.2. Insulin determination
Serum insulin concentrations were analyzed by Cornell University’s Animal Health
Diagnostic Center Endocrinology Laboratory using a commercially available human
insulin radioimmunoassay (RIA; EMD Millipore Corp, Billerica, MA). This assay was
validated for use in equine serum as follows; 4 equine samples were serial dilutions with
assay buffer parallel to the standard curve. Four different quantities of porcine insulin
(Sigma-Aldrich, St. Louis, MO) were used to spike samples and concentrations averaged
96% of expected. Cross-reactivity of the RIA antibody with equine insulin was not reported
by the manufacturer however, cross-reactivity was reported as 100% with porcine insulin.
Homology between equine and porcine insulin is 98%. Assay sensitivity is reported as 2.72
IU/mL by the manufacturer. Mean intra-assay coefficient of variation was 7.4 and interassay coefficient of variation was 6.3%.
7.2.3. Whole blood gene expression
Blood was collected via jugular venipuncture into 2 (15 mL) glass heparinized
vacutainer tubes at each time point (0 and 60) and kept warm and consistently inverted to
prevent separation until arrival at the lab. Following arrival, one tube per horse per time
point was stimulated with 1 µg LPS (catalogue #L5293; Sigma). This dose was based on
an earlier study in equine monocytes [274] and modified based on data from a pilot study
that determined responses to LPS in equine whole blood (data not shown). The second tube
served as an unstimulated control. All tubes were incubated at 37º Celsius on an automated
shaker (Max Q4450, Thermo Fisher Scientific, Waltham, MA) for 2 hours. Following this
2 H incubation, 3 mL of blood was transferred into Tempus™ Blood RNA Tubes (Life
Technologies, Grand Island, NY). Tubes were vigorously shaken following addition of
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blood and incubated at room temperature for 24 hrs. Tubes were then stored at -20 ºC for
later analysis. Tubes were thawed prior to analysis and Tempus Spin RNA isolation kit
(Thermo Fisher Scientific, Waltham, MA) was used following the manufacturer’s
instructions to isolate total RNA. Once isolated, cDNA was generated by transcription of
1 µg of RNA as previously described [197]. Briefly, RNA was combined with a master
mix (Promega, Madison, WI) and incubated at 42o C for 15 min and at 95o C for 5 min. The
resulting cDNA (4.5 µL) was combined with 5 µL of Master Mix (SensiMix HI-ROX 2x,
Bioline) and the primer-probe of interest (0.5 µL; TaqMan™). Primer-probes were equinespecific (Applied Biosystems, Foster City, CA). An Applied Biosystems Real-Time PCR
system (ABI Viia7) was used to run samples against: Housekeeping gene betaglucuronidase

(β-gus;

(Ec04260298_s1),

TNF-α

(Ec03468606_m1),

IL-8

Ec03470630_m1),
(Ec03467871_m1),
(Ec0346880_m1),

IL-6
TLR4
IL-10

(Ec03468678_m1),
(Ec03468994_m1),
(Ec03468647_m1),

IL-1β
IFN-γ
CCL5

(Ec03468106_m1), and CCL2 (Ec03468496_m1) [199]. All samples analyzed in duplicate
and after an initial 10 min incubation at 95o C underwent 10 cycles of 15s at 95o C followed
by 60s at 60o C. Changes in gene expression, relative to both β-gus and mean CT for nonID horses’ time 0 media samples set as a calibrator, were calculated using the CT method
[200]. Results are expressed as relative quantity (RQ), calculated as 2-CT.
7.2.6. Statistical analysis
Prior to analysis, data points determined to be outliers as established as being 1.5
times the interquartile range below or above the 1st or 3rd quartiles, respectively were
removed from the data set. Analysis of data were completed with repeated measures
ANOVA using PROC MIXED, SAS 9.4 (SAS Institute Inc., Cary, NC). Horse ID, group
(ID vs non-ID controls), time (0 vs 60 min OST time points), and treatment (non-stimulated
tubes vs those stimulated with LPS) were set at fixed effects and all possible interactions
were considered. The repeated measure was set as time, with the subject of horse ID.
Pairwise comparisons were made using protected LSD. All data were normally distributed
as determined by analysis of residuals. Residuals were visually normally distributed and
had a skew of < 2 and kurtosis of < 7. Differences were considered statistically significant
when P < 0.05 and trends were considered at P < 0.10.
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7.3. Results
While ID horses met the criteria for hyperinsulinemia, having resting insulin
concentrations > 20 µIU/mL, they were not significantly in higher serum insulin
concentrations (Table 7.1) compared to controls at time point 0 prior to oral sugar
administration (P = 0.1108). However, they significantly increased from time point 0 to
time point 60 (P = 0.0002) and were higher at that time point compared to controls (P <
0.0001).
Results for gene expression of inflammatory markers in LPS treated and
unstimulated whole blood samples from ID and control horses both prior to (time point 0)
and 60 min following oral sugar administration (time point 60) are presented in Figures 7.1
and 7.2. Regardless of metabolic status or time point, LPS stimulation was able to
significantly increase whole blood gene expression for all variables measured (P < 0.005),
with the exception of CCL2 (P = 0.3013, Figure 7.2). It especially effected interleukin gene
expression, inducing the highest expression in IL-1β and IL-6 (Figure 7.1).
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Figure 7.1. Mean (± SEM) mRNA gene expression represented as relative quantities (RQ)
of (A) TNF-α, (B) IL-8, (C) IL-1β, (D) IL-6, (E) IL-10, and (F) IFN-γ in equine whole
blood both incubated for 2 hrs with 1 µg LPS (LPS stimulated; left panel of the graphs)
and incubated without LPS (Unstimulated; right panel of the graphs) at two different time
points (baseline prior to oral sugar administration (time point 0) and 60 min following (time
point 60)). Differences between ID and controls (P < 0.05) are represented by *.
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There were some overall effects of time on gene expression. For TLR-4 (Figure
7.2), time point 0 was lower compared to time point 60 (P = 0.0126). However, time point
0 was higher compared to time point 60 for CCL2 (MCP-1) gene expression (P = 0.018).
Additionally, there was a trend for an effect of time (P = 0.0972) for IFN-γ (Figure 7.1),
with horses at time point 0 lower compared to time point 60.

Figure 7.2. Mean (± SEM) mRNA gene expression represented as relative quantities (RQ)
of (A) CCL5 (RANTES), (B) CCL2 (MCP-1), and (C) TLR-4 in equine whole blood both
incubated for 2 hrs with 1 µg LPS (LPS stimulated; left panel of the graphs) and incubated
without LPS (Unstimulated; right panel of the graphs) at two different time points (baseline
prior to oral sugar administration (time point 0) and 60 min following (time point 60)).
Differences between ID and controls within time point (P < 0.05) are represented by *.
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IL-8 gene expression had a significant overall effect of group (P = 0.0189; Figure
7.1), with control horses higher compared to ID horses. There was also a significant group
by treatment interaction (P = 0.0329). All groups and treatments were significantly
different from each other for IL-8 gene expression (P < 0.0018), with the exception of
unstimulated samples where control and ID horses were not different (P = 0.726). There
was also a significant group by time point interaction (P = 0.0125) for CCL2 gene
expression, with control horses higher compared to ID horses within time point 0 (P =
0.0217) and control horses having a significant decrease in gene expression between time
points 0 and 60 (P = 0.0009).
While there were no significant three-way group by time by treatment interactions,
there were some significant pairwise comparisons. For TLR-4 gene expression (Figure
7.2), ID horses had an increase from time point 0 to time point 60 in their LPS stimulated
samples (P = 0.0098). ID horses were lower compared to controls for gene expression of
IL-8 in LPS stimulated samples at time point 60 (P = 0.0021) and there was a trend for a
difference for ID to be lower compared to control horses for LPS stimulated samples at
time point 0 (0.0976), as well as a trend for an increase in control horses’ LPS simulated
samples between time point 0 and 60 (P = 0.0722). ID horses had a trend for an increase
in IL-10 (Figure 7.2) from time point 0 to time point 60 in LPS stimulated samples (P =
0.0663). IFN-γ gene expression in ID horses increased from time point 0 to time point 60
in LPS stimulated samples (P = 0.055). Finally, for CCL2 gene expression, control horses
LPS treated samples decreased in CCL2 gene expression between time points 0 and 60 (P
= 0.0017). Control horses had a higher gene expression in LPS treated samples at time
point 0 compared to ID horses (P = 0.0248). There was also a trend for control horses
unstimulated samples to be higher at time point 0 compared to 60 (P = 0.0938), and for
time point 0 unstimulated samples the control horses had a trend to be higher compared to
the ID horses (P = 0.0805).

7.4. Discussion
While gene expression was increased in response to incubation with LPS for all
markers of inflammation (with the exception of CCL2), expression was increased
minimally for most. It was particularly low for CCL5 (RANTES) and CCL2 (MCP-1),
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genes associated with the MyD88-independent TRIF pathway. Similar results have
previously been seen by others in monocytes of metabolically normal horses stimulated
with 100 pg/mL LPS [274]. Surprisingly, TLR-4 gene expression was also low. This may
be due to potential crosstalk between TLR-4 and TLR-2 [275]. Interestingly, the cytokine
and chemokine with significant differences between ID and controls, IL-8 and CCL2, have
been shown to be released in human keratinocytes in response to a TLR2/TLR1
heterodimer specific mitogen [276]. In other species, MyD88 dependent TLR-4 signaling
has been demonstrated to be activated prior to MyD88 independent signaling, and TLR-4
internalized within 60-120 min following LPS binding [277, 278]. Therefore, lower gene
expression of TLR-4 and other proinflammatory cytokines typically associated with
MyD88 dependent signaling (such as TNF-α) is likely due to LPS incubation length. After
2 h, MyD88 dependent signaling has presumably passed its peak activity, TLR-4
internalized and in the process of being degraded, and later stage activation of MyD88
independent signaling in process. However, more work would be needed to see if this is
the case in the horse. In particular, further investigations of these pathways in adipose tissue
macrophages would be of interest.
Small sample size and subsequent lack of power likely contributed to the lack of
differences between ID and control horses. Interestingly, though not statically significant,
horses with ID often had an opposing inflammatory responses to oral sugar administration
in stimulated samples compared to controls. This is similar to previous, where we
demonstrated that in response to the OST, PMA (phorbol myristate acetate) stimulated
lymphocytes of horses with ID had either an increase or no change in markers of
inflammation as opposed to metabolically normal controls, who had a decrease in these
same markers of inflammation [47]. For this work, CCL2, CCL5, IL-1β, and IL-6 gene
expression in ID horses LPS stimulated samples numerically increased in response to oral
sugar whereas control horses decreased. In addition, while the three-way group by time by
treatment interaction was not significant for any variable measured, some pairwise
comparisons were significant. These differences showed that ID horses LPS stimulated
samples had an increased TLR-4 and IFN-γ gene expression in response to oral sugar for
with ID horses higher at time point 60 compared to controls. Additionally, control horses
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LPS treated samples decreased in CCL2 gene expression between time points 0 and 60,
whereas ID horses did not.
There were significant effects of metabolic status on IL-8 and CCL2 gene
expression. Obese humans or those with metabolic dysfunction have been shown to have
increased circulating or levels of TNF-α, IL-6, CCL2, and IL-8 [279-282]. Healthy elderly
humans have been shown to have an increased whole blood inflammatory cytokine protein
production (IL-1, IL-6, and IL-8) in response to LPS stimulation compared with young
controls [283]. This has similarly been observed in elderly horses and those with PPID,
with reported increases in IL-8 LPS stimulated gene expression in equine leukocytes [284].
Further, McFarlane and colleagues described increased chemotactic ability in elderly
horses and those with PPID [285]. However, IL-8 lymphocyte gene expression was not
different between obese hyperinsulinemic and non-obese normoinsulinemic controls in
another study [31], although investigators did see an increase in neutrophil oxidative
activity in the obese hyperinsulinemic group. For the horses in this work, all were classified
as adults with no difference in age between the control and ID groups. Therefore, lower
IL-8 LPS stimulated whole blood gene expression in ID horses, in particular in response to
oral sugar administration, indicates a reduced chemotactic and therefore reduced neutrophil
function in metabolically dysfunctional animals. Interestingly, the other inflammatory
marker with significant differences related to group was the chemokine CCL2, or MCP-1.
At time point 0 control horses were higher compared to ID horses for this chemokine,
further supporting the hypothesis that horses with metabolic dysfunction may have a
decreased innate immune response.

7.5. Conclusions
These data suggest that equine whole blood gene expression of inflammatory
markers, particularly interferons, are induced by LPS. Increases in gene expression in
response to LPS appear to occur primarily in MyD88 dependent associated genes, with
little or no increase in gene expression MyD88 independent TRIF associated genes, as
evidenced by weak induction of TRIF associated inflammatory markers, CCL5 (RANTES)
and CCL2 (MCP-1). Oral sugar administration appears to affect LPS induced gene
expression of inflammatory markers, with a significant effect on CCL2 (MCP-1) and TLR-
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4, and a trend for changes in IFN-γ and IL-10 gene expression. Further, reduced whole
blood gene expression of chemokines IL-8 and CCL2 in ID compared to control horses
indicate that horses with metabolic dysfunction may have an impaired innate immune
response, however more work is need to further understand possible differences and their
implications in the horse.

Copyright © Sarah E. Elzinga 2017
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CHAPTER 8 THE EFFECT OF ALGAL DOCOSAHEXAENOIC ACID (DHA)
CONTAINING SUPPLEMENTATION ON METABOLIC AND INFLAMMATORY
PARAMETERS OF HORSES WITH EQUINE METABOLIC SYNDROME (EMS)
There is a high incidence of obesity in the equine population, with some reporting
up to 51% of the population classified as overweight or obese. Obesity in horses is
associated with more serious health concerns such as insulin dysregulation (ID) and equine
metabolic syndrome (EMS). Accepted treatments for EMS are limited and not always
effective. Omega-3 fatty acid supplementation has been suggested as a therapeutic for
humans with metabolic dysfunction, as it has been purported to improve insulin sensitivity
and reduce inflammation in these individuals. However, no work has been conducted to
investigate the effects of the omega-3 fatty acid docosahexaenoic acid (DHA) provided
from an algal source on metabolic or inflammatory parameters in the metabolic syndrome
horse. To investigate its possible effects on insulin and glucose dynamics as well as
inflammation in horses with EMS, 10 mixed-sex and mixed-breed adult (8-21 years old)
EMS horses were selected. Horses were supplemented with a DHA-rich microalgae
containing 16 g DHA/horse/day top dressed on a vehicle or vehicle only for 46 days. Pre
and post supplementation blood samples were collected via jugular venipuncture. Blood
samples were used to isolate serum and plasma. Further, plasma was utilized for isolation
of peripheral blood mononuclear cells (PBMCs). Classification of the animals’
inflammatory state was carried out by serologic enzyme-linked immunosorbent assay
(ELISA), and analysis of PBMCs via flow cytometry and reverse transcription polymerase
chain reaction (RT-PCR). Circulating fatty acids and triglyceride, leptin, and adiponectin
concentrations were also determined. Insulin and glucose dynamics were assessed pre and
post supplementation with an oral sugar test (OST) and a frequently sampled intravenous
glucose tolerance test (FSIGTT). Post supplementation, horses receiving DHA rich
microalgae had a significant increase in many circulating fatty acids, in particular an
increase in DHA (P < 0.001), compared to controls. Treated horses also had lower serum
triglycerides post supplementation (P = 0.023) and there was a trend (P = 0.066) for a
reduction in the amount of TNF-α produced per lymphocyte post supplementation in the
treated horses. Interestingly, post supplementation horses given DHA rich microalgae did
not have the same rise in insulin concentrations 60 minutes post oral sugar administration
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(P = 0.689) as seen in controls (P = 0.012). These results indicate that DHA rich microalgae
supplementation is able to affect circulating fatty acids, reduce inflammation, and modulate
metabolic parameters in EMS horses. Considering the negative impact of obesity on the
health of the horse, continued research on the underlying mechanisms and treatment of
associated diseases is imperative.

8.1. Introduction
More than 30% of the human population is considered to be obese [2]. Obesity is
an increasing problem not only in humans, but in the horse population as well. Similar to
statistics in people, reports indicate that the percentage of overweight or obese horses may
range anywhere from 20.6-51% [3-6]. Obesity in horses, as in humans, has been connected
to more serious health concerns such as insulin dysregulation (ID) [12] and equine
metabolic syndrome (EMS). EMS was defined in a 2010 ACVIM consensus statement as
the following: regional (neck crest, rump, etc.) or general adiposity, hyperinsulinemia or
abnormal glycemic or insulinemic response to challenge, and a history of or predisposition
towards laminitis [23]. Traditionally EMS is treated with dietary restriction and exercise.
While this treatment is effective in most instances by increasing insulin sensitivity and
decreasing inflammation [29], it is a process that can take months. In addition, due to
complications from underlying or other conditions (such as laminitis), an increased
exercise regimen is not always possible. There are two pharmaceutical options available at
this time. They act to decrease hepatic glucose production (Metformin) and increase
metabolism via synthetic thyroid hormone (levothyroxine sodium). However, metformin
and levothyroxine sodium are used off label in the EMS animal and the mechanism of
action of either is not well known. In addition, published findings have yielded conflicting
results as to the long term safety and efficacy of these drugs in the horse [9, 154-156].
Therefore investigation into alternative methods of treatment for inflammation and insulin
resistance associated with EMS is warranted.
One method that has proven effective in humans with Metabolic Syndrome (MetS)
[24], diabetes, obesity, or those with metabolic dysfunction [157] is supplementation with
omega-3 fatty acids. Supplementation with the long chain omega-3 fatty acids
docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA), is shown to improve insulin
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sensitivity [162, 163], promote oxidation of body fat, decrease lipogenesis, and reduce
inflammation [167, 168, 286]. Omega-3 fatty acid supplementation in horses has been
shown to positively influence glucose clearance [171] and reduce inflammatory mediators
[174-176]. It has also been shown in horses to change circulating fatty acid concentrations,
including DHA, triglycerides, and phospholipids [159, 177, 178]. In addition, increases in
DHA concentrations following supplementation have been noted not only in circulation,
but are incorporated into skeletal muscle [160]. Therefore, the objective of this study was
to determine the effects of omega-3 fatty acid supplementation in the form of a DHA-rich
microalgae on metabolic and inflammatory responses in horses with EMS.

8.2. Materials and Methods
Ten EMS horses of mixed-sex and mixed-breed who were residing on the
University of Kentucky’s Maine Chance Farm were selected for this study. All horses were
acclimated at least 2 months prior to the start of study to dry lot paddocks, with 2 horses
housed per paddock, and to feed and feeding protocols. Horses were provided a low fat
diet of mixed grass hay fed at 2% body wt (BW)/day split between a morning (0800-1000,
EST) and afternoon (1500-1600, EST) feeding. Nutrient analysis of the hay is presented in
Table 8.1. Horses were also provided with the morning feeding; 1 lb/day balancer pellet
(Essential K®, Tribute Equine Nutrition, OH) and 1 lb/day alfalfa pellet (Hallway feeds,
Farmers Feed Mill, KY), and had access to water and a mineral block ad libitum. EMS
horses were randomly assigned to one of two groups, treatment group (n=6; mean age 13.2
± 4.4 years) or control (n=4; mean age 11.5 ± 2.6 years). Horses in were not different in
age between treated groups (P = 0.48). At the start of the 46 day supplementation period
the treatment group received a DHA-rich microalgae supplement (FORPLUS™, Alltech, Inc,
Nicholasville KY) containing 16 g DHA mixed with 25 ml water, 15 ml molasses (Double
S Liquid Feed Services, Inc., Danville, IL), and 4 ml anise extract (A1 Spice World, Glen
Head, NY) top dressed onto their balancer and alfalfa pellets to make the supplement
palatable and to ensure horses received their entire daily portion of supplement. Control
horses received the vehicle of 25 ml water, 15 ml molasses, and 4 ml anise extract without
the algal supplement top dressed onto their balancer and alfalfa pellets only. Analysis of
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algal supplements nutritional and fatty acid content was performed by Eurofins Analytical
Laboratories (New Orleans, LA, USA) and is presented in Table 8.2.
Table 8.1. Mixed grass hay dietary analysis.
Component
DM
DE (Mcal/kg) 1X
2.68
ME (Mcal/kg) 1X
2.26
% Moisture (as fed)
8.5
% Dry Matter (as fed)
91.5
% Crude Protein
16.3
% Adjusted Crude Protein
16.3
% Acid Detergent Fiber
41.0
% Neutral Detergent Fiber
55.3
% NFC
22.5
% Starch
1.6
% WSC (water soluble carbohydrates)
6.0
% NSC
7.6
% ESC (simple sugars)
4.5
% Crude Fat
2.8
% TDN
59
NEL, Mcal/Lb
0.56
NEM, Mcal/Lb
0.54
NEG, Mcal/Lb
0.29
% Calcium
1.01
% Phosphorus
0.27
% Magnesium
0.18
% Potassium
2.18
% Sodium
0.043
PPM Iron
137
PPM Zinc
23
PPM Copper
9
PPM Manganese
26
PPM Molybdenum
3.5
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Table 8.2. Algal supplement dietary analysis and fatty acid content.
Component
As fed basis
% Moisture
2.4
% Acid Hydrolysis Fat
58
% Crude Fiber
0.9
Calculated % Carbohydrate
17.3
Combustion % Protein
13.5
% Total Ash
3.1
% Calcium
0.34
% Phosphorus
0.47
% Sulfur
0.74
% Potassium
0.55
% Sodium
0.10
PPM Iron
13
PPM Zinc
36
PPM Copper
2
PPM Selenium
0.13
Fatty Acid
% of fat content
C6:0 Caproic acid
< 0.10%
C7:0 Heptanoic acid
< 0.10%
C8:0 Caprylic acid
< 0.10%
C9:0 Nonanoic acid
< 0.10%
C10:0 Capric acid
< 0.10%
C11:0 Undecaniod acid
< 0.10%
C12:0 Lauric acid
0.13 %
C13:0 Tridecanoic acid
< 0.10%
C14:0 Myristic acid
4.16%
C14:1 Myristoleic acid
< 0.10%
C15:0 Pentadecanoic acid
1.98%
C15:1 Pentadecenoic acid
< 0.10%
C16:0 Palmitic acid
52.55%
C16:1 Palmitoleic acid
0.11%
C17:0 Margaric acid
0.82%
C17:1 Margaroleic acid
< 0.10%
C18:0 Stearic acid
1.65%
C18:1n7c Vaccenic acid
< 0.10%
C18:1n9c Oleic acid
< 0.10%
C18:1n9t Elaidic acid
< 0.10%
C18:2n6c Linoleic acid
< 0.10%
C18:2n6t Linolelaidic acid
< 0.10%
C18:3n3c alpha-linolenic acid
< 0.10%
C18:3n6c gamma-linolenic acid
< 0.10%
C19:0 Nonadecanoic acid
< 0.10%
C20:0 Aracidic acid
0.21%
C20:1 Eicosenoic acid
< 0.10%
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Table 8.2 Algal supplement dietary analysis and fatty acid content. (continued)
Fatty Acid
% of fat content
C20:2n6c Eicosadienoic acid
< 0.10%
C20:3n3c Eicosatrienoic acid
0.74%
C20:3n6c homo-gamma-Linolenic acid
0.13%
C20:4n6c Arachidonic acid
0.14%
C20:5n3c Eicosapentaenoic acid
0.56%
C21:0 Heneicosanoic acid
< 0.10%
C22:0 Behenic acid
0.11%
C22:1 Erucic acid
< 0.10%
C22:2n6c Docosadienoic acid
0.41%
C22:5n3c Docosahexaenoic acid
0.17%
C22:6n3c Docosahexaenoic acid
27.74%
C23:0 Tricosanoic acid
< 0.10%
C24:0 Lingoceric acid
0.11%
C24:1 Nervonic acid
0.32%
Analysis of algal supplement fatty acid content by highperformance liquid chromatography (HPLC)
Originally, the study was intended to be carried out with 12 horses and as a
crossover-design, with a 60 day washout period. However, 2 horses were dropped from the
study for health reasons. In addition, the second half of the crossover was not completed
due to significantly elevated concentrations of circulating DHA in treated horses compared
to controls as far as 263 days (P = 0.01, DHA-rich microalgae treated horses median 0.30;
IQR 0.24 – 0.40 versus control horses median 0.06; IQR 0.06 – 0.172) following cessation
of supplementation. All experimental procedures were approved by the University of
Kentucky’s IACUC (institutional animal care and use committee).
8.2.1. EMS determination
EMS was determined by the criteria established in a 2010 ACVIM consensus
statement [23]. In brief, hyperinsulinemia, general or regional obesity, and a history of or
predisposition to laminitis. A portable agriculture scale (model 700, Tru Test Inc., Mineral
Wells, TX) was used to establish body weight, which was monitored weekly. Body
condition score (BCS) was determined and averaged between three trained investigators
using the 1-9 Henneke scoring system [186], with a 1 representing an extremely emaciated
animal and a 9 representing an extremely obese animal. The same trained individuals
scored and regional adiposity via the 0-5 cresty neck score (CNS) system established by
Carter et al. [187], with a 0 representing no neck crest and a 5 representing a crest so large
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it permanently droops to one side of the neck. Blood collection for serum and plasma
samples was carried out via jugular venipuncture. To ascertain the presence of insulin
dysregulation, an oral sugar test (OST) was performed; following overnight fasting serum
samples were collected and 0.15 ml/kg of Karo Light Corn syrup (ACH food companies,
Cordova, TN) orally administered and a second serum sample collected 60 minutes later
[13, 23]. Serum samples were kept at -20º C until analysis. A fasting insulin level of >20
μIU/mL was considered indicative of hyperinsulinemia, and an increased insulin
(>60μU/mL) 60 minutes post administration of oral sugar was classified as insulin
dysregulation [13, 23]. These cut-off values were also utilized as they are recommended
by the Tufts University Equine Endocrinology Group (EEG).
Horses were screened using the TRH (thyrotropin releasing hormone) stimulation
test and low-dose dexamethasone suppression testing to ensure that none were affected by
pituitary pars intermedia dysfunction (PPID). TRH stimulation testing was carried out as
previously described [191, 192]. Briefly; an A.M. (between 0800 and 1200, EST) baseline
blood sample was taken via jugular venipuncture. Following this, a 1ml dose of TRH
dissolved to 1 mg/ml in 0.9% saline (Sigma-Aldrich, St. Louis, MO) was administered
intravenously (IV) and 10 minutes post TRH injection a second blood sample was taken.
Ethylenediaminetetraacetic acid (EDTA) containing tubes were used to collect blood
samples. Tubes were placed on ice and transported to the lab for immediate centrifugation
and plasma isolation [193]. Plasma was stored at -20 º C until shipped on dry ice to Cornell
University for determination of ACTH concentrations. Low-dose dexamethasone
suppression testing was performed as previously described [194]. In brief, an afternoon
(1550-1800 hours) baseline jugular blood sample was taken. Following this, an
intramuscular (IM) dexamethasone bolus (0.04 mg/kg BW) was administered and a second
blood sample taken 19 hours later. A gel serum separator tube was used to collect samples.
Tubes were centrifuged, and serum isolated and frozen at -20 º C until cortisol analysis. As
recommended by the EEG, concentrations of ACTH 10 minutes post TRH injection in
excess of 100 pg/mL or concentrations of cortisol exceeding 1.0 µg/dL 19 hours following
dexamethasone injection were considered positive for PPID. Any animals meeting these
criteria were excluded.
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Analysis of ACTH, cortisol, and insulin were performed by Cornell University’s
Animal Health Diagnostic Center Endocrinology Laboratory. The Millipore porcine
insulin RIA kit (EMD Millipore Corporation, Darmstadt, Germany) was used to measure
insulin concentrations [47], ACTH was measured via an automated chemiluminescent
enzyme immunoassay system (Immulite, Erlangen, Germany) [195], and cortisol
concentrations were determined using the Siemens Immulite Cortisol kit (Siemens,
Erlangen, Germany).
8.2.2. Sample collection and timeline
Serum and EDTA plasma samples were taken after an overnight fast at baseline
and following the OST both prior to (day 0; time point 1) and following supplementation
(day 46; time point 2). Horses were administered a frequently sampled intravenous glucose
tolerance test (FSIGTT; see below) one day following blood collection and OST. Serum
samples were utilized for determination of insulin, leptin, and triglyceride analysis. EDTA
plasma samples were used to determine fatty acid concentrations.
8.2.3 Frequently sampled intravenous glucose tolerance test (FSIGTT)-Optimized
At time points 1 and 2 a FSIGTT was performed as previously described [287]. In
brief; an indwelling, long-term intravenous catheter was placed to administer treatments
and collect blood samples. Following baseline blood sample collection, a 50% glucose (100
mg/kg, IV) was administered, followed 20 minutes later by administration of insulin (20
mU/kg, IV). Blood samples were obtained at -10, -5, 0, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16,
19, 22, 23, 24, 25, 27, 30, 35, 40, 50, 60, 70, 80, 90, 100, 120, 150, and 180 minutes after
glucose administration. Blood samples from the FSIGTT were analyzed for glucose
concentrations on an YSI analyzer (YSI Incorporated, Xylem Inc., Yellow Springs, OH).
8.2.4 Endocrine and lipid measures
Serum samples from the OST for time points 1 and 2, as well as EDTA plasma
from the FSIGTT were sent to Cornell University’s endocrinology lab for determination of
insulin using RIA (see above). In addition, fasting serum samples were sent to Cornell
University’s Clinical Pathology lab for leptin and triglyceride analysis via colometric assay
using a Roche ModP analyzer (Roche Diagnostics, Indianapolis, IN) [49]. Fasting EDTA
plasma samples from time points 1 and 2 were sent to Michigan State University’s
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Diagnostic Center for Population and Animal Health for plasma fatty acid analysis using
high-performance liquid chromatography (HPLC) [288].
8.2.4. Peripheral blood mononuclear cell (PBMC) inflammatory cytokine production
Heparinized blood was used to isolate peripheral mononuclear cells (PBMCs) by
Ficoll-Paque PlusTM (Amersham Biosciences, Piscataway, NJ) gradient centrifugation
[197]. Cells were frozen in 10% fetal bovine serum (FBS; Sigma–Aldrich, St. Louis, MO),
40% dimethyl sulfoxide (DMSO), and 50% Roswell Park Memorial Institute medium
(RPMI-1640, Gibco, Grand Island, NY) until thawed for in vitro stimulation. For
stimulation, 107 PBMC were incubated in 1 ml c-RPMI (RPMI-1640 with 2.5% fetal
equine serum (FES; Sigma–Aldrich, St. Louis, MO), 100 U/ml penicillin/streptomycin
(Sigma), and 55 mM 2-mercaptoethanol (Gibco) media. Cells were incubated at 37 °C, 5%
CO2 with Brefeldin A (10 mg/ml; Sigma) and select wells with the positive control phorbol
12-myristate 13-acetate (PMA; 25 ng/ml; Sigma) and ionomycin (1 mM; Sigma) for 4 hrs.
Following this, determination of cytokine gene expression was carried out by separating
aliquots of the cells and placing them into Trizol (Ambion) to isolate RNA (see below).
Remaining cells were assayed by flow cytometry for interferon gamma (IFN-γ) and tumor
necrosis factor alpha (TNF-α) production. Cells were fixed in 2% paraformaldehyde
(Sigma) and stored overnight at 4oC. After overnight storage, IFN-γ and TNFα intracellular
staining was carried out as previously described [198]. After the cells were stained, aliquots
of cells were resuspended in FACS flow and flow cytometric acquisition was performed
on a FACSCALIBUR™ (Becton Dickinson, San Jose, CA). Determination of the percent
of IFN-γ and TNFα lymphocytes was accomplished with the use of CELL QUEST™
(Becton Dickinson) [42].
A modified Trizol method was used to extract total RNA from PBMC cultures (see
above). One µg of RNA was reverse transcribed into cDNA, as previously described [42,
197]. In brief; 1 µg of each RNA sample and a reverse transcription master mix (Promega,
Madison, WI) was incubated for 15 min at 42oC and for 5 min at 95oC. Reactions included
5µl cDNA and 20µl of master mix. Master mix included; 6.25µl nuclease-free water
(Qiagen), 1.25µl primer/probe 20X assay mix (Applied Biosystems, Foster City, CA), and
12.5µl TaqManTM (Applied Biosystems). Equine-specific, inventoried, intron-spanning
primers and probes were used with Applied Biosystems Real-Time PCR (ABI 7900HT)
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against the following genes: Housekeeping gene beta-glucuronidase (β-gus) and the
following genes; IFN-γ (catalog number 4331182), interleukin 6 (IL-6; catalog number
4351372), interleukin 10 (IL-10; catalogue number 4331182), TNF-α (catalog number
4331182), and transferrin (catalog number 4351372). Samples were processed in duplicate
and incubated for 95oC for 10 min. They then underwent 40 cycles at 95oC for 15s and
60oC for 60s. Relative changes in gene expression were determined by the CT method
[200], with mean CT for week 0 set as the calibrator for all samples. Relative quantity, or
RQ, was calculated as 2-CT and used to express results.
8.2.5. Serum Cytokine Analysis
8.2.5.1. TNF-α ELISA
Serum concentrations of TNF-α protein were determined using a commercially
available equine TNF-α ELISA kit (R&D, Minneapolis, MN). This assay is optimized for
equine serum samples diluted at a minimum of 1:2 [289]. All steps of the ELISA were
performed according to the manufacturer’s instructions, with the exception of the
following; coating antibody provided was prepared in carbonate buffer (15 mmol Na2CO3,
35 mmol NaHCO3, pH 9.6) and the final 2 incubation times were increased from 20 min
to 30 min. In addition, single absorbance was measured at A450.
8.2.5.2. IL-6 ELISA
Serum concentrations of IL-6 were determined using an IL-6 ELISA validated for
use in the horse with an analytical sensitivity of 780 pg/mL [290]. The ELISA utilizes a
polyclonal goat anti-horse IL-6 antibody (AF1886, R&D Systems, Inc., Minneapolis, MN)
to coating ELISA plates (Immunoplate Maxisorp, Nalge Nunc Int., Rochester, NY). The
antibody was diluted to a final concentration of 1 μg/mL in carbonate buffer (15 mmol
Na2CO3, 35 mmol NaHCO3, pH 9.6) and incubated overnight at 4 °C. Afterwards, the
coating solution was discarded and the plates blocked for 30 min at room temperature with
the addition of phosphate buffered saline (PBS, pH 7.2) containing 0.5% (w/v) bovine
serum albumin. Plates were washed five times with phosphate buffer (2.5 mmol NaH2PO4,
7.5 mmol Na2HPO4, 145 mmol NaCl, 0.1% (v/v) Tween 20, pH 7.2). A recombinant
equine IL-6 (1886-EL, R&D Systems, Inc., Minneapolis, MN) diluted in 2-fold serial
dilutions ranging from 50 to 0.78 ng/mL was used as standard to determine IL-6
concentrations in the samples. The serum was diluted in phosphate buffer, added to the
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plates in triplicate wells and incubated for 90 min at room temperature. After five washes,
biotinylated goat anti-horse IL-6 (AF1886, R&D Systems, Inc., Minneapolis, MN) diluted
1:100 in phosphate buffer was added, incubated for 60 min, and washed again. A
streptavidin–horseradish peroxidase solution (Jackson ImmunoResearch Lab., West
Grove, PA) was added to the plates for another 30 min. After a final wash, substrate buffer
(33.3 mmol citric acid, 66.7 mmol NaH2PO4, pH 5.0) was added and incubated for 20 min
in the dark. The reaction was stopped by adding one volume of 0.5 mol H2SO4. Plates were
read in an ELISA reader (Bio-Tek, Winooski, VT) at 450 nm absorbance.
8.2.5.3. CRP ELISA
A commercially available equine specific kit (Kamiya Biomedical Company,
Tukwila, WA) was used to measure C - reactive protein (CRP) in the serum according to
manufacturer’s instructions and as previously described [291].
8.2.6. Data Analysis
Data were analyzed via Sigma Plot 13.0 (Systat Software, San Jose, CA). A twoway repeated measured ANOVA was used with fixed effects set as treated vs control and
time point and all possible interactions analyzed. Data not normal were log transformed
and resulted in normality. Results were considered statistically significant when P < 0.05
and trends considered at P < 0.10.

8.3. Results
8.3.1. Lipid, phenotypic, and endocrine measures
Plasma fatty acid concentrations as a percentage of total circulating fatty acids are
presented in Table 8.3. DHA-rich microalgae treated horses were higher at time point 2
compared to all horses at time point 1 and control horses at time point 2 in DHA (P <
0.001) and C:22 2n6c (P < 0.001) concentrations. However, DHA-rich microalgae treated
horses at time point 2 were lower compared to all others for C18:1n9c (P = 0.02) and
C18:3n6c (P = 0.035) plasma concentrations. Control horses at time point 2 had higher
concentrations of C16:1n7c compared to control horses at time point 1 (P = 0.009), but
were not different compared to treated horses regardless of time point. In addition, there
was an overall effect of time point for C20:3n3c (P = 0.011) and C24:1n9c (P = 0.025)
concentrations, with horses at time point 2 higher compared to horses at time point 1.
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Table 8.3. Plasma fatty acid results for DHA-rich microalgae treated and control EMS horses both pre (time point 1) and post (time
point 2) a 46-day supplementation period.
Plasma Fatty Acid
Control horses
Control horses
Treated horses
Treated horses
Concentrations (% of total fatty acids)
time point 1
time point 2
time point 1
time point 2
C22:6n3c Docosahexaenoic acid
0.05 + 0.1 a
0.05 + 0.1 a
0.01 + 0.1 a
1.94 + 0.1 b
C14:0 Myristic Acid
0.86 + 0.1
0.97 + 0.1
0.88 + 0.1
0.89 + 0.1
C16:0 Palmitic Acid
15.87 + 0.7
16.69 + 0.7
16.31 + 0.6
17.22 + 0.6
a
b
a, b
C16:1n7c Palmitoleic Acid
1.10 + 0.2
1.49 + 0.2
1.13 + 0.1
1.15 + 0.1 a, b
C17:0 Margaric Acid
0.36 + 0.03
0.35 + 0.03
0.44 + 0.02
0.39 + 0.02
C18:0 Steric Acid
15.38 + 0.7
15.40 + 0.7
15.97 + 0.6
15.35 + 0.6
C18:1n7c Cis-Vaccenic Acid
1.50 + 0.2
1.43 + 0.2
1.55 + 0.1
1.53 + 0.1
b
b
b
C18:1n9c Oleic Acid
16.10 + 1.5
17.67 + 1.5
15.74 + 1.2
12.64 + 1.2 a
C18:2n6c Linoleic Acid Methyl Ester
43.76 + 2.0
41.13 + 2.0
43.49 + 1.6
44.89 + 1.6
C18:3n3c Alpha linolenic Acid
0.23 + 0.04
0.23 + 0.04
0.25 + 0.03
0.18 + 0.03
b
b
b
C18:3n6c y-Linolenic Acid
3.64 + 0.3
3.15 + 0.3
3.24 + 0.3
1.81 + 0.3 a
C20:2n6c Eicosadienoic Acid
0.15 + 0.02
0.21 + 0.02
0.14 + 0.01
0.16 + 0.01
C20:3n3c Eicosatrienoic Acid
0.59 + 0.1
0.75 + 0.1
0.56 + 0.1
0.89 + 0.1
C20:3n6c Homo-y Linolenic Acid
0.19 + 0.04
0.17 + 0.04
0.12 + 0.03
0.24 + 0.03
C:22 2n6c Docosadienoic Acid
0.07 + 0.02 a
0.07 + 0.02 a
0.04 + 0.02 a
0.22 + 0.02 b
C22:4n6c
0.004 + 0.01 a
0.009 + 0.01 a
-0.002 + 0.01 a
0.316 + 01 b
C22:5n3c Docosapentaenoic Acid
0.12 + 0.02
0.15 + 0.02
0.09 + 0.02
0.13 + 0.02
C24:1n9c Nervonic Acid
0.07 + 0.02
0.10 + 0.02
0.04 + 0.02
0.09 + 0.02
Plasma fatty acid concentrations as measured by high performance liquid chromatography (HPLC) in EMS control (n=4) versus DHArich microalgae treated (n=6) horses. Data are expressed as the percentage of total fatty acid concentrations. Results are presented as
least square mean plus or minus standard error of the mean. Within a row, differences (P < 0.05) are represented by differing superscripts.

OST results and phenotypic data, along with serum leptin and triglycerides are
presented in Table 8.4. There were no differences in fasting insulin between control and
treated horses’ both pre and post supplementation (P = 0.568). However, control horses
had higher insulin concentrations 60 minutes post oral sugar administration at time point 2
compared to time point 1 (P = 0.012). Similarly, when considering the change in insulin
concentrations 60 minutes post oral sugar administration compared to baseline insulin
concentrations (delta change), control horses had an increase (P = 0.009) from time point
1 to time point 2 whereas DHA-rich microalgae treated horses did not (P = 0.419). In
addition, control horses did not have greater delta insulin concentrations at time point 1 (P
= 0.143) compared to treated horses, but they did have a greater delta insulin at time point
2 (P = 0.027). DHA-rich microalgae treated horses had lower serum triglycerides at time
point 2 compared control horses (P = 0.017) and compared to treated horses at time point
1 (P = 0.023). Control horses at time point 1 were not different from control horses at time
point 2 or from treated horses at any time point. There were no differences between treated
or control horses for serum leptin, regardless of time point. While there was an overall
difference in time point for BCS (P < 0.001), with all horses being higher at time point 2
versus time point 1, there were no differences either pre or post supplementation between
treated and control horses. Nor were there any differences between treated or control horses
for CNS or weight.
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Table 8.4. Endocrine data, phenotypic measures, and serum leptin and triglyceride concentrations for DHA-rich microalgae treated and
control EMS horses both pre (time point 1) and post (time point 2) a 46-day supplementation period.
Endocrine and
Control horses
Control horses
Treated horses
Treated horses
phenotypic measures
time point 1
time point 2
time point 1
time point 2
Basal Insulin (µIU/ml)
21.58 ± 6.89
22.85 ± 6.89
32.61 ± 5.62
29.76 ± 5.62
Insulin 60 min post oral sugar
68.90 ± 12.29 a
106.25 ± 12.29 b
78.13 ± 10.04 a, b
82.02 ± 10.04 a, b
administration (µIU/ml)
Change in insulin concentrations
47.31 ± 9.69
83.40 ± 9.69
45.53 ± 7.91
52.26 ± 7.91
(OST 60 min-basal insulin; µIU/ml)
Log BCS
0.79 ± 0.01 a
0.84 ± 0.01 b
0.82 ± 0.01 a
0.86 ± 0.01 b
CNS
2.29 ± 0.44
2.25 ± 0.44
2.97 ± 0.36
3.08 ± 0.36
Weight (kg)
515.60 ± 34.54
517.19 ± 34.54
562.63 ± 28.03
568.16 ± 28.03
Leptin (ng/mL)
7.23 ± 1.40
6.72 ± 1.40
7.18 ± 1.14
7.94 ± 1.14
Triglycerides (mg/dL)
47.75 ± 6.62 a, b
59.00 ± 6.62 b
49.17 ± 5.40 b
35.33 ± 5.40 a
Phenotypic measures, endocrine data, and serum leptin and triglyceride concentrations in EMS control (n=4) versus DHA-rich
microalgae treated (n=6) horses. Results are presented as least square mean plus or minus standard error of the mean. Within a row,
differences (P < 0.05) are represented by differing superscripts.

8.3.2. FSIGTT
As shown in Table 8.5, there were no treatment differences in insulin sensitivity
(SI), acute insulin response to glucose (AIRg), disposition index (DI), or glucose
effectiveness (Sg). Nor were there any differences over time in SI, DI, or Sg. While there
was an increase in acute insulin response to glucose for time point 2 compared to time point
1 (P = 0.008), there was not a treatment by time point interaction.

Table 8.5. MinMod analysis of FSIGTT data for DHA-rich microalgae treated and control
EMS horses both pre (time point 1) and post (time point 2) a 46-day supplementation
period.
Insulin
sensitivity
Control horses Control horses Treated horses Treated horses
measures
time point 1
time point 2
time point 1
time point 2
AIRg (acute
158.9 ± 73.8 a
394.4 ± 73.8 b
153.5 ± 60.2 a
335.8 ± 60.2 b
insulin response
to glucose)
SI (insulin
0.442 ± 0.215
0.352 ± 0.215
0.324 ± 0.176
0.449 ± 0.176
sensitivity)
DI (disposition
73.4 ± 77.8
106.0 ± 77.8
73.5 ± 63.5
185.8 ± 63.5
index)
Sg (glucose
0.022 ± 0.009
0.025 ± 0.009
0.034 ± 0.007
0.018 ± 0.007
effectiveness)
Measures of insulin resistance in EMS control (n=4) versus DHA-rich microalgae treated
(n=6) horses from MinMod analysis of FSIGTT data obtained from insulin and glucose
EDTA plasma concentrations. Results are presented as least square mean plus or minus
standard error of the mean. Within a row, differences (P < 0.05) are represented by differing
superscripts.
8.3.3. Peripheral blood mononuclear cell (PBMC) inflammatory cytokine production
Flow cytometry analysis of TNF-α and IFN-γ intracellular protein (Table 8.6)
showed no significant differences between DHA-rich microalgae treated and control horses
for the percent of lymphocytes positive (% gated) for IFN-γ or TNF-α protein, nor for IFNγ intensity of fluorescence per lymphocyte (mean fluorescence activity-MFI). There was a
trend (P = 0.066) for an interaction between treatment and time point for TNF-α MFI, with
DHA-rich microalgae treated horses having a lower MFI at time point 2 compared to time
point 1. Control horses were not different between time points or from treated horses,
regardless of time point. There was an overall time point difference for IFN-γ MFI (P =
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0.006), with horses at time point 1 higher compared to time point 2, and an overall
treatment versus control difference with TNF-α % gated higher in treated horses compared
to controls (P < 0.001).

Table 8.6. PBMC inflammatory cytokine production for DHA-rich microalgae treated and
control EMS horses both pre (time point 1) and post (time point 2) a 46-day
supplementation period.
Inflammatory
cytokine
Control horses Control horses Treated horses Treated horses
measures
time point 1
time point 2
time point 1
time point 2
IFN-γ % gated
20.13 ± 2.55
20.22 ± 2.55
24.51 ± 2.08
23.56 ± 2.08
IFN-γ MFI
126.43 ± 7.98
101.86 ± 7.98
108.45 ± 6.52
94.43 ± 6.52
TNF-α % gated 39.56 ± 2.76
40.96 ± 2.76
53.10 ± 2.25
58.79 ± 2.25
TNF-α MFI
57.39 ± 6.12
58.52 ± 6.12
64.11 ± 5.00
54.98 ± 5.00
IFN-γ RQ
13296 ± 2192
9383 ± 2192
11395 ± 1790
9642 ± 1790
TNF-α RQ
330.5 ± 136.6
315.4 ± 136.6
619.0 ± 111.6
605.3 ± 111.6
IL-6 RQ
48.41 ± 8.74
40.75 ± 8.74
42.91 ± 7.14
39.28 ± 7.14
IL-1β RQ
3.31 ± 0.91
3.36 ± 0.91
1.86 ± 0.74
1.12 ± 0.74
IL-10 RQ
142.56 ± 34.56 144.06 ± 34.56 221.66 ± 28.22 173.84 ± 28.22
PBMC inflammatory data in EMS control (n=4) versus DHA-rich microalgae treated (n=6)
horses. Flow cytometry data is represented by % gated and MFI, which characterize the
percent of lymphocytes positive for IFN-γ or TNF-α protein (% gated) and the intensity of
florescence, or mean cytokine activity, per lymphocyte. RT-PCR data is represented by
relative quantity (RQ) of gene expression. Results are presented as least square mean plus
or minus standard error of the mean. Within a row, differences (P < 0.05) are represented
by differing superscripts.
Lymphocyte gene expression of IFN-γ, TNF-α, IL-6, IL-1β, and IL-10 was not
different between time points, regardless of treatment. There was an overall treatment
versus control difference, with IL-1β expression higher in controls compared to treated
horses (P = 0.009).
8.3.4. Serum cytokine analysis
Circulating concentrations of IL-6, TNF-α, and CRP protein as measured by ELISA
were not different between DHA-rich microalgae treated or control horses (Table 8.7).
There were no overall differences between time points 1 or 2, or any overall differences
between treated or control horses.
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Table 8.7. Serum inflammatory cytokine and CRP results for DHA-rich microalgae treated
and control EMS horses both pre (time point 1) and post (time point 2) a 46-day
supplementation period.
Serum inflammatory Control horses Control horses Treated horses Treated horses
cytokines and CRP
time point 1
time point 2
time point 1
time point 2
TNF-α
18.5 ± 596.6
19.1 ± 596.6
57.0 ± 487.1 1375.1 ± 487.1
Log IL-6
0.32 ± 0.32
0.34 ± 0.32
1.05 ± 0.26
1.25 ± 0.26
C-reactive Protein
272.4 ± 837.1 566.9 ± 837.1 278.5 ± 683.5 1636.5 ± 638.5
Circulating inflammatory cytokines and CRP in EMS control (n=4) versus DHA-rich
microalgae treated (n=6) horses. Data are expressed as ELISA units. Results are presented
as least square mean plus or minus standard error of the mean. Within a row, differences
(P < 0.05) are represented by differing superscripts.
8.4. Discussion
As expected, treated horses had increases in circulating DHA as well as other fatty
acid concentrations post supplementation, similar to what has been observed in other work
[159, 288, 292]. Also similar to previous studies [177], DHA-rich microalgae treated
horses in this study had a reduction in serum triglycerides following supplementation.
Human studies have likewise indicated a positive effect of omega 3 fatty acid
supplementation on lipids and lipid metabolism [169, 170], including lipids which are
implicated in insulin resistance and inflammation, such as ceramide [140]. Indeed, linoleic
and DHA containing phosphatidylcholine and sphingomyelin were found to be increased
in rats following an exercise regimen, whereas arachidonic acid containing
phosphatidylcholines, phosphatidylethanolamine, and phosphatidylinositol were increased
in rats following high fat feeding [125]. In addition, exercised rats were more insulin
sensitive compared to rats fed a high fat diet. Considering that dietary supplementation
with omega-3 fatty acids can improve concentrations of these lipids [169, 293], this
supports their usage in individuals with metabolic dysfunction. Further, these studies
further indicate a link between circulating fatty acids, insulin sensitivity, and inflammation.
Supplementation with omega 3 fatty acids in equines has been proposed as a way
to improve glucose and insulin dynamics [172], similar to the improved insulin sensitivity
seen in rats, pigs, and humans following supplementation [164-166]. DHA rich algal
supplementation has also been shown in horses following dexamethasone administration
to improve baseline glucose and insulin concentrations, as well as the modified insulin to
glucose ratio [173]. In this study, there was a positive effect on metabolic parameters in
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horses fed 16 g/day DHA from an algal source for 46 days. Specifically, treated horses did
not have the same increase in insulin responses to an OST. These improved insulin
responses to the OST indicate that supplementation provided a protective effect from
increases in insulin responses seen in the control group. This increase in insulin measured
in the control horses may be in part due to seasonal changes, however more work is needed
to explore possible seasonal effects on insulin and insulin responses to the OST in the EMS
animal.
In humans and in mice, metabolic dysfunction has long been associated with
increases in inflammation [267, 294]. These increases in inflammation have been proposed
for the EMS horse or pony as well [28, 295, 296]. For this study, treated horses had a trend
for a decrease in TNF-α MFI post supplementation, indicating immune modulating antiinflammatory effect of DHA-rich microalgae supplementation in EMS horses. There were
no differences in gene expression of PBMC inflammatory markers as measured by RTPCR, suggesting modification likely occurs post transcriptionally. Indeed, no differences
were seen in circulating inflammatory markers as measured by ELISA either pre or post
supplementation. This is likely due in part to small sample sizes and large variability.
Results from other work regarding the effect of omega 3 fatty acid supplementation on
inflammatory parameters in the horse has been mixed. While fish oil supplementation has
not been shown to lower prostaglandin E2 (PGE2) production in lipopolysaccharide (LPS)
stimulated PBMCs from yearling horses [292], there has been an effect following 14 weeks
of fish oil supplementation on PGE2 production in healthy equine LPS stimulated
bronchoalveolar lavage fluid (BAL) cells compared to those supplemented with corn oil
[297]. Feeding seal blubber oil as a source of omega 3 fatty acids has also been shown to
have anti-inflammatory effects in the BAL of horses with recurrent airway obstruction
[298]. The algal source used for this work largely contained DHA with only minor amounts
of EPA, and DHA has been shown to be more effective in reducing inflammation compared
to EPA [299, 300]. This may have been one of the reasons for the observed the trend in
reduction of TNF-α MFI following supplementation.
The major limitation of this study was small sample size. Interestingly, treated
horses had significantly elevated circulating DHA concentrations 263 days following
cessation of supplementation. Others have reported that 42 days [159] and 56 days [301]
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post supplementation DHA and EPA concentrations were not different from controls. This
discrepancy may be explained by the fact that in the current study, horses had increased
adiposity compared to presumably metabolically normal horses used in other studies. In
people and in horses, DHA and EPA supplementation appears to be dose responsive [158,
159]. In addition, it has been shown in humans that DHA can be stored in adipose tissue
for years [161]. Therefore, treated horses may have stored DHA in large amounts in
adipose tissue and slowly released it over an extended period of time. An addition
explanation may be that most other equine studies have utilized a fish oil source of DHA
and EPA, whereas the current study which utilized an algal source of DHA. Considering
that DHA has been shown to be more readily incorporated into tissue than EPA [302],
DHA vs EPA concentrations or the ratio of DHA to EPA may influence DHA incorporation
into and release from tissue.

8.5. Conclusions
DHA-rich

microalgae

supplementation

positively

affected

metabolic,

inflammatory, and lipid parameters following 46 days of 16 g/day algal DHA
supplementation in a group of EMS horses. While supplementation did not normalize
insulin levels, given long-term it may prove useful as a nutritional therapy in addition to
diet and exercise for horse with this syndrome. However, more work is needed to
investigate this further, and to better understand mechanisms responsible for the capacity
of DHA-rich microalgae to modulate these parameters.

Copyright © Sarah E. Elzinga 2017
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CHAPTER 9 DISCUSSION
Given the health concerns associated with insulin dysregulation (ID) in the horse,
little is known about its underlying mechanisms or the involvement of the immune system
and inflammation in this endocrine and metabolic dysregulation. Our overall hypothesis
for this work was that due in part to changes in their gut microbiome and plasma lipidome,
horses with ID will have changes in circulating proinflammatory markers, in particular in
response to glycemic challenge, that further drive metabolic dysfunction.
It has been well established in human and mouse models that metabolic dysfunction
has an inflammatory component [267, 294]. While this is proposed to be the case in the ID
horse or pony [28, 295, 296], results have been mixed. There have been reports of increased
IL-1β and IL-6 gene expression in equine nuchal adipose tissue [41] and increased TNFα plasma or serum concentrations in ID horses [28]. Increases in plasma TNF-α
concentrations have also been observed in ponies with a history of pasture-associated
laminitis [237]. Correlative analysis has likewise linked insulin insensitivity, obesity, and
inflammation in horses with ID [8]. Often, differences in inflammatory markers in horses
with ID are seen at the gene expression level, are limited to adipose tissue, and are not
observed in circulation [8, 39, 41]. Indeed, others have shown lower peripheral blood
mononuclear cell (PBMC) cytokine gene expression of IL-1, IL-6, and a trend for lower
TNF- α in horses with ID compared to normal controls [31]. Similarly, we observed no
differences in baseline PBMC PMA stimulated cytokine protein concentrations or gene
expression, although there was a trend for lower IL-6 and TNF- α gene expression in ID
horses [42]. In fact, in a subsequent study, we further observed that control horses were
higher at baseline in PBMC PMA stimulated cytokine protein concentration or gene
expression [47]. However, ID horses then had an opposing inflammatory response to oral
glycemic challenge wherein they were higher in IFN-γ and TNF-α protein concentrations
as well as IFN-γ gene expression 60 min following oral administration of a glycemic
challenge compared to controls.
There has been evidence in other species that there is an inflammatory response to
feeding, so called postprandial inflammation, similar to what we have observed. There have
been reported increases following a high fat or high fat meal combined with glucose in
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circulating concentrations of intercellular Adhesion Molecule-1 (ICAM-1), a systemic
soluble adhesion molecule [43, 44]. Soluble adhesion molecules have a role in both the
inflammatory process and immune response [202] and have been proposed as a biomarker
of cardiovascular disease in humans [203, 204]. There have also been reports in both
normal and diabetic individuals of postprandial increases in adhesion molecules or proinflammatory cytokines where diabetic subjects have a greater postprandial response
compared to normal controls [43, 45]. While others did not see differences in postprandial
inflammatory markers between diabetic and non-diabetic individuals [205], this may be
due to differences in meal type or carbohydrate complexity [206]. In horses, the majority
of data assessing the inflammatory status of ID horses has been in a basal or fasting state
and examined circulating or tissue levels of inflammation. Postprandial inflammatory
responses in the horse are not well studied. In metabolically normal horses, IL-1β was
shown to increase in response to a high sugar high starch meal [46]. Differences in
postprandial inflammation in individuals with metabolic dysfunction has several proposed
explanations. One of which may be difference in circulating endotoxin concentrations
similar to what is seen in humans with type 2 diabetes [303]. Endotoxin concentrations
have also increased in response to a meal in humans, particularly one high in fat [59, 60].
These increases in endotoxin may stem from differences in the gut microbiota, especially
considering the proposed interactions between the gut microbiota, metabolic, and
inflammatory processes [62, 63]. We were able to show that horses with ID have
differences in their gut microbiota compared to metabolically normal controls. Specifically
changes in community structure, suggesting overgrowth or undergrowth of different
community members. A member of the Verrucomicrobia phylum was the most abundant
in ID horses. This phyla has been shown to be increased in diet-induced obese minipigs
[78]. One of the genus in this phyla, Akkermansia, is inversely associated in humans with
fasting glucose, waist-to-hip ratio, and subcutaneous adipose measures [221]. Further, the
abundance of Verrucomicrobia is proposed as a method to monitor the progression of
glucose intolerance in people [222]. ID horses also had a decreased representation of
Fibrobacter as compared to controls. Fibrobacter has been shown to decrease, along with
increases in lactic acid producing bacteria, in response to both intestinal disease and
changes in diet [225]. Increases in Verrucomicrobia and under representation of
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Fibrobacter in ID horses may indicate that horses with metabolic dysfunction have adapted
protective mechanisms, perhaps due in part to an acidic environment, however this has yet
to be established in the ID horse.
While alterations in the gut microbiota of horses with ID possibly contributed to
the differences in postprandial inflammatory responses we observed, we did not see any
differences between ID and control horses in circulating lipopolysaccharide (LPS)
concentrations either prior to or following supplementation with a mannan rich fraction of
the yeast cell wall or in response to glycemic challenge. Nor did supplementation have an
appreciable effect on metabolic or inflammatory parameters. However, there was an effect
of date (pre vs post supplementation period) and glycemic challenge on serum insulin and
glucose, as well as many inflammatory markers. In horses there have been some indications
that metabolic parameters are influenced by season. Horses with PPID are reportedly
higher in serum insulin in the fall months [256] and healthy horses had a higher area under
the curve for glucose concentrations in response to the combined glucose-insulin tolerance
test in February compared to August and November and June compared to November
[257]. This was not observed by others who saw no differences in serum glucose or insulin
concentrations in respect to season in a group of healthy or ID horses [258]. For our work,
serum glucose and insulin had an apparent effect of season wherein the ID horses had an
even greater increase from July to September as compared to controls.
Inflammation and the immune response have in other species been shown to be
affected by season [259-261]. In baboons and Siberian hamsters the immune response
appears to be suppressed in the fall and into the winter seasons [259, 260]. This may be the
case in the horse as well [262-264], with a reported increase in IFN-γ and decrease in IL-4
in the winter as opposed to the summer months [265]. However, PBMC IFN-γ gene
expression was conversely shown to be increased in the summer as opposed to winter
months in another group of horses [266]. We observed an increase in gene expression of
the proinflammatory cytokines IFN-γ and TNF-α as well as TLR-4 from the summer (July)
to the fall (September) and a decrease in anti-inflammatory gene expression of IL-10 as
well as IL-6, and protein concentrations of IFN-γ and TNF-α from lymphocytes. This
supports the hypothesis that seasonal variations in inflammatory cytokines are present in
both ID and metabolically normal horses. In fact, our results indicate that ID horses may

138

be particularly sensitive to seasonal changes in inflammation, as they had differences or
trends to differ from controls dependent upon date for gene expression of TLR-4, IL-6, and
TNF-α as well as lymphocyte protein concentrations of TNF-α and IFN-γ.
Not only have we observed differences between ID and metabolically normal
horses’ inflammatory responses and gut microbiota with this work, but we have also seen
changes in circulating plasma lipid concentrations. ID horses had increases in serum
triglycerides and leptin, as well as plasma diacylglycerides, triacylglycerides,
monoacylglyceride, and ceramide. They also had decreases in plasma sphingomyelins,
sulfatide, and choline plasmalogens as compared to controls. Lipids have been shown in
humans and mice to be able to influence multiple biological functions, including; cell
signaling, gene expression, and activation of inflammatory pathways in multiple cell types
[112-114]. Changing lipid concentrations has also been shown to impact insulin resistance
[114, 228, 240]. Bioactive lipids (including ceramide and sulfatides) are also able to serve
as chemoattractant and intracellular messengers [118, 119]. One of the lipid moieties we
observed to be increased in ID horses, ceramide, has received attention in human research
as it is increased in skeletal muscle of obese individuals with metabolic dysfunction [208].
Further, it appears to have a prominent role in both cell signaling and metabolism [113,
115, 116]. ID horses also had decreased levels of critical membrane lipids, sphingomyelins
and plasmalogens, indicating possible changes in membrane fluidity and permeability
[109-111]. These differences, along with increased levels of tri-, di-, and
monoacylglycerides, may point to changes in cell signaling and add to existing metabolic
dysfunction in ID horses. However, the full impact of changes in plasma lipid
concentrations in ID horses as it relates to cell signaling and metabolism is unclear.
Considering that lipids can influence inflammatory signaling, including acting as
chemoattractants for lymphocytes [118], and the fact that inflammation has a role in the
immune response, it is perhaps not surprising that the immune system can recognize both
foreign [126] and self-lipids [127-129] as antigens. In addition, a reduced cell mediated
immune response (CMI) has been observed in obese humans and mice [134-137]. Data
generated from stimulated PBMCs, as in our results, more strongly reflects cellular
responses opposed to systemic responses. Indeed, we show that at fasting in PBMC
stimulated lymphocytes, ID horses often are lower in proinflammatory cytokine protein or
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gene expression compared to controls. This indicates a reduced CMI response in these
animals. In response to a Hepatitis B vaccine, a reduced hepatitis specific antibody and T
cell activation but increased levels of IFN-γ and TNF-α as well as T and B cell proliferation
have been observed in diet-induced obese mice [135]. In influenza vaccinated obese
humans, PBMCs had a lower functional protein expression in response to viral challenge
[138]. When we vaccinated a group of ID and non-ID controls, we observed a normal
humoral response to vaccination, regardless of metabolic status, compared to nonvaccinated saline controls. This is similar to what is seen in humans where body mass
index, but not diabetes status, was positively correlated with a greater decline in influenza
antibody titers 12 months following influenza vaccination [138]. While we did not observe
an effect of metabolic status on humoral immune responses to vaccination, there was some
evidence that CMI responses were different in ID compared to control horses. Flu
stimulated PBMC IL-2 gene expression was lower in ID horses and TNF-α gene expression
did not change over time in ID horses whereas control horses had differences between pre
and post vaccination time points. ID horses also had lower PMA stimulated PBMC gene
expression of IFN-γ and IL-2 compared to controls, dependent upon time point. As TNFα and IFN-γ play important roles in CMI immune responses [248, 249] and IL-2 is
associated with lymphocyte proliferation [247], it lends further evidence for a reduced CMI
response in horses with ID. However, it is important to note that while this work observed
differences in immune responses of horses with ID, the physiological impact of these
differences, in particular in the face of challenge, remains to be seen.
To better understand mechanisms behind alterations is inflammatory signaling
pathways, we also examined gene expression of inflammatory cytokines and markers
involved in TLR-4 inflammatory signaling pathways in equine whole blood both
unstimulated and stimulated with endotoxin. For all horses and all inflammatory markers
(with the exception of CCL2; chemokine (C-C motif) ligand 2), LPS was able to stimulate
gene expression. However, stimulation was minimal or nonexistent for chemokine (C-C
motif) ligand 5 (CCL5, or RANTES) and CCL2 (or MCP-1, monocyte chemoattractant
protein-1), which are associated with the MyD88 independent signaling pathway. Others
have similarly demonstrated this in LPS stimulated monocytes from metabolically normal
horses [274]. Interesting, there was an effect of metabolic status on two chemokines,
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interleukin 8 (IL-8) and CCL2, with ID horses having lower gene expression compared to
controls. Conversely, healthy elderly humans LPS stimulated whole blood gene expression
[283], obese humans or those with metabolic dysfunction circulating levels [279-282] and
LPS stimulated leukocytes in elderly horses or those with PPID [284] have all shown an
increased IL-8 gene expression as compared to controls. However, others have shown no
difference in lymphocyte gene expression of IL-8 in obese hyperinsulinemic horses
compared to non-obese normoinsulinemic controls [31], although neutrophil oxidative
activity was increased in the obese hyperinsulinemic group. Our horses did not differ in
age and were all classified as adults. Lower IL-8 and CCL2 concentrations therefore
indicate that ID horses may have decreased innate immune function.
Treatment strategies for both humans and animals with metabolic dysfunction have
been varied. One of the proposed dietary strategies in humans and horses has been
supplementation with omega-3 fatty acids, specifically docosahexaenoic acid (DHA) and
eicosapentaenoic acid (EPA) [157]. We observed, similar to others [159, 288, 292], that
following supplementation with a DHA rich algae, ID horses had significant increases in
serum DHA concentrations, among other fatty acids. Also similar to others [177], we
observed a significant decrease in serum triglycerides in response to supplementation.
There was also a trend for a decrease in lymphocyte TNF-α protein production. Others
have not seen an effect of omega 3 fatty acid supplementation on prostaglandin E2 (PGE2)
as an inflammatory marker in PBMCs of yearling horses [292], although it did impact
PGE2 production and other markers of inflammation in adult horses bronchoalveolar
lavage fluid (BAL) in other studies [297, 298]. These differences in results are possibly
due to different sources of omega 3 fatty acids as well as the resulting differences in DHA
to EPA ratio, especially considering that DHA appears to have a more potent antiinflammatory effect compared to EPA [299, 300]. Importantly for this work,
supplementation with a DHA rich algae in ID horses also resulted in an improved
insulinemic response to an oral sugar challenge. Others have shown that following
dexamethasone administration in horses, DHA rich algae reduced both glucose and insulin
concentrations and improved their modified insulin to glucose ratio [173]. However, we
are the first to demonstrate a positive metabolic effect of DHA rich microalgae
supplementation in the ID horse.
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With these results we have been able to show that compared to metabolically
normal controls, horses with ID have differences in their gut microbiota, specifically a
decrease in microbial diversity and overall community structure. Horses with ID also have
differences in their plasma lipidome, with increased tri-, di- and mono-acylglycerides as
well as ceramide but lower levels of sphingomyelins, sulfatide, and choline plasmalogens.
In addition, ID horses demonstrated an abnormal inflammatory response to glycemic
challenge, having an inverse, often proinflammatory response, compared to controls. ID
horses were able to mount a normal humoral response to routine vaccination, however
lower IFN-γ and IL-2 gene expression indicated a possible reduced cell mediated immune
(CMI) responses to vaccination. Circulating endotoxin concentrations did not appear to be
influenced by metabolic status or glycemic challenge. While there was a minor effect of
yeast cell wall supplementation on inflammatory markers, it did not influence serum
glucose of insulin concentrations. However, there appeared to be a seasonal effect as well
as an effect of glycemic challenge on both metabolic and inflammatory markers, indicating
that ID horses may be particularly sensitive to changes in either diet or season. Endotoxin
stimulation of whole blood was able to induce inflammatory gene expression primarily in
MyD88 dependent associated genes for all horses. In ID horses, a reduced whole blood
gene expression of the chemokines IL-8 and CCL2 may further point to a suppressed innate
immune response in these horses. Finally, we were able to show that supplementation with
DHA rich algae can improve insulin responses and may potentially improve inflammatory
parameters in ID horses. Overall this work has indicated differences in inflammation in the
ID horse, primarily in a TLR-4 MyD88 dependent associated gene and particularly in
response to oral glycemic challenge. It also demonstrated changes in their circulating lipid
concentrations and gut microbiota as well as a possible reduced innate immune or cell
mediated immune responses in these animals.
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